<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006132.pub2" GROUP_ID="EYES" ID="821006012511323538" MERGED_FROM="" MODIFIED="2013-03-29 12:43:34 +0000" MODIFIED_BY="Anupa Shah" REVIEW_NO="HEWA01" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.2">
<COVER_SHEET MODIFIED="2013-03-29 12:43:34 +0000" MODIFIED_BY="Anupa Shah">
<TITLE>Interventions for improving adherence to ocular hypotensive therapy</TITLE>
<CONTACT MODIFIED="2013-03-29 12:43:34 +0000" MODIFIED_BY="Anupa Shah"><PERSON ID="8889" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Heather</FIRST_NAME><LAST_NAME>Waterman</LAST_NAME><POSITION>Professor of Nursing &amp; Ophthalmology</POSITION><EMAIL_1>heather.waterman@manchester.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Nursing, Midwifery and Social Work</DEPARTMENT><ORGANISATION>University of Manchester</ORGANISATION><ADDRESS_1>Room 6.31a, University Place</ADDRESS_1><ADDRESS_2>Oxford Road</ADDRESS_2><CITY>Manchester</CITY><ZIP>M13 9PL</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 161 306 7861</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-03-29 12:43:34 +0000" MODIFIED_BY="Anupa Shah"><PERSON ID="8889" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Heather</FIRST_NAME><LAST_NAME>Waterman</LAST_NAME><POSITION>Professor of Nursing &amp; Ophthalmology</POSITION><EMAIL_1>heather.waterman@manchester.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Nursing, Midwifery and Social Work</DEPARTMENT><ORGANISATION>University of Manchester</ORGANISATION><ADDRESS_1>Room 6.31a, University Place</ADDRESS_1><ADDRESS_2>Oxford Road</ADDRESS_2><CITY>Manchester</CITY><ZIP>M13 9PL</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 161 306 7861</PHONE_1></ADDRESS></PERSON><PERSON ID="7430" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jennifer</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Evans</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Lecturer</POSITION><EMAIL_1>jennifer.evans@lshtm.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane Eyes and Vision Group, ICEH</DEPARTMENT><ORGANISATION>London School of Hygiene &amp; Tropical Medicine</ORGANISATION><ADDRESS_1>Keppel Street</ADDRESS_1><CITY>London</CITY><ZIP>WC1E 7HT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7958 8316</PHONE_1></ADDRESS></PERSON><PERSON ID="9FB4475582E26AA2014A55945BA64F31" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Trish</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Gray</LAST_NAME><POSITION>Nurse Researcher/ PhD Student</POSITION><EMAIL_1>trish.gray@manchester.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Academic Department of Ophthalmology</DEPARTMENT><ORGANISATION>Manchester Royal Eye Hospital</ORGANISATION><ADDRESS_1>Oxford Road</ADDRESS_1><CITY>Manchester</CITY><ZIP>M13 9WH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 0161 276 5614</PHONE_1><FAX_1>+44 0161 273 6354</FAX_1></ADDRESS></PERSON><PERSON ID="AF09039082E26AA201609AF9A565F96B" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>David</FIRST_NAME><LAST_NAME>Henson</LAST_NAME><POSITION>Professor of Ophthalmology and Vision Sciences</POSITION><EMAIL_1>david.henson@manchester.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Academic Department of Ophthalmology</DEPARTMENT><ORGANISATION>Manchester Royal Eye Hospital</ORGANISATION><ADDRESS_1>Oxford Road</ADDRESS_1><CITY>Manchester</CITY><ZIP>M13 9WH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 161 276 5507</PHONE_1><FAX_1>+44 161 273 6354</FAX_1></ADDRESS></PERSON><PERSON ID="01212F6482E26AA201A256C7F160E4C1" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Robert</FIRST_NAME><LAST_NAME>Harper</LAST_NAME><POSITION>Consultant Optometrist</POSITION><EMAIL_1>robert.harper@cmft.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Optometry Department</DEPARTMENT><ORGANISATION>Central Manchester &amp; Manchester Children's NHS Trust</ORGANISATION><ADDRESS_1>Manchester Royal Eye Hospital</ADDRESS_1><ADDRESS_2>Oxford Road</ADDRESS_2><CITY>Manchester</CITY><ZIP>M13 9WH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 161 276 5508</PHONE_1><FAX_1>+44 161 273 6354</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-07-16 11:38:35 +0100" MODIFIED_BY="Anupa Shah">
<UP_TO_DATE>
<DATE DAY="26" MONTH="6" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="26" MONTH="6" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="18" MONTH="7" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2013-03-29 12:42:27 +0000" MODIFIED_BY="Anupa Shah">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-03-29 12:42:20 +0000" MODIFIED_BY="Anupa Shah">
<DATE DAY="28" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>Issue 4 2013: New searches have been conducted. One new co-author, Jennifer Evans, has joined the review team for the update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-03-29 12:42:27 +0000" MODIFIED_BY="Anupa Shah">
<DATE DAY="28" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>Issue 4 2013: Eight new trials have been included.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<DATE DAY="1" MONTH="9" YEAR="2009"/>
<DESCRIPTION>
<P>Issue 1, 2010: 'Results of the search' amended as the number of trials stated to be eligible for inclusion in the review was incorrect. Eleven trials were relevant for the review; three ongoing and eight completed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-10-21 11:04:47 +0100" MODIFIED_BY="Anupa Shah">
<DATE DAY="5" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-12-23 12:21:04 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2008-12-23 12:20:30 +0000" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>University of Manchester</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2008-12-23 12:21:04 +0000" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>Central Manchester and Manchester Children's University Hospitals NHS Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2008-12-23 12:21:04 +0000" MODIFIED_BY="[Empty name]">
<NAME>Pfizer Limited</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-03-16 12:02:15 +0000" MODIFIED_BY="Anupa Shah">
<SUMMARY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<TITLE MODIFIED="2008-10-01 14:40:34 +0100" MODIFIED_BY="Trish Gray">Interventions for helping people use eye drops as prescribed for raised eye pressure or glaucoma</TITLE>
<SUMMARY_BODY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>A large number of people do not use eye drops as prescribed. Glaucoma is a slowly progressive eye disease, which can result in severe vision loss. Drops prescribed for raised eye pressure or glaucoma are aimed at lowering the pressure to assist in reducing the rate of progression, or preventing the conversion of raised eye pressure to glaucoma. It is important that these eye drops are used continually, usually for life. Approximately one-third of people who are prescribed eye drops for the first time fail to continue collecting prescriptions within the first year and even when patients collect prescriptions they do not always use the drops as frequently as they should. A number of reasons are thought to be the cause, for example, forgetfulness, being prescribed a large number of medications, difficulties instilling drops, lack of knowledge about glaucoma, a busy lifestyle and seeing no benefit.</P>
<P>This review is based on 16 studies (1565 participants) that tried out different methods to help people to use drops as prescribed. All the studies took place in industrialised countries (Belgium, Denmark, France, Greece, Iceland, Japan, Sweden, Switzerland, UK and USA) and recruited participants in outpatient clinics. The following interventions were included: simplifying drop routines, reminder devices, automated telephone service, providing information about glaucoma and offering advice regarding day to day issues with eye care. Those studies which combined the provision of information about glaucoma and eye drops with other interventions, such as helping people to fit instillation of eye drops into their daily routine, appear to be more successful. Unfortunately, not all of these studies were of high quality and, therefore, until more evidence is available we cannot recommend any particular method. Good quality research is needed in this area in order to develop a better understanding of patients' individual needs and to help us provide more effective eye care services.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-03-15 10:08:54 +0000" MODIFIED_BY="Anupa Shah">
<ABS_BACKGROUND MODIFIED="2013-03-15 10:08:54 +0000" MODIFIED_BY="Anupa Shah">
<P>Poor adherence to therapy is a significant healthcare issue, particularly in patients with chronic disease such as open-angle glaucoma. Treatment failure may necessitate unwarranted changes of medications, increased healthcare expenditure and risk to the patient if surgical intervention is required. Simplifying eye drop regimes, providing adequate information, teaching drop instillation technique and ongoing support according to the patient need may have a positive effect on improving adherence.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-10-21 12:20:19 +0100" MODIFIED_BY="Anupa Shah">
<P>To summarise the effects of interventions for improving adherence to ocular hypotensive therapy in people with ocular hypertension (OHT) or glaucoma.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-02-04 12:13:45 +0000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (<I>The Cochrane Library</I> 2012, Issue 6), MEDLINE (June 1946 to June 2012), EMBASE (June 1980 to June 2012), Cumulative Index to Nursing and Allied Health Literature (CINAHL) (June 1937 to June 2012), PsycINFO (1806 to June 2012), PsycEXTRA (1908 to June 2012), Web of Science (1970 to June 2012), ZETOC (1993 to June 2012), OpenGrey (System for Information on Grey Literature in Europe) (<A HREF="http://www.opengrey.eu/">www.opengrey.eu/</A>), the <I>meta</I>Register of Controlled Trials (<I>m</I>RCT) (<A HREF="http://www.controlled-trials.com/">www.controlled-trials.com</A>), ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>) and the WHO International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://www.who.int/ictrp/search/en">www.who.int/ictrp/search/en</A>). We did not use any date or language restrictions in the electronic searches for trials. The electronic databases were last searched on 26 June 2012. We did not search the National Research Register (NNR) as this resource has now been now archived. We contacted pharmaceutical manufacturers to request unpublished data and searched conference proceedings for the Association for Research in Vision and Ophthalmology (ARVO), and the Annual Congress for the Royal College of Ophthalmologists (RCO). </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-02-06 13:25:59 +0000" MODIFIED_BY="Anupa Shah">
<P>We included randomised controlled trials (RCTs) and quasi-RCTs that compared interventions to improve adherence to ocular hypotensive therapy for patients with OHT or glaucoma.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-11-22 10:18:25 +0000" MODIFIED_BY="Anupa Shah">
<P>At least two authors independently assessed the search results for eligibility and extracted data for included trials onto specifically designed forms. We did not pool data due to clinical and methodological heterogeneity.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-02-06 13:26:49 +0000" MODIFIED_BY="Anupa Shah">
<P>Sixteen trials (1565 participants) met the inclusion criteria. Seven studies investigated some form of patient education. In six of these studies this education was combined with other behavioural change interventions including tailoring daily routines to promote adherence to eye drops. Eight studies compared different drug regimens (one of these trials also compared open and masked monitoring) and one study investigated a reminder device. The studies were of variable quality and some were at considerable risk of bias; in general, the length of follow-up was short at less than six months with only two studies following up to 12 months. Different interventions and outcomes were reported and so it was not possible to produce an overall estimate of effect. There was some evidence from three studies that education combined with personalised interventions, that is, more complex interventions, improved adherence to ocular hypotensive therapy. There was less information on other outcomes such as persistence and intraocular pressure, and no information on visual field defects, quality of life and cost. There was weak evidence as to whether people on simpler drug regimens were more likely to adhere and persist with their ocular hypotensive therapy. A particular problem was the interpretation of cross-over studies, which in general were not reported correctly. One study investigated a reminder device and monitoring but the study was small and inconclusive.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Although complex interventions consisting of patient education combined with personalised behavioural change interventions, including tailoring daily routines to promote adherence to eye drops, may improve adherence to glaucoma medication, overall there is insufficient evidence to recommend a particular intervention. The interventions varied between studies and none of the included studies reported on the cost of the intervention. Simplified drug regimens also could be of benefit but again the current published studies do not provide conclusive evidence. Future studies should follow up for at least one year, and could benefit from standardised outcomes.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-03-16 12:02:15 +0000" MODIFIED_BY="Anupa Shah">
<BACKGROUND MODIFIED="2013-02-06 13:30:26 +0000" MODIFIED_BY="Anupa Shah">
<P>There are a number of terms that describe whether medications are taken as prescribed. Adherence has superseded the term compliance and although synonymous with compliance, has fewer negative connotations and is intended to be non-judgemental (<LINK REF="REF-Haynes-1979" TYPE="REFERENCE">Haynes 1979</LINK>; <LINK REF="REF-Horne-2006" TYPE="REFERENCE">Horne 2006</LINK>). Adherence will, therefore, be used throughout the review.</P>
<P>A useful taxonomy for describing adherence to medication helps to clarify the confusion surrounding the proliferation of ambiguous terms on medication adherence. In this taxonomy, non-adherence to medications is said to occur by late or non-initiation of prescribed treatment, by sub-optimal implementation of the regimen and by early discontinuation of therapy sometimes referred to as persistence (<LINK REF="REF-Vrijens-2012" TYPE="REFERENCE">Vrijens 2012</LINK>). Although persistence may be achieved by the patient collecting all dispensed prescriptions, it does not necessarily follow that the medication will be taken as prescribed. Because adherence is difficult to measure, persistence (which can be objectively measured) is often employed as an outcome for studies investigating adherence (<LINK REF="REF-Wilensky-2006" TYPE="REFERENCE">Wilensky 2006</LINK>; <LINK REF="REF-Yu-2005" TYPE="REFERENCE">Yu 2005</LINK>). Another term often confused with adherence is concordance. Concordance describes an agreement reached after negotiation between a patient and a healthcare professional that respects the beliefs and wishes of the patient in determining whether, when and how medicines are to be taken. Although reciprocal, this is an alliance in which healthcare professionals recognise the primacy of the patient's decision about taking the recommended medications (<LINK REF="REF-Royal-Pharmaceutical-Society-of-Great-Britain-1997" TYPE="REFERENCE">Royal Pharmaceutical Society of Great Britain 1997</LINK>).</P>
<P>Concordance is not synonymous with compliance or adherence. Concordance focuses on the consultation process rather than specific patient behaviour and has an underlying ethos of a shared approach to decision making (<LINK REF="REF-Weis-2003" TYPE="REFERENCE">Weis 2003</LINK>). The concept involves the pooling of patients' and health professionals' beliefs, experiences and expertise to arrive at mutually agreed goals (<LINK REF="REF-Bissell-2004" TYPE="REFERENCE">Bissell 2004</LINK>). To ensure completeness for this review, our search strategy will incorporate the above terms and any other terminology associated with adherence.</P>
<P>Poor adherence most often leads to increased resource utilisation, owing to a reduction in effectiveness and associated increase in the risk of therapeutic failure (<LINK REF="REF-Urquhart-1999" TYPE="REFERENCE">Urquhart 1999</LINK>). Treatment failure may necessitate more frequent hospital appointments and diagnostic tests, unwarranted increases in doses or changes of medications, waste of unfinished pharmaceutical supplies, increased healthcare expenditure and risk to the patient if subsequent surgical intervention is required. Electronic monitoring devices are considered the gold standard for measuring adherence because they are an objective measure of behaviour but experimenter&#8217;s bias may be a limitation. A systematic review of seven studies using this method reports that there are a sizeable group of 20% or less of patients who are defined as non-adherent (<LINK REF="REF-Reardon-2011" TYPE="REFERENCE">Reardon 2011</LINK>). Other studies also identify from electronic monitoring that patients' behaviour can be grouped into such categories as fully adherent, non-persistent, taking regular breaks/dosing holidays or erratic frequent missing of doses (<LINK REF="REF-Ajit-2010" TYPE="REFERENCE">Ajit 2010</LINK>; <LINK REF="REF-Herman-2010" TYPE="REFERENCE">Herman 2010</LINK>). Research from a systematic review of medical chart reviews (six studies) indicates that at one year 67% (range 62% to 78%) of patients remained persistent with their anti-glaucoma medication (<LINK REF="REF-Reardon-2011" TYPE="REFERENCE">Reardon 2011</LINK>).  </P>
<P>In chronic, asymptomatic diseases such as open-angle glaucoma (OAG), adherence is a particular issue. The treatment for glaucoma aims to prevent disease progression, yet provides no subjective improvement in well-being, and may even cause ocular or systemic side effects, or both (<LINK REF="REF-Diggory-1995" TYPE="REFERENCE">Diggory 1995</LINK>).</P>
<P>In a systematic review by <LINK REF="REF-Olthoff-2005" TYPE="REFERENCE">Olthoff 2005</LINK> non-adherence ranged from 4.6% to 80% across 34 studies. A more recent review found the prevalence of non-adherence to glaucoma treatment to range from 23% to 60% over 12 months (<LINK REF="REF-Lu-2010" TYPE="REFERENCE">Lu 2010</LINK>). A variety of definitions for non-adherence and assessment methods were found to be in use. This emphasises our poor understanding and the poor classification of adherence.</P>
<CONDITION MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Glaucoma is an optic neuropathy characterised by an acquired loss of retinal ganglion cells, atrophy of the optic nerve and loss of visual field (<LINK REF="REF-Maier-2005" TYPE="REFERENCE">Maier 2005</LINK>). Increased intraocular pressure (IOP) may be present as in open-angle glaucoma (OAG) and angle-closure glaucoma (ACG). Glaucomatous optic neuropathy and field loss with normal IOP is known as normal tension glaucoma (NTG). Elevated IOP in the absence of glaucomatous appearance of the optic nerve head or visual field is known as ocular hypertension (OHT). Intraocular pressure control (reduction and control of fluctuations) has a role in preventing the onset (for patients with OHT) and reducing the rate of progression of glaucoma (<LINK REF="REF-Heijl-2002" TYPE="REFERENCE">Heijl 2002</LINK>). It is routinely monitored in clinical practice in conjunction with other risk factors such as the structural appearance of the optic nerve head and visual field status (<LINK REF="REF-Spry-2005" TYPE="REFERENCE">Spry 2005</LINK>).</P>
<P>Glaucoma is the leading cause of irreversible blindness worldwide. A review of 34 studies involving patients with OAG and ACG estimated the prevalence of glaucoma to be 60.5 million by 2010 (74% with OAG) rising to nearly 80 million by 2020; with an ageing population accounting for a large proportion of this rise (<LINK REF="REF-Quigley-2006" TYPE="REFERENCE">Quigley 2006</LINK>). A meta-analysis confirmed previous estimates that black populations had the highest prevalence of OAG at 4.2%, ranging from 2.9% at the age of 40 years to 16.9% at 80+ years (<LINK REF="REF-Rudnicka-2006" TYPE="REFERENCE">Rudnicka 2006</LINK>). The prevalence for white populations was 2.1%, ranging from 0.4% at age 40 years to 6.6% at 80+ years, and for Asian populations was 1.4%, ranging from 0.6% to 3.8% for the same age range.</P>
<P>In its early stages, glaucoma is asymptomatic and approximately one in two people with the disease may be undiagnosed (<LINK REF="REF-Quigley-2006" TYPE="REFERENCE">Quigley 2006</LINK>). In a north London-based cross-sectional survey, 74% of those found to have a definite diagnosis of glaucoma and 84% of suspected glaucoma cases were not known to an eye care service (<LINK REF="REF-Reidy-1998" TYPE="REFERENCE">Reidy 1998</LINK>). People at risk of developing glaucoma are more likely to present late if they have no family history of glaucoma or do not visit an optometrist regularly (<LINK REF="REF-Fraser-1999" TYPE="REFERENCE">Fraser 1999</LINK>). The majority of cases are detected during routine eye examination and, therefore, increasing public awareness of the disease may be valuable for early detection. Patients newly diagnosed with OHT or glaucoma should have the opportunity to make informed choices about their long-term care. <LINK REF="REF-Deokule-2004" TYPE="REFERENCE">Deokule 2004</LINK> found only 52% of patients could name their medication or frequency of instillation correctly. An Australian study reports that of 200 patients with glaucoma, 32% could not state their prescribed therapeutic regimen and that those with three or more prescribed eye drops were five times more likely not to know their medication (<LINK REF="REF-O_x0027_Hare-2009" TYPE="REFERENCE">O'Hare 2009</LINK>). Providing adequate information, advice and ongoing support according to patient need may have a positive effect on improving adherence.</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment of patients with OHT or glaucoma aims to prevent visual disability and preserve overall well-being (<LINK REF="REF-Burr-2012" TYPE="REFERENCE">Burr 2012</LINK>). Therapy focuses on lowering IOP levels in an attempt to slow the rate of disease progression or prevent the conversion of OHT to glaucoma within a person&#8217;s lifetime (<LINK REF="REF-NICE-2009" TYPE="REFERENCE">NICE 2009</LINK>).</P>
<P>First-line treatment usually consists of mono-therapy, commencing with an uncomplicated regime of one drop per day. Even the simplest regimes are subject to poor persistence rates, as <LINK REF="REF-Vanelli-2009" TYPE="REFERENCE">Vanelli 2009</LINK> found that it was medication-naive patients with prescribed non-oral medicines (diabetes mellitus, insulin; glaucoma, eye drops; asthma, inhalers) who were most at risk of discontinuation in the first 30 days of therapy compared with those who were more experienced. This supports the early provision of patient education and support in an attempt to prevent early discontinuation (<LINK REF="REF-Lunnela-2010" TYPE="REFERENCE">Lunnela 2010</LINK>). For many patients, multiple therapy is required and this has led to the introduction of fixed-combination drops (two active ingredients in a single drop) for patients requiring more than one preparation. The aim of fixed combination drops is to enable a more complex dosing regimen while allowing the patient to benefit from a once only dose which may improve adherence (<LINK REF="REF-Brown-1997" TYPE="REFERENCE">Brown 1997</LINK>). The previous version of our review (<LINK REF="REF-Gray-2009" TYPE="REFERENCE">Gray 2009</LINK>) shows that there were a few studies which have attempted to investigate this issue and, unfortunately, there was insufficient evidence to confirm this claim.</P>
</INTERVENTION>
<THEORY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Although complicated regimes do appear to affect adherence, there is no evidence to date that indicates that there are any determinants, such as age, race or level of education, that can predict accurately potential patients who will not adhere. However, previous studies have found numerous patient-identified barriers to adherence with anti-glaucoma medication, such as communication difficulties between patient and physician, lack of knowledge about glaucoma and the purpose of eye drops, forgetfulness, lack of motivation, living alone, poor dexterity, a busy lifestyle and seeing no benefit (<LINK REF="STD-Granstrom-1982" TYPE="STUDY">Granstrom 1982</LINK>; <LINK REF="REF-Kholdebarin-2008" TYPE="REFERENCE">Kholdebarin 2008</LINK>; <LINK REF="REF-Lacey-2009" TYPE="REFERENCE">Lacey 2009</LINK>; <LINK REF="REF-Patel-1995" TYPE="REFERENCE">Patel 1995</LINK>; <LINK REF="REF-Schwartz-2008" TYPE="REFERENCE">Schwartz 2008</LINK>; <LINK REF="REF-Taylor-2002" TYPE="REFERENCE">Taylor 2002</LINK>; <LINK REF="REF-Tsai-2003" TYPE="REFERENCE">Tsai 2003</LINK>). These factors would seem to be amenable to interventions.</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>A previous Cochrane review synthesised the evidence relating to adherence to a range of medications including oral and inhaled drugs (<LINK REF="REF-Haynes-2008" TYPE="REFERENCE">Haynes 2008</LINK>). Topical eye drops, however, were not included. <LINK REF="REF-Olthoff-2005" TYPE="REFERENCE">Olthoff 2005</LINK> published a systematic review relating to poor adherence with ocular hypotensive treatment. This review raised a number of interesting issues and did conclude that poor adherence is a considerable concern. The authors suggested that future research should take a more objective approach of measuring adherence by means of medication monitors. <LINK REF="REF-Olthoff-2005" TYPE="REFERENCE">Olthoff 2005</LINK> excluded drug trials on the basis that drug use under everyday circumstances may differ completely from the situation in a clinical trial. We are aware of this, however, we believe drug studies should be included. Studies that compare adherence rates for patients on different drug regimes, such as daily combination drops versus twice or three times daily mono-therapy, may prove to be beneficial in informing future prescribing practices. <LINK REF="REF-Olthoff-2005" TYPE="REFERENCE">Olthoff 2005</LINK> also excluded studies if they reported involuntary non-adherence, e.g. due to co-morbidity. Again, the authors of this review believe that such trials are important. If a patient is unable to adhere to a prescribed regime due to a co-existing condition such as Alzheimer's disease, this has implications for future service provision. This is an update of our original Cochrane review published in 2009 (<LINK REF="REF-Gray-2009" TYPE="REFERENCE">Gray 2009</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-10-21 12:21:31 +0100" MODIFIED_BY="Anupa Shah">
<P>To summarise the effects of interventions for improving adherence to ocular hypotensive therapy in people with OHT or glaucoma.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-02-06 13:36:43 +0000" MODIFIED_BY="Anupa Shah">
<SELECTION_CRITERIA MODIFIED="2013-02-06 13:35:17 +0000" MODIFIED_BY="Anupa Shah">
<CRIT_STUDIES MODIFIED="2011-10-07 11:06:50 +0100" MODIFIED_BY="Trish Gray">
<P>We included randomised controlled trials (RCTs) and quasi RCTs that compared interventions to improve adherence to ocular hypotensive therapy.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-10-21 12:21:35 +0100" MODIFIED_BY="Anupa Shah">
<P>We included patients with a clinical diagnosis of glaucoma or OHT who were prescribed ocular hypotensive therapy. There were no age or gender limitations.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>We included any intervention that aimed to improve adherence to ocular hypotensive therapy versus other interventions or usual care. There were no restrictions on the type of ocular hypotensive medications used. Studies included were likely to match one of the following four comparisons:</P>
<OL>
<LI>Usual care versus adherence intervention and usual care.</LI>
<LI>Usual care versus adherence intervention alone.</LI>
<LI>Usual care and adherence intervention versus usual care and an alternative adherence intervention.</LI>
<LI>Adherence intervention versus an alternative adherence intervention.</LI>
</OL>
<P>Interventions may include, but are not exclusive to, the following:<BR/>
</P>
<UL>
<LI>Patient education programmes.</LI>
<LI>Verbal and written information.</LI>
<LI>Follow-up support; telephone or postal reminders to collect prescriptions and/or medication reminder charts.</LI>
<LI>Rescheduling of eye drop therapy; simplification of dosing, e.g. reducing the number of drops per day or tailoring regimes to daily activities.</LI>
<LI>Eye drop instillation training.</LI>
<LI>Identification of adherence barriers and individualised adherence plan.</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-02-06 13:35:17 +0000" MODIFIED_BY="Anupa Shah">
<P>A gold standard for measuring adherence to glaucoma therapy does not exist; methods vary greatly. This review incorporated any measure for a study that met the inclusion criteria.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<UL>
<LI>Adherence to therapy measured as defined in each study; including, but not limited to patient interviews, questionnaires, patient diaries or electronic monitoring devices. This includes dichotomous (success/failure), nominal (reasons for non/poor adherence) and discrete data (proportions of missed doses over a specific time period).</LI>
<LI>Persistence with therapy measured by repeat prescriptions (prescription refill) or dispensing counts, or both. This includes dichotomous (success/failure) and discrete data (proportions of uncollected prescriptions over a specific time period).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-02-06 13:35:17 +0000" MODIFIED_BY="Anupa Shah">
<UL>
<LI>Intraocular pressure reduction measured via tonometry.</LI>
<LI>Progression of optic nerve head damage as defined by each study.</LI>
<LI>Progressive visual field loss as defined by each study.</LI>
<LI>Quality of life</LI>
<UL>
<LI>We collected quality of life data where available and where reported in association with adherence outcomes. Many recognised tools are available, such as the MOS SF36 (<LINK REF="REF-Iester-2002" TYPE="REFERENCE">Iester 2002</LINK>), IPQ-R (<LINK REF="REF-Moss_x002d_Morris-2002" TYPE="REFERENCE">Moss-Morris 2002</LINK>) or VFQ-25 (<LINK REF="REF-Mangione-2001" TYPE="REFERENCE">Mangione 2001</LINK>; <LINK REF="REF-Spaeth-2006" TYPE="REFERENCE">Spaeth 2006</LINK>). We included any validated quality of life measure as reported in the trials.</LI>
</UL>
<LI>Adverse effects.</LI>
<UL>
<LI>Serious adverse events (fatal, life-threatening or require hospitalisation).</LI>
<LI>Adverse events that result in discontinuation of treatment.</LI>
<LI>Any other adverse events.</LI>
</UL>
<LI>Patients' knowledge of glaucoma and its treatment.</LI>
<LI>Costs.</LI>
</UL>
<P>Secondary outcome measures may involve the analysis of both continuous and ordinal data.</P>
<SUBSECTION>
<HEADING LEVEL="5">Follow-up</HEADING>
<P>Studies measuring adherence and persistence may vary. We have included all studies meeting the criteria and categorised as follows:<BR/>
</P>
<UL>
<LI>Short-term = &lt; six months.</LI>
<LI>Medium-term = six months to &lt; one year.</LI>
<LI>Long-term = &#8805; one year.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2012-07-16 12:16:12 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) 2012, Issue 6, part of <I>The Cochrane Library</I>. <A HREF="http://www.thecochranelibrary.com/">www.thecochranelibrary.com</A> (accessed 26 June 2012), MEDLINE (June 1946 to June 2012), EMBASE (June 1980 to June 2012), Cumulative Index to Nursing and Allied Health Literature (CINAHL) (June 1937 to June 2012), PsycINFO (1806 to June 2012), PsycEXTRA (1908 to June 2012), Web of Science (1970 to June 2012), ZETOC (1993 to June 2012), OpenGrey (System for Information on Grey Literature in Europe) (<A HREF="http://www.opengrey.eu/">www.opengrey.eu/</A>), the <I>meta</I>Register of Controlled Trials (<I>m</I>RCT) (<A HREF="http://www.controlled-trials.com/">www.controlled-trials.com</A>), ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>), and the WHO International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://www.who.int/ictrp/search/en">www.who.int/ictrp/search/en</A>). We did not use any date or language restrictions in the electronic searches for trials. The electronic databases were last searched on 26 June 2012. We did not search the National Research Register (NNR) as this resource has now been now archived.</P>
<P>See: Appendices for details of search strategies for CENTRAL (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), MEDLINE (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), EMBASE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), CINAHL (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>), PsycINFO and PsycEXTRA (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>), Web of Science (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>), ZETOC (<LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>), OpenGrey (<LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>), <I>m</I>RCT (<LINK REF="APP-09" TYPE="APPENDIX">Appendix 9</LINK>), ClinicalTrials.gov (<LINK REF="APP-10" TYPE="APPENDIX">Appendix 10</LINK>) and the ICTRP (<LINK REF="APP-11" TYPE="APPENDIX">Appendix 11</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>We searched reference lists of identified trial reports to find additional trials. We contacted primary investigators of identified trials for details of additional trials. We also contacted pharmaceutical manufacturers of ocular hypotensive medications such as Pfizer, Allergan, Alcon and Merck Sharp and Dohme to request unpublished data that they were willing to release. We searched the following conference proceedings for relevant abstracts both electronically and by hand:<BR/>
</P>
<UL>
<LI>Annual Meeting for the Association for Research in Vision and Ophthalmology (ARVO) (2000 to 2008).</LI>
<LI>Annual Congress for the Royal College of Ophthalmologists (RCO) (1993 to 2008).</LI>
</UL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-02-06 13:36:43 +0000" MODIFIED_BY="Anupa Shah">
<STUDY_SELECTION MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Two review authors working independently assessed the titles and abstracts of all reports identified by the electronic and manual searches as per '<LINK TAG="SELECTION_CRITERIA" TYPE="SECTION">Criteria for considering studies for this review</LINK>'. We obtained full reports for potentially eligible studies and for those where we had insufficient information. Review authors were not masked to names of the investigators, the institutions, journal of publication or results when making their assessments. In cases where additional information was needed before a decision could be made as to whether to include a trial, we attempted to obtain this information by contacting investigators. We resolved disagreements by consensus. We scrutinised results for duplicate publications from the same data set. Details of excluded studies have been retained and reasons for exclusion are documented in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<SUBSECTION>
<HEADING LEVEL="4">Extraction of study characteristics</HEADING>
<P>At least two authors independently extracted the data from each paper onto data extraction forms, designed specifically for the review with guidance from the Cochrane Eyes and Vision Group. We compared the extracted data for differences and discrepancies were resolved by discussion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Data entry</HEADING>
<P>Data was entered by one author into Review Manager 5 (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>) (JE) and subsequently checked by another author (HW). We approached the investigators for more information where data were missing or difficult to determine from a trial report. We designed study-specific data collection forms to capture data that were not available from the published report.</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-02-06 13:36:43 +0000" MODIFIED_BY="Anupa Shah">
<P>At least two authors independently assessed each study for risk of bias, using the Cochrane Collaboration tool for assessing the risk of bias as described in Chapter 8 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Any disagreements were resolved by discussion. We graded the following items as low risk of bias, high risk of bias or unclear. We sought additional information from the authors of any study graded unclear.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Selection bias</HEADING>
<P>We assessed the generation of the allocation sequence and allocation concealment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Performance bias</HEADING>
<P>We assessed the extent to which participant and care providers were masked to the treatment group (blinding).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Detection bias</HEADING>
<P>We assessed whether the outcome assessor was masked to the intervention group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Attrition bias</HEADING>
<P>We recorded the amount of missing data and whether participants were analysed in the groups to which they were originally randomly allocated.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-02-06 09:37:56 +0000" MODIFIED_BY="Anupa Shah">
<P>There was considerable clinical heterogeneity with respect to the type of intervention and methodological heterogeneity with respect to the measurement of outcomes so we did not perform any meta-analyses.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-11-22 10:19:59 +0000" MODIFIED_BY="Anupa Shah">
<P>We did not conduct any data synthesis but tabulated data from the different studies according to type of intervention.</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-12-07 14:52:05 +0000" MODIFIED_BY="[Empty name]">
<P>We did not plan any sensitivity analyses.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-03-16 12:02:15 +0000" MODIFIED_BY="Anupa Shah">
<STUDY_DESCRIPTION MODIFIED="2013-03-16 12:02:15 +0000" MODIFIED_BY="Anupa Shah">
<SEARCH_RESULTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>For the original review published in 2009, the electronic searches identified a total of 1519 titles and abstracts. We did not find any additional references by searching conference abstracts or by contacting pharmaceutical companies. One further study was identified by someone who peer reviewed the review. We assessed the titles and abstracts and agreed to look at 68 full-text papers. We rejected 31 papers for lack of relevance to the review as many were discussion papers and not studies. A further 27 were excluded for not meeting one or more inclusion criteria. Details of these 27 studies are included in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies'</LINK> table). Ten publications reporting 11 studies were considered eligible for inclusion. Three of these studies were ongoing (see '<LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>' table). The remaining eight completed studies (<LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>; <LINK REF="STD-Laster-1996" TYPE="STUDY">Laster 1996</LINK>; <LINK REF="STD-Norell-1979" TYPE="STUDY">Norell 1979</LINK>; <LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK>; <LINK REF="STD-Schenker-1999" TYPE="STUDY">Schenker 1999</LINK>; <LINK REF="STD-Sheppard-2003" TYPE="STUDY">Sheppard 2003</LINK>; <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>; <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>) are compared in detail below and further details can be found in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table.</P>
<P>An update search was run in June 2012 which retrieved a further 654 records. The Trials Search Co-ordinator scanned the search results and removed 476 records which were not relevant to the scope of the review. We assessed the titles and abstracts of the remaining 178 records for potential inclusion in the review. We rejected 144 records. There were 13 reports of ongoing studies (see '<LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>' for trial details). We obtained the full text of 21 publications for further assessment. We included the following eight studies in the review: <LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK>; <LINK REF="STD-Hermann-2011a" TYPE="STUDY">Hermann 2011a</LINK>; <LINK REF="STD-Hermann-2011b" TYPE="STUDY">Hermann 2011b</LINK>; <LINK REF="STD-I_x002d_SIGHT" TYPE="STUDY">I-SIGHT</LINK>; <LINK REF="STD-Muir-2012" TYPE="STUDY">Muir 2012</LINK>; <LINK REF="STD-Nakakura-2012" TYPE="STUDY">Nakakura 2012</LINK>; <LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK>; <LINK REF="STD-Ring-2011" TYPE="STUDY">Ring 2011</LINK>. We excluded the following 13 studies: <LINK REF="STD-Gulkilik-2011" TYPE="STUDY">Gulkilik 2011</LINK>; <LINK REF="STD-Inoue-2011" TYPE="STUDY">Inoue 2011</LINK>; <LINK REF="STD-Inoue-2012" TYPE="STUDY">Inoue 2012</LINK>; <LINK REF="STD-Lorenz-2011" TYPE="STUDY">Lorenz 2011</LINK>; <LINK REF="STD-NCT00230763" TYPE="STUDY">NCT00230763</LINK>; <LINK REF="STD-NCT00262626" TYPE="STUDY">NCT00262626</LINK>; <LINK REF="STD-NCT00328835" TYPE="STUDY">NCT00328835</LINK>; <LINK REF="STD-NCT00329095" TYPE="STUDY">NCT00329095</LINK>; <LINK REF="STD-NCT00348062" TYPE="STUDY">NCT00348062</LINK>; <LINK REF="STD-NCT01415401" TYPE="STUDY">NCT01415401</LINK>; <LINK REF="STD-Rolle-2012" TYPE="STUDY">Rolle 2012</LINK>; <LINK REF="STD-Rossi-2011" TYPE="STUDY">Rossi 2011</LINK>; <LINK REF="STD-Sanchez_x002d_Pulgarin-2011" TYPE="STUDY">Sanchez-Pulgarin 2011</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-03-16 12:02:15 +0000" MODIFIED_BY="Anupa Shah">
<P>See <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for a summary and individual tables for each included trial ('<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>').</P>
<P>We attempted to contact the study authors as a number of details were missing for all included studies. Where contact was made we sent study-specific data collection forms via e-mail or post. The information below is based on a combination of published evidence and correspondence with authors. We have reviewed and analysed <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK> and <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK> as two separate studies as the results were presented separately by the study authors, although published within the same paper.</P>
<SUBSECTION>
<HEADING LEVEL="4">Study design</HEADING>
<P>There were 14 RCTs and two quasi-RCTs (<LINK REF="STD-Ring-2011" TYPE="STUDY">Ring 2011</LINK>; <LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK>). Although not specified in the published article, <LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK> conducted randomisation by rotation.</P>
<P>Five studies were cross-over studies (<LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>; <LINK REF="STD-Laster-1996" TYPE="STUDY">Laster 1996</LINK>; <LINK REF="STD-Schenker-1999" TYPE="STUDY">Schenker 1999</LINK>; <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>; <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>) and the rest were parallel-group designs.</P>
<P>There were six multi-centre studies (<LINK REF="STD-I_x002d_SIGHT" TYPE="STUDY">I-SIGHT</LINK>; <LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK>; <LINK REF="STD-Nakakura-2012" TYPE="STUDY">Nakakura 2012</LINK>; <LINK REF="STD-Schenker-1999" TYPE="STUDY">Schenker 1999</LINK>; <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>; <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>) and the rest were single-centre.</P>
<P>All the studies were conducted in industrialised countries (Belgium, Denmark, France, Greece, Iceland, Japan, Sweden, Switzerland, UK and USA) and recruited participants in outpatient clinics.</P>
<P>Four studies were commercially sponsored by Merck &amp; Co (<LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>; <LINK REF="STD-Schenker-1999" TYPE="STUDY">Schenker 1999</LINK>; <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>; <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>), one study was part-funded by Pfizer (<LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK>) and one by Alcon (<LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK>), five studies were funded or part-funded by government or charitable organisations (<LINK REF="STD-I_x002d_SIGHT" TYPE="STUDY">I-SIGHT</LINK>; <LINK REF="STD-Laster-1996" TYPE="STUDY">Laster 1996</LINK>; <LINK REF="STD-Muir-2012" TYPE="STUDY">Muir 2012</LINK>; <LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK>; <LINK REF="STD-Ring-2011" TYPE="STUDY">Ring 2011</LINK>); and six did not state funding sources or had no funding (<LINK REF="STD-Hermann-2011a" TYPE="STUDY">Hermann 2011a</LINK>; <LINK REF="STD-Hermann-2011b" TYPE="STUDY">Hermann 2011b</LINK>; <LINK REF="STD-Nakakura-2012" TYPE="STUDY">Nakakura 2012</LINK>; <LINK REF="STD-Norell-1979" TYPE="STUDY">Norell 1979</LINK>; <LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK>; <LINK REF="STD-Sheppard-2003" TYPE="STUDY">Sheppard 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>The 16 studies involved 1565 participants. The studies were relatively small: the median trial size was 74; the largest trial recruited 312 participants (<LINK REF="STD-I_x002d_SIGHT" TYPE="STUDY">I-SIGHT</LINK>); and the smallest study recruited 13 participants (<LINK REF="STD-Laster-1996" TYPE="STUDY">Laster 1996</LINK>).</P>
<P>The average age of participants included in these studies ranged from 55 to 73 (median value 66 years). The range of ages went from 18 to 91. In the 15 studies reporting gender, the proportion of women ranged from 1% to 85%, with a median value of 58%. Eleven studies reported ethnicity: the proportion of the study population who were white ranged from 9% (<LINK REF="STD-I_x002d_SIGHT" TYPE="STUDY">I-SIGHT</LINK>) to 100% (<LINK REF="STD-Hermann-2011a" TYPE="STUDY">Hermann 2011a</LINK>; <LINK REF="STD-Hermann-2011b" TYPE="STUDY">Hermann 2011b</LINK>), the proportion black ranged from 0% to 91% (<LINK REF="STD-I_x002d_SIGHT" TYPE="STUDY">I-SIGHT</LINK>) and the proportion Asian ranged from 0% (five studies) to 10% (<LINK REF="STD-Ring-2011" TYPE="STUDY">Ring 2011</LINK>). <LINK REF="STD-Nakakura-2012" TYPE="STUDY">Nakakura 2012</LINK> and <LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK> were conducted in Japan but ethnic group was not specifically reported.</P>
<P>Almost all studies included people diagnosed with OAG or OHT and prescribed ocular hypotensive eye drops. The exception was the Japanese trial (<LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK>) which recruited people diagnosed with primary angle-closure glaucoma.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>The interventions varied considerably, although there were a few common themes as categorised below. For most studies the follow-up period was categorised as short-term (less than six months). The exception to this was <LINK REF="STD-Muir-2012" TYPE="STUDY">Muir 2012</LINK> which followed up to six months and <LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK> and <LINK REF="STD-I_x002d_SIGHT" TYPE="STUDY">I-SIGHT</LINK> followed up to 12 months. <LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK> also collected some follow-up data at 24 months.</P>
<SUBSECTION>
<HEADING LEVEL="5">Education or education combined with behavioural change interventions</HEADING>
<P>There were seven studies which had employed some form of educational programme to improve adherence (<LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK>; <LINK REF="STD-I_x002d_SIGHT" TYPE="STUDY">I-SIGHT</LINK>; <LINK REF="STD-Muir-2012" TYPE="STUDY">Muir 2012</LINK>; <LINK REF="STD-Norell-1979" TYPE="STUDY">Norell 1979</LINK>; <LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK>; <LINK REF="STD-Ring-2011" TYPE="STUDY">Ring 2011</LINK>; <LINK REF="STD-Sheppard-2003" TYPE="STUDY">Sheppard 2003</LINK>).</P>
<P>In <LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK> patients were allocated to receive either individualised patient care in addition to standard care or standard care alone. Individualised patient care was provided by a glaucoma trained nurse and involved an assessment of healthcare needs and beliefs about illness and medicines (lasting approximately 45 minutes), an educational session (of approximately 20 minutes duration) and an interactive training session, to learn the technique of instilling eye drops (lasting approximately 10 minutes). Frequency and purpose of follow-up visits or telephone calls over one year was agreed with patients. It was expected that the duration of intervention activities would vary according to patient need.</P>
<P>In <LINK REF="STD-I_x002d_SIGHT" TYPE="STUDY">I-SIGHT</LINK> the intervention group was given a tailored automated telephone intervention and tailored printed materials. The telephone intervention was delivered using interactive voice recognition technology and consisted of individually tailored messages to encourage adherence. This covered taking medication, keeping appointments, obtaining refills as well as information on glaucoma. The participant received 12 telephone calls over a nine-month period. After each telephone call, written materials were sent to the participants. The control group was given usual care.</P>
<P>In <LINK REF="STD-Muir-2012" TYPE="STUDY">Muir 2012</LINK> participants received an educational intervention. This was a 20-minute individual session with the study co-ordinator (who had a background in ophthalmic research but was not a clinician). The participants watched a video about glaucoma which explained the structure of the eye and glaucoma and showed how to instil drops. The language used in the video, and other printed material, was tailored to the participants' literacy which was measured using the Test of Functional Health Literacy in Adults (<LINK REF="REF-Parker-1995" TYPE="REFERENCE">Parker 1995</LINK>). The control group received standard care as usual from an ophthalmologist.</P>
<P>
<LINK REF="STD-Norell-1979" TYPE="STUDY">Norell 1979</LINK> implemented a 30-minute education and tailoring programme using a parallel-group design which took place as part of the clinic appointment. The intervention group received basic information on glaucoma and its treatment supplied by a tape-slide show and leaflet, then patients' knowledge and understanding was checked by an ophthalmic assistant and insufficiently mastered information was re-emphasised; participants were encouraged to ask questions and discuss problems with medication. This was followed by 'tailoring' which consisted of a patient interview with an ophthalmic assistant to ascertain daily routine and to advise on best times to instil eye drops within the daily routine. Advice was also given on storage of drops. Finally, times and drop routines were written for each patient. No description was given regarding the control group apart from the fact that the participants did not receive the intervention. The intervention was implemented after the first 20 days of monitoring. Patients were then followed up for a further 20 days post intervention to evaluate the difference between the periods and the groups.</P>
<P>The intervention in <LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK> consisted of a 10-minute educational video, a structured discussion with the study co-ordinator, reminder telephone calls and a dosing aid. The educational content <I>"stressed the importance of regular drop-taking, its rationale and expected effects, alternatives to eyedrops, and methods to maximize cooperation, such as linking drops to a daily activity, keeping a drop-taking calendar diary, and using family members to help in reminding them"</I>. The discussion with the study co-ordinator aimed "<I>to develop a strategy for improving adherence that included finding the best time of day to take the medication, distributing a blank calendar diary and going over details of how to keep it, and discussing individual patient barriers to taking the medication"</I>. The telephone calls were made once per week for the first follow-up month and then every other week for the next two months and included a questionnaire <I>"about drop-taking behavior, difficulty with drops, side effects, and eliciting questions about therapy"</I> and the dosing aid had audible and visible alarms. The control group were told it was important to take drops as prescribed.</P>
<P>In <LINK REF="STD-Ring-2011" TYPE="STUDY">Ring 2011</LINK> the intervention group watched a <I>"specifically designed patient education film"</I> and received standard written educational material. The control group received standard written educational material alone. Patients were followed up three months later to evaluate the difference in outcomes between the two groups.</P>
<P>
<LINK REF="STD-Sheppard-2003" TYPE="STUDY">Sheppard 2003</LINK> evaluated the effectiveness of a glaucoma monitoring nurse-led clinic using a parallel-group design, involving consultations of 15 minutes duration divided into two parts. Part one consisted of a standard assessment designed to monitor and record health details, such as current health status and recent ocular history and eye examinations including visual acuity, visual field test and IOP test using Goldmann's applanation tonometry. Part two comprised of a semi-structured educational session tailored to individual patient needs (details not provided). The control group attended a general ophthalmic clinic involving consultations of 10 minutes duration which included the standard assessment and eye examinations as above, a fundus examination and the remainder of time utilised according to each individual clinician (details not provided). Differences in patient outcomes were followed up at 12 weeks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Reminder devices</HEADING>
<P>
<LINK REF="STD-Laster-1996" TYPE="STUDY">Laster 1996</LINK> monitored participants using a medication alarm (the Prescript TimeCap) reminder device which comprised of a cap fitted onto a pre-weighed drop bottle. This device comprised of:</P>
<UL>
<LI>a digital display that showed the time and day of the week when the container was last opened (the display reminded the patient when the most recent dose of medication was taken);</LI>
<LI>an alarm that beeped when a dose was due and if the beep was ignored the digital face flashed to provide a visual reminder that a dose had been missed.</LI>
</UL>
<P>Patients undergoing the control period used a pre-weighed drop bottle without the TimeCap. As this was a cross-over study each patient acted as their own control. Patients were monitored for two periods of 30 days.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Drug comparisons</HEADING>
<P>Drug studies that compared ocular hypotensive therapy met the inclusion criteria if the dosage frequencies differed and adherence was compared between the two frequencies</P>
<UL>
<LI>
<LINK REF="STD-Hermann-2011a" TYPE="STUDY">Hermann 2011a</LINK> compared brimonidine twice daily with brimonidine three times daily over four weeks with open and masked monitoring of adherence.</LI>
<LI>
<LINK REF="STD-Hermann-2011b" TYPE="STUDY">Hermann 2011b</LINK> compared brimonidine twice daily with brimonidine three times daily over four weeks.</LI>
<LI>
<LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK> compared 2% dorzolamide three times daily with 2% pilocarpine four times daily using a cross-over design. Both groups continued to receive 0.5 timolol twice daily. Patients were monitored for two periods of 14 days.</LI>
<LI>
<LINK REF="STD-Nakakura-2012" TYPE="STUDY">Nakakura 2012</LINK> compared latanoprost 0.005%/timolol 0.5% plus brinzolamide 1% with dorzolamide 1%/timolol 0.5% plus latanoprost 0.005%.</LI>
<LI>
<LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK> compared latanoprost mono-therapy once daily with multi-therapy of 0.5% timolol twice daily and 1% dorzolamide three times daily using a parallel-group design. Participants were monitored for 12 weeks.</LI>
<LI>
<LINK REF="STD-Schenker-1999" TYPE="STUDY">Schenker 1999</LINK> compared 0.5% timolol gel once daily with 0.5% timolol solution twice daily using a cross-over design; patients were monitored for two periods of six weeks.</LI>
<LI>
<LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK> and <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK> compared 2% dorzolamide/0.5% timolol combination therapy twice daily with 2% pilocarpine four times daily and 0.5% timolol twice daily using a cross-over design. Participants were monitored for two periods of 14 days.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Adherence</HEADING>
<P>All studies measured adherence. There were four main ways of measuring adherence: by self report, by electronic monitoring, prescription refills or weighing bottles.</P>
<P>Data on adherence were collected via self report in 10 studies (<LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK>; <LINK REF="STD-I_x002d_SIGHT" TYPE="STUDY">I-SIGHT</LINK>; <LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>; <LINK REF="STD-Laster-1996" TYPE="STUDY">Laster 1996</LINK>; <LINK REF="STD-Nakakura-2012" TYPE="STUDY">Nakakura 2012</LINK>; <LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK>; <LINK REF="STD-Schenker-1999" TYPE="STUDY">Schenker 1999</LINK>; <LINK REF="STD-Sheppard-2003" TYPE="STUDY">Sheppard 2003</LINK>; <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>; <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>). Questionnaires were administered via an interviewer and were delivered at baseline in four studies (<LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>; <LINK REF="STD-Sheppard-2003" TYPE="STUDY">Sheppard 2003</LINK>; <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>; <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>) and on the last day of each cross-over period for the cross-over studies (<LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>; <LINK REF="STD-Laster-1996" TYPE="STUDY">Laster 1996</LINK>; <LINK REF="STD-Schenker-1999" TYPE="STUDY">Schenker 1999</LINK>; <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>; <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>). The remainder assessed at the end of the study period.</P>
<P>Three studies used the Comparison of Ophthalmic Medications for Tolerability (COMTol) questionnaire (<LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>; <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>; <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>) which aims to measure common side effects of ocular hypertensive therapy and the extent to which these side effects affect health-related quality of life, compliance and patient satisfaction (<LINK REF="REF-Barber-1997" TYPE="REFERENCE">Barber 1997</LINK>). The questionnaire includes one adherence question: <I>"How often did you miss one or more drops</I>?" Patients were asked to mark on a scale from 0 to 6; 0 = never and 6 = always.</P>
<P>
<LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK> measured adherence based on the Reported Adherence to Medication Scale (<LINK REF="REF-Horne-1999" TYPE="REFERENCE">Horne 1999</LINK>) using the following questions.</P>
<OL>
<LI>
<I>"Some people say that it is easy to forget drops.  Do you agree or disagree with the following statement: I sometimes forget to use my drops&#8221;</I>
</LI>
<LI>
<I>"How often do you forget drops?&#8221;</I>
</LI>
<LI>
<I>"Some people miss drops out, stop taking them for a while or adjust the times to suit their needs.  Do you agree or disagree with the following statement: I sometimes miss out drops or alter the times to suit my own needs&#8221;. </I>
</LI>
<LI>
<I>&#8220;How often do you miss/stop using drops or adjust the times to suit your own needs?&#8221;  </I>
</LI>
</OL>
<P>Patients were then asked to approximate how many drops they missed per month. Answers were scored using an ordinal scale of none, 1 to 3, 4 to 6 and 7 or more. Patients were also asked what the longest period without administering drops was and what caused them to omit doses. These questions were entered as free text.</P>
<P>
<LINK REF="STD-I_x002d_SIGHT" TYPE="STUDY">I-SIGHT</LINK> defined non-adherence as self report of missing doses of any glaucoma medication within one month of the interview. They also asked about missed doses within seven days and two weeks.</P>
<P>
<LINK REF="STD-Laster-1996" TYPE="STUDY">Laster 1996</LINK> asked patients to report the percentage of time (0% to 100%) they adhered to their eye drop therapy for each of the two 30-day phases studied.</P>
<P>
<LINK REF="STD-Nakakura-2012" TYPE="STUDY">Nakakura 2012</LINK> asked the following question: <I>"How often do you forget administration per week?" </I>(never/within two times per week/more than three times per week).</P>
<P>
<LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK> asked patients how many times they had forgotten to apply the eye drops, and responses were classified into four groups: less than once a week, once a week, two or three times a week, and four or more times a week.</P>
<P>
<LINK REF="STD-Schenker-1999" TYPE="STUDY">Schenker 1999</LINK> measured adherence using the following question: <I>"During the last two weeks, how often did you miss one or more doses of test medication"</I> with the answer classified as never/rarely/occasionally/frequently/always</P>
<P>
<LINK REF="STD-Sheppard-2003" TYPE="STUDY">Sheppard 2003</LINK> conducted structured telephone interviews. Adherence was measured using an 11-point response scale (0 = never uses drops, 10 = always uses drops) but did not state over what time period. Participants were also asked if they encountered problems instilling drops and the reasons for not instilling drops.</P>
<P>Adherence was measured by electronic monitoring in four studies:</P>
<UL>
<LI>
<LINK REF="STD-Hermann-2011a" TYPE="STUDY">Hermann 2011a</LINK> and <LINK REF="STD-Hermann-2011b" TYPE="STUDY">Hermann 2011b</LINK> used an electronic monitoring device that was reported to detect eye drop usage with a sensitivity of 99% and specificity of 98% (confidence interval not given) (<LINK REF="REF-Hermann-2006" TYPE="REFERENCE">Hermann 2006</LINK>). In <LINK REF="STD-Hermann-2011a" TYPE="STUDY">Hermann 2011a</LINK> patients were randomised to either a group which were aware or not aware of adherence monitoring to test whether masking this information has an effect on adherence whereas in <LINK REF="STD-Hermann-2011b" TYPE="STUDY">Hermann 2011b</LINK> no patients were told that their adherence was being monitored.</LI>
<LI>
<LINK REF="STD-Norell-1979" TYPE="STUDY">Norell 1979</LINK> used a medication monitor. The monitor consisted of a plastic box with a holder for a 25 ml bottle. The holder was designed to protect the bottle and to facilitate replacement of the eye dropper cap. An elastic flap linked to a micro switch inside the box signalled to the electronic part of the monitor whether the cap was on or off. A sliding lid in the bottom of the monitor could be removed to exchange the bottle and battery but it was sealed when the monitor was given to the patients. The electronic system recorded information on whether or not the bottle had been opened during the last hour. When the monitor was connected to a separate read-out device, this information, together with the time signal was displayed on an electrocardiographic recorder. Patients were not told the purpose of the medication monitor until after data collection was complete.</LI>
<LI>
<LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK> used a dosing aid that recorded the time and date of delivery on an internal, battery-operated chip and had been previously evaluated to have acceptable accuracy (<LINK REF="REF-Friedman-2007" TYPE="REFERENCE">Friedman 2007</LINK>). Patients were aware that the devices recorded their drop-taking.</LI>
</UL>
<P>
<LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK> measured prescription refill and used this to measure adherence. It was not stated whether patients were aware of being monitored for prescription refill adherence. <LINK REF="STD-I_x002d_SIGHT" TYPE="STUDY">I-SIGHT</LINK> defined refill non-adherence as <I>"failure to refill any glaucoma medication prescription within a 1-month period after it was prescribed"</I> as indicated in pharmacy records, or as a physician note on refill non-adherence. No information was provided on whether patients knew for what reason prescription data was to be collected. <LINK REF="STD-Muir-2012" TYPE="STUDY">Muir 2012</LINK> reviewed pharmacy records and determined the <I>"number of days without medication"</I> which was defined as<I> "the difference between the number of days that medication was available to the subject according to the pharmacy records and the prescribed dosing and the number of days that medication was required over the study period"</I>. Again, no information is provided on whether patients knew for what reason prescription data were to be collected.</P>
<P>Two studies weighed the eye drop bottle to measure adherence. <LINK REF="STD-Ring-2011" TYPE="STUDY">Ring 2011</LINK> measured adherence by weighing bottles<B>. </B>The<B> </B>weight of eye drop bottle was taken before and after the study period and the target weight as per prescription was compared to actual weight afterwards. <LINK REF="STD-Laster-1996" TYPE="STUDY">Laster 1996</LINK> weighed each bottle before the intervention and weighed it again on return so the amount of medication could be calculated. It is unclear in either study whether patients were told that bottles would be weighed to calculate adherence to eye drop therapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Persistence</HEADING>
<P>In <LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK> patients who discontinued therapy and did not restart during the study period were defined as not being persistent. <LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>; <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK> and <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK> reported the numbers of patients who continued or completed treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Intraocular pressure</HEADING>
<P>Only a few studies declared how they measured IOP. Those that did reported they used Goldman's Applanation Tonometer. For <LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK> measurements were taken from the medical records of patients at 12 months immediately after the follow-up period and then at 24 months. In <LINK REF="STD-Nakakura-2012" TYPE="STUDY">Nakakura 2012</LINK> an experienced ophthalmologist measured IOP at baseline, four weeks and 12 weeks. <LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK> provided little information other than reporting that intraocular pressure was measured before and after the intervention. Measurements were taken at each visit between 10am and noon prior to washout, at baseline and at four-week intervals for <LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK>. For <LINK REF="STD-Schenker-1999" TYPE="STUDY">Schenker 1999</LINK> they were taken immediately before instillation (trough/0 hour), and two hours after instillation (peak) of morning medication at three-week intervals. Measurements were taken at trough and peak at baseline and the beginning and end of each cross-over period for <LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>, <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK> and <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Visual field defects</HEADING>
<P>Four studies assessed for visual field defects (<LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>; <LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK>; <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>; <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>) using the Humphrey Field Analyser, except in <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK> where some sites used an Octopus perimeter. All tested at baseline and at the end of the treatment period.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life measures</HEADING>
<P>Three studies (<LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>; <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>; <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>) measured the effect of eye drops on quality of life as part of the COMTol questionnaire (<LINK REF="REF-Barber-1997" TYPE="REFERENCE">Barber 1997</LINK>). Patients were asked whether their quality of life was interfered with by side effects and activity limitations. Responses were marked on a scale of 0 to 5; 0 = not at all, 5 = extremely. This was measured at baseline and after each treatment period.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Only the drug comparison studies reported adverse events. In the three studies using the ComTol questionnaire <I>(</I>
<LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>; <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>; <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>) participants were asked about ocular symptoms (burning/stinging; red, itchy, dry eyes; discharge; swelling; tearing), taste (bitter/unusual), vision (blurred vision, dimming of vision, trouble seeing at night), accommodation (trouble reading, trouble focusing near-to-far) and brow ache. Participants were asked how frequently any of the above symptoms occurred on a scale of 0 to 6 (0 = never, 6 = always) and how bothersome the symptoms were also on a scale of 0 to 6 (0 = not bothered, 6 = extremely bothered). In addition, headache was reported by participants in both studies. <LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK> did not specify the questions asked to determine adverse events, yet reported that the following ocular adverse effects were observed: mild irritation, conjunctival hyperaemia, superficial punctate keratitis and eye lid pigmentation. The authors also reported the systemic adverse events of bradycardia and orthostatic hypertension. <LINK REF="STD-Schenker-1999" TYPE="STUDY">Schenker 1999</LINK> also did not specify the questions asked, yet reported the following symptoms: upper respiratory infection, blurred vision, eye burning/stinging, headache, conjunctival injection and eye itching. <LINK REF="STD-Nakakura-2012" TYPE="STUDY">Nakakura 2012</LINK> asked about stinging/burning, foreign body administration, blurred vision, conjunctival hyperaemia and "comfortableness". Conjunctival hyperaemia and superficial punctate keratopathy were also assessed clinically.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Patients' knowledge of glaucoma</HEADING>
<P>Four studies measured patients' knowledge or understanding of glaucoma (<LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK>; <LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK>; <LINK REF="STD-Ring-2011" TYPE="STUDY">Ring 2011</LINK>; <LINK REF="STD-Sheppard-2003" TYPE="STUDY">Sheppard 2003</LINK>). Three of the studies used different measures. <LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK> compared patients' knowledge of glaucoma between the intervention group and control group administering a questionnaire (the Revised Glaucoma Adherence Questionnaire, GAQ-R, <LINK REF="REF-Gray-2010" TYPE="REFERENCE">Gray 2010</LINK>) by interview at the end of the 12-month follow-up period. <LINK REF="STD-Ring-2011" TYPE="STUDY">Ring 2011</LINK> asked 10 questions on patients' knowledge of glaucoma (<LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK>) at baseline and three months after the intervention. <LINK REF="STD-Sheppard-2003" TYPE="STUDY">Sheppard 2003</LINK> assessed patients' understanding of glaucoma by two questions: <I>"What is glaucoma?"</I> and <I>"How does glaucoma affect the eye?"</I> using a multiple choice format before and after the intervention. No information was provided in <LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK> about how knowledge of glaucoma was measured. <LINK REF="STD-Muir-2012" TYPE="STUDY">Muir 2012</LINK> stated that they collected data on <I>"self-reported disease knowledge"</I> but did not report this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Costs</HEADING>
<P>None of the studies reported the costs of the interventions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other outcomes</HEADING>
<P>
<LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK> measured other outcomes including patients' perception of glaucoma as an illness, the Revised Illness Perception Questionnaire, their beliefs about glaucoma (<LINK REF="REF-Moss_x002d_Morris-2002" TYPE="REFERENCE">Moss-Morris 2002</LINK>), Beliefs about Medicines Questionnaire (<LINK REF="REF-Horne-1999" TYPE="REFERENCE">Horne 1999</LINK>) and patients' satisfaction with quality of care, the Patient Enablement Instrument (<LINK REF="REF-Howie-1998" TYPE="REFERENCE">Howie 1998</LINK>). <LINK REF="STD-I_x002d_SIGHT" TYPE="STUDY">I-SIGHT</LINK> assessed patients as non-adherent to appointments if physicians had made a record as such in notes or if there were no rescheduling of appointment within three months.</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Reasons for excluding studies are presented in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table. The majority of studies were not randomised trials and those that were did not measure adherence. These were mainly drug trials. One drug trial (<LINK REF="STD-Shibuya-2003" TYPE="STUDY">Shibuya 2003</LINK>) did measure adherence, however, the two ocular hypotensive therapies being compared were instilled via the same frequency ('once a day') and, therefore, we could not include this study. The authors of this study did not find a significant difference in adherence between the two ophthalmic solutions. We contacted authors of five studies for more information before a decision regarding eligibility could be made. A French study (<LINK REF="STD-Bron-2004" TYPE="STUDY">Bron 2004</LINK>) did question patients about their adherence level but did not publish the results. When asked for the results the authors stated that, <I>"such an evaluation is unreliable"</I>. Very little information was available regarding a study by <LINK REF="STD-Hunter-1999" TYPE="STUDY">Hunter 1999</LINK>, found via the UK National Research Register. As there was no published paper and we were unsuccessful in contacting the author, we could not proceed further with this study.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-03-16 11:52:39 +0000" MODIFIED_BY="Anupa Shah">
<P>Details of 'Risk of bias' assessments for individual trials are presented in the 'Risk of bias' tables and figures (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<ALLOCATION MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Within the published papers, information was sparse concerning sequence and allocation concealment. Only a minority of studies reported adequate methods of sequence generation (<LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK>; <LINK REF="STD-Hermann-2011a" TYPE="STUDY">Hermann 2011a</LINK>; <LINK REF="STD-Hermann-2011b" TYPE="STUDY">Hermann 2011b</LINK>; <LINK REF="STD-I_x002d_SIGHT" TYPE="STUDY">I-SIGHT</LINK>; <LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK>; <LINK REF="STD-Sheppard-2003" TYPE="STUDY">Sheppard 2003</LINK>) and only <LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK>, <LINK REF="STD-Hermann-2011b" TYPE="STUDY">Hermann 2011b</LINK> and <LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK> reported adequate methods to conceal allocation prior to assignment. Following contact with authors, we were able to judge more accurately for some studies. A further five studies (<LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>; <LINK REF="STD-Laster-1996" TYPE="STUDY">Laster 1996</LINK>; <LINK REF="STD-Schenker-1999" TYPE="STUDY">Schenker 1999</LINK>; <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>; <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>) described adequate sequence generation, either by using a computer-generated system or by drawing lots. We judged one quasi-randomised study (<LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK>) as high risk for using a rotation method, one trial (<LINK REF="STD-Norell-1979" TYPE="STUDY">Norell 1979</LINK>) as unclear, for not providing adequate information, and <LINK REF="STD-Ring-2011" TYPE="STUDY">Ring 2011</LINK> ran the educational film on random days, rather than randomly allocating participants.</P>
<P>Six studies concealed allocations adequately until assignment using sealed opaque envelopes (<LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK>; <LINK REF="STD-Hermann-2011b" TYPE="STUDY">Hermann 2011b</LINK>, <LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>;<LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK>; <LINK REF="STD-Schenker-1999" TYPE="STUDY">Schenker 1999</LINK>; <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>; <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>). We graded three studies as high risk (<LINK REF="STD-Laster-1996" TYPE="STUDY">Laster 1996</LINK>; <LINK REF="STD-Ring-2011" TYPE="STUDY">Ring 2011</LINK>; <LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK>) for not concealing allocations and the rest were unclear (<LINK REF="STD-Hermann-2011a" TYPE="STUDY">Hermann 2011a</LINK>; <LINK REF="STD-Norell-1979" TYPE="STUDY">Norell 1979</LINK>; <LINK REF="STD-Sheppard-2003" TYPE="STUDY">Sheppard 2003</LINK>), as we could not obtain adequate information.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-03-16 11:52:39 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed masking according to those involved, e.g. the participants, study personnel involved in data collection such as interviewers and outcome assessors involved in data analysis. Much of the information regarding masking was obtained through contacting authors rather than the published evidence. Due to the nature of the included studies it was particularly difficult to mask participants. It could be argued that for drug trials, placebo drops could be used so that the frequency of instillation was the same for both groups, but since the hypothesis is that adherence may be related to the frequency of drop instillation this would be counterproductive.</P>
<P>For the studies involving interventions such as education, individualised care planning and reminder devices, 'performance bias' is an integral part of the intervention so we did not grade these studies for this parameter.</P>
<P>With respect to detection bias, <LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK>, <LINK REF="STD-Hermann-2011a" TYPE="STUDY">Hermann 2011a</LINK>, <LINK REF="STD-Hermann-2011b" TYPE="STUDY">Hermann 2011b</LINK>, <LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>, <LINK REF="STD-Norell-1979" TYPE="STUDY">Norell 1979</LINK>, <LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK>, <LINK REF="STD-Schenker-1999" TYPE="STUDY">Schenker 1999</LINK>, <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK> and <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK> reported that their studies were observer-masked or used techniques such as electronic monitoring where masking was not relevant. The remaining studies did not state any masking details which made judgements difficult. We judged four studies as high risk for detection bias; three (<LINK REF="STD-Laster-1996" TYPE="STUDY">Laster 1996</LINK>; <LINK REF="STD-Nakakura-2012" TYPE="STUDY">Nakakura 2012</LINK>; <LINK REF="STD-Ring-2011" TYPE="STUDY">Ring 2011</LINK>) had no masking procedures in place and the other (<LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK>) masked the interviewer but not the outcome assessor. We classified <LINK REF="STD-Sheppard-2003" TYPE="STUDY">Sheppard 2003</LINK> as unclear.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>We judged five studies as low risk for incomplete outcome data; for either having no missing data or adequately addressing missing outcome data, with attrition rates of less than 20% (<LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK>; <LINK REF="STD-Hermann-2011a" TYPE="STUDY">Hermann 2011a</LINK>; <LINK REF="STD-I_x002d_SIGHT" TYPE="STUDY">I-SIGHT</LINK>; <LINK REF="STD-Nakakura-2012" TYPE="STUDY">Nakakura 2012</LINK>; <LINK REF="STD-Norell-1979" TYPE="STUDY">Norell 1979</LINK>). We judged two studies as high risk (<LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>; <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>). For <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK> and <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>, the attrition rates were unclear from the paper and no further clarification was provided by study authors. The number of participants excluded from analyses varied across outcomes. The European study (<LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>) suffered the greatest number of exclusions (22/93 (24%)) for the quality of life data. The numbers of participants involved in intraocular pressure and visual field analyses were unavailable for this study and, therefore, may also have exceeded 20%. In the remaining studies it was difficult to judge the impact of missing data and we graded these as unclear.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray">
<P>As we did not have access to study protocols we could not judge studies as low or high risk of bias for this aspect. We marked all studies as unclear for selective reporting due to insufficient evidence, with the exception of <LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK> where it was clear from the report that all outcomes were reported.</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-02-06 13:54:37 +0000" MODIFIED_BY="Anupa Shah">
<P>We did not perform a meta-analysis because there was clinical heterogeneity with respect to the interventions, and methodological heterogeneity with respect to the measurement of outcomes.</P>
<SUBSECTION>
<HEADING LEVEL="3">Adherence</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Patient education or patient education combined with other behavioural change interventions</HEADING>
<P>
<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> summarises the effect of patient education or patient education combined with other behavioural change interventions on adherence to ocular hypotensive therapy.</P>
<P>
<LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK>, <LINK REF="STD-Norell-1979" TYPE="STUDY">Norell 1979</LINK> and <LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK> reported that adherence changed significantly with education and other behavioural change interventions. In <LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK> the proportion of people who were classified as adherent during the one-year follow-up was 70% in the intervention group compared to 43% in the control group. In <LINK REF="STD-Norell-1979" TYPE="STUDY">Norell 1979</LINK> 13% of the time patients exceeded eight-hour dose intervals in the intervention group compared to 24% in the control group during a 20-day period. In <LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK> there was a higher adherence rate in the intervention group over three months (0.73) compared to the control group (0.51). All these differences were clinically and statistically significant.</P>
<P>
<LINK REF="STD-I_x002d_SIGHT" TYPE="STUDY">I-SIGHT</LINK>, <LINK REF="STD-Muir-2012" TYPE="STUDY">Muir 2012</LINK>, <LINK REF="STD-Ring-2011" TYPE="STUDY">Ring 2011</LINK> and <LINK REF="STD-Sheppard-2003" TYPE="STUDY">Sheppard 2003</LINK> did not find any statistical differences between the intervention and control. In <LINK REF="STD-I_x002d_SIGHT" TYPE="STUDY">I-SIGHT</LINK> 30% of the intervention group and 27% of the control group did not report missing drops in the last month. In <LINK REF="STD-Muir-2012" TYPE="STUDY">Muir 2012</LINK> the intervention group had, on average, 63 days without medication compared to 65 in the control group over six months. In <LINK REF="STD-Ring-2011" TYPE="STUDY">Ring 2011</LINK> adherence as defined in the study (eye drop bottles within 10% of target weight) was similar between intervention and control groups. In <LINK REF="STD-Sheppard-2003" TYPE="STUDY">Sheppard 2003</LINK> it was difficult to judge as no data were presented to support the statement that there were no differences between intervention and control groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Reminder devices</HEADING>
<P>
<LINK REF="STD-Laster-1996" TYPE="STUDY">Laster 1996</LINK> was a cross-over study that reported data without providing information on the cross-over periods. Out of 13 participants, five people reported being adherent (100% compliance over 30 days) when using the TimeCap reminder device, one participant reported being adherent when not using the TimeCap device and seven were not adherent irrespective of whether using the device or not. It is difficult to interpret these data without knowing more information as to the time periods when the data were collected. <LINK REF="STD-Laster-1996" TYPE="STUDY">Laster 1996</LINK> also reported that people using the TimeCap instilled approximately 3 grams more (mean difference (MD) 2.87, 95% confidence interval (CI) 1.70 to 4.03, P &lt; 0.001) of eye drops over a 30-day period than those without.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison of different drug regimens</HEADING>
<P>
<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> summarises the effect of drug regimen on adherence. The 'simpler' dosing regimen is classified as the intervention in this table. The specific dosing regimens are summarised in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>Two studies measured adherence using an electronic monitoring device (<LINK REF="STD-Hermann-2011a" TYPE="STUDY">Hermann 2011a</LINK>; <LINK REF="STD-Hermann-2011b" TYPE="STUDY">Hermann 2011b</LINK>) and the other six studies measured adherence using self report.</P>
<P>The table shows that in all eight studies the simpler dosing regimen was associated with greater adherence, although these differences were not always statistically significant, There were some uncertainties as to the analysis of the cross-over studies because in all cases they reported data for both periods combined. In addition, in most studies there were also differences in the type of drug used which may mean that drawing conclusions as to the association between adherence and simpler drug regimens may be too simplistic.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Monitoring</HEADING>
<P>
<LINK REF="STD-Hermann-2011a" TYPE="STUDY">Hermann 2011a</LINK> compared open and masked monitoring and measured adherence using an electronic monitor. They found little effect of type of monitoring on adherence (see table 3 of trial report on page e303). The adherence rate in people taking brimonidine twice daily was 69.5% (standard deviation (SD) 17%) in people who were informed that they were being monitored compared to 77.1% (SD 6.0%) in people who did not know that they were being monitored. In people taking brimonidine three times daily the open monitoring group had an adherence rate of 65.3% (SD 14%) compared to people in the masked monitoring group who had an adherence rate of 62.4% (SD 9.1%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Persistence</HEADING>
<P>There were fewer data reported on persistence.</P>
<SUBSECTION>
<HEADING LEVEL="4">Patient education or patient education combined with other behavioural change interventions</HEADING>
<P>In <LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK> persistence was defined when patients who discontinued therapy did not restart during the study period. Overall there were 17/127 patients who did not persist. In the intervention group 59/64 persisted compared to 51/63 in the standard care group (risk ratio 1.14, 95% CI 0.99 to 1.31).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison of different drug regimens</HEADING>
<P>In <LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK> 72/75 (96.0%) patients continued with the simpler regimen (dorzolamide three times daily) and 51/74 (68.9%) continued with the more complicated regimen (pilocarpine four times daily). However, these data represent the two periods of this cross-over study combined - in fact 75 patients in total were recruited into the study but no information on persistence in the different time periods was reported.</P>
<P>
<LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK> did not find much difference between two groups; 87/92 (94.6) completed treatment with the simpler regimen (combination treatment with dorzolamide/timolol) compared to 84/91 (92.3%) who completed treatment with the more complex regimen. Again the cross-over design has been ignored in this analysis. In the US study (<LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>) the results were different: 90/93 (96.8%) completed treatment with the simpler combination regimen compared to 60/95 (63.2%) with the more complex regimen.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intraocular pressure</HEADING>
<P>Intraocular pressure was found to be significantly reduced in only one of the four studies that measured this outcome (<LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK>). They found a mean difference of -2.30 (95% CI -3.85 to -0.75, P = 0.004). This difference is likely to be independent of the adherence results as there was no difference in adherence between the two groups as reported above. There was no difference in intraocular pressure for three studies. <LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK> measured at peak at the end of each study period (MD 0.10, 95% CI -0.43 to 0.63, P = 0.71) and <LINK REF="STD-Schenker-1999" TYPE="STUDY">Schenker 1999</LINK> also measured at peak at the end of each study period (MD -0.10, 95% CI -0.79 to 0.59, P = 0.78). Although both studies measured intraocular pressure at several intervals, we have reported the peak measurement as this result was presented by both studies. We could not analyse intraocular pressure for the remaining two studies (<LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>; <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>), as the number of participants involved was not stated in the paper and the authors could not provide these data when contacted. According to the published results, however, a significant difference was not found between treatment groups in both studies.</P>
<P>Of the new studies included in the current update, <LINK REF="STD-Hermann-2011a" TYPE="STUDY">Hermann 2011a</LINK> reported baseline intraocular pressure only and <LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK> found no difference in intraocular pressure between the two groups at 12 months and 24 months, but there was some suggestion of decreased "fluctuation" in the intervention group at over 24 months (Table 4). <LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK> found no difference between the intervention groups with respect to intraocular pressure but did not report the actual data. They also did not find any association between adherence rate and intraocular pressure. <LINK REF="STD-Nakakura-2012" TYPE="STUDY">Nakakura 2012</LINK> found very similar intraocular pressure in both groups (14.1 mmHg (SD 2.7) versus 14.2 mmHg (SD 2.7).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Visual field defects</HEADING>
<P>We could only analyse the results of one study (<LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK>) for visual field defects, and we did not find a significant difference between the two groups (MD 0.90, 95% CI -3.85 to 2.05, P = 0.55). We could not analyse the results for <LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK> as paired data were not presented and for <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK> and <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK> due to missing data (as above, we could not obtain data for the number of participants involved in visual field testing). The study authors for all three studies did not find a significant difference for emerging or worsening of defects. None of the new studies included in this 2012 update (<LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK>; <LINK REF="STD-Hermann-2011a" TYPE="STUDY">Hermann 2011a</LINK>; <LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK>; <LINK REF="STD-Ring-2011" TYPE="STUDY">Ring 2011</LINK>) reported visual field defects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>Quality of life was analysed in three studies via the self report COMTol tool (<LINK REF="REF-Barber-1997" TYPE="REFERENCE">Barber 1997</LINK>). Side effects for patients prescribed pilocarpine drops alone or pilocarpine plus timolol drops interfered with quality of life; both of these regimes required drops to be instilled four times a day (<LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>: MD -1.60, 95% CI -2.04 to -1.16, P &lt; 0.001; <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK> and <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>: MD 1.10, 95% CI -1.35 to -0.85, P &lt; 0.001, I<SUP>2 </SUP>= 60%). There were also more reported activity limitations when the frequency of drop instillation increased (<LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>: MD -1.60, 95% CI -2.04 to -1.16, P &lt; 0.001; <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK> and <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>: MD -0.72, 95% CI -0.97 to -0.47, P &lt; 0.001, I<SUP>2 </SUP>= 92%). Patients instilling drops less frequently, dorzolamide three times a day (<LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>) or dorzolamide/timolol combination drops (<LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>; <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>) twice a day, reported significantly less interference to their quality of life by side effects or activity limitations.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Patient knowledge</HEADING>
<P>
<LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK> found that patients who received education combined with an individualised package had better knowledge of glaucoma and its treatment compared to those who received standard care. The median knowledge score (<LINK REF="REF-Gray-2010" TYPE="REFERENCE">Gray 2010</LINK>) was 14 (range 2 to 18) for the intervention group and 6 (range 0 to 17) for the control group (Mann&#8211;Whitney P &lt; 0.001).</P>
<P>Data on patient knowledge were provided by <LINK REF="STD-Ring-2011" TYPE="STUDY">Ring 2011</LINK>. For two out of the 10 questions, the control group showed greater improvement in knowledge over the three-month period (i.e. answered questions correctly). However, for most questions the differences between intervention and control groups three months after the intervention were not statistically significant.</P>
<P>
<LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK> and <LINK REF="STD-Sheppard-2003" TYPE="STUDY">Sheppard 2003</LINK> reported no differences between intervention and control groups with respect to patient knowledge, but <LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK> did not report the actual data. <LINK REF="STD-Muir-2012" TYPE="STUDY">Muir 2012</LINK> collected but did not report data on patient knowledge.</P>
<SUBSECTION>
<HEADING LEVEL="4">Costs</HEADING>
<P>No data were reported on the cost of the interventions.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-03-16 11:56:50 +0000" MODIFIED_BY="Anupa Shah">
<SUMMARY_OF_RESULTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>There was some evidence that patient education combined with other more complex behavioural change interventions improved adherence to ocular hypotensive therapy (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>), however overall the findings were not conclusive. The studies were variable quality; some studies were at considerable risk of bias, and in general the length of follow-up was short, i.e. less than six months. Only three studies followed up for six months or more.</P>
<P>It was not possible to combine the results of different studies due to differences in reporting outcomes. In three studies, people who received patient education combined with other more complex behavioural change interventions to improve adherence to eye drops were more likely to take their medication as prescribed. However, in four studies no effect was observed. The intervention was more complex and individually tailored in the studies that showed an effect. There was less information on other outcomes such as persistence and intraocular pressure, and no information on visual field defects and quality of life.</P>
<P>There was weak evidence as to whether people on simpler drug regimens were more likely to adhere and persist with their ocular hypotensive therapy (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). Again studies were of variable quality and short-term. A particular problem was the interpretation of cross-over studies which in general were not reported correctly.</P>
<P>One study investigated a reminder device and monitoring. However, this study was small and inconclusive.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-03-16 11:56:50 +0000" MODIFIED_BY="Anupa Shah">
<SUBSECTION>
<HEADING LEVEL="3">Follow-up and duration of intervention</HEADING>
<P>Follow-up of patient outcome in the studies which incorporated an educational intervention ranged from 20 days to one year (24 months for a few outcomes) with the most being around three months. <LINK REF="REF-Reardon-2011" TYPE="REFERENCE">Reardon 2011</LINK> found that persistence significantly diminishes at the end of the first year for patients newly prescribed ocular hypotensive therapy. Arguably, a longer follow-up period would be most efficacious in understanding the long-term effects of these types of interventions. Similarly, the reminder device (<LINK REF="STD-Laster-1996" TYPE="STUDY">Laster 1996</LINK>) was tested for only two periods of 30 days. Monitoring for a longer period of time may have given a more accurate picture of the device's true effect and may have produced a different result.</P>
<P>Some of the interventions focusing on education were of extremely short duration. One (<LINK REF="STD-Norell-1979" TYPE="STUDY">Norell 1979</LINK>) lasted 30 minutes and the other (<LINK REF="STD-Sheppard-2003" TYPE="STUDY">Sheppard 2003</LINK>) 15 minutes. In <LINK REF="STD-Ring-2011" TYPE="STUDY">Ring 2011</LINK> intervention lasted for as long as the video (not specified). More recent studies have designed interventions which have lasted for longer periods, incorporating long-term support: <LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK> provided reminders for up to three months, <LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK> provided nursing support for up to one year and <LINK REF="STD-I_x002d_SIGHT" TYPE="STUDY">I-SIGHT</LINK> provided advice and reminders via an automated tailored health communication over nine months. More and better designed studies are required in order to understand the effectiveness of short versus long-term interventions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">'Hawthorne effect'</HEADING>
<P>For <LINK REF="STD-Sheppard-2003" TYPE="STUDY">Sheppard 2003</LINK>, a significant difference was not found between the groups. When scores were compared to baseline results, however, both groups were found to have significant improvement in adherence levels. This result potentially masks the true effect of the intervention and may reflect the 'study effect' often termed the 'Hawthorne effect' (<LINK REF="REF-Leonard-2006" TYPE="REFERENCE">Leonard 2006</LINK>; <LINK REF="REF-Leonard-2008" TYPE="REFERENCE">Leonard 2008</LINK>; <LINK REF="REF-Mangione_x002d_Smith-2002" TYPE="REFERENCE">Mangione-Smith 2002</LINK>). Both groups may have changed behaviour as a result of being involved in a research study due to the additional attention received. Specific details for care received by the control group were limited for this study; the authors stated that, <I>"time was utilised according to each individual clinician"</I>. A number of factors may be involved; control group patients may have become more interested in their disease and asked more questions than they would have done normally. Adherence was assessed at baseline and at completion and, therefore, patients may have changed their behaviour by adhering to their drop regime, knowing that they would be questioned about their adherence level again at the end of the study as they had been at the beginning. Doctors may have spent more time than usual discussing eye drop therapy and adherence issues with control group patients knowing that they were also being observed. If the study had been of longer duration, for example, with a one-year follow-up period, the 'Hawthorne effect' may have subsided over time. Whilst the Hawthorne effect may be particularly pertinent to <LINK REF="STD-Sheppard-2003" TYPE="STUDY">Sheppard 2003</LINK>, it may also have been a factor in the outcomes of the other studies. This is with regard to what researchers tell participants about the study, especially concerning what and how the outcomes are to be measured. In the case of this review, it is unclear in many of the studies whether patients knew in advance how adherence was to be measured objectively if they knew at all. Usually, good ethical practice demands transparency with patients but this may have the potential to cause reactivity bias. As reported in this review, <LINK REF="STD-Hermann-2011a" TYPE="STUDY">Hermann 2011a</LINK> found that there was no significant difference in adherence between those patients masked and unmasked to adherence monitoring. Although more research is needed to further our understanding of this issue.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Measures of adherence</HEADING>
<P>Ten studies measured adherence via self report.This is said to be unreliable as patients tend to over-estimate their adherence level, as <LINK REF="REF-Rotchford-1998" TYPE="REFERENCE">Rotchford 1998</LINK> found when self report results were compared with prescription refill rates. The subjective measure of self report, however, is the most utilised method for assessing adherence in glaucoma as in other long-term conditions (<LINK REF="STD-Chang-1991" TYPE="STUDY">Chang 1991</LINK>; <LINK REF="REF-Nelson-2006" TYPE="REFERENCE">Nelson 2006</LINK>; <LINK REF="REF-Senior-2004" TYPE="REFERENCE">Senior 2004</LINK>; <LINK REF="REF-Ulrik-2006" TYPE="REFERENCE">Ulrik 2006</LINK>). Three of the studies (<LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>; <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>; <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>) in our review used the previously validated COMTol tool (<LINK REF="REF-Barber-1997" TYPE="REFERENCE">Barber 1997</LINK>). <LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK> and <LINK REF="STD-Schenker-1999" TYPE="STUDY">Schenker 1999</LINK> validated the reliability of the questionnaire used during their studies and the remainder did not discuss validation of the tool used. All were numerical scales which allowed patients to mark along the scale where they thought their answer should be, without judgemental or leading questions. Numerical and Likert scales are frequently used (<LINK REF="REF-Ross-2004" TYPE="REFERENCE">Ross 2004</LINK>; <LINK REF="REF-Treharne-2004" TYPE="REFERENCE">Treharne 2004</LINK>) and have been validated (<LINK REF="REF-DiMatteo-1993" TYPE="REFERENCE">DiMatteo 1993</LINK>; <LINK REF="REF-Horne-1999" TYPE="REFERENCE">Horne 1999</LINK>; <LINK REF="REF-Moss_x002d_Morris-2002" TYPE="REFERENCE">Moss-Morris 2002</LINK>; <LINK REF="REF-Wetzels-2006" TYPE="REFERENCE">Wetzels 2006</LINK>) for adherence studies involving patients with long-term conditions. They can provide a constructive measure, yet one must bear in mind that positive findings are likely to over-estimate the true effect. <LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK> appeared to have the least robust tool which asked patients whether they forgot drops on a narrow scale, ranging from less than once a week to four or more times a week. The categories used may have led patients to answer 'less than once a week'. This study compared the least frequent dosage (once a day) with a rather complicated regime of one drop three times a day and another drop twice a day and found no difference between the groups. It may well have been the assessment tool that produced such positive results for both groups rather than the interventions being compared.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Measures of persistence</HEADING>
<P>Prescription refill rates and dispensing counts are objective methods for assessing patients' continuity of therapy and have been used successfully in ophthalmology (<LINK REF="REF-Reardon-2004" TYPE="REFERENCE">Reardon 2004</LINK>; <LINK REF="REF-Reardon-2011" TYPE="REFERENCE">Reardon 2011</LINK>; <LINK REF="REF-Rotchford-1998" TYPE="REFERENCE">Rotchford 1998</LINK>). While these methods accurately measure persistence, they do pose some problems; an accurate measurement of prescribed drops can usually be obtained via the patient's doctor - obtaining dispensing information is sometimes more difficult if patients use several pharmacies. Also, patients may obtain repeat prescriptions for a number of medications and, therefore, receive their eye drops as part of their regularly repeated supply. This does not necessarily mean that the drops will be used as prescribed or used at all. Combining both adherence and persistence measures may help to combat the latter issue.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Monitoring device</HEADING>
<P>The monitoring devices used by <LINK REF="STD-Norell-1979" TYPE="STUDY">Norell 1979</LINK> and <LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK> could be viewed as the most reliable tools. It is particularly unfortunate that we could not assess the risk of bias effectively for <LINK REF="STD-Norell-1979" TYPE="STUDY">Norell 1979</LINK> in order to provide a more comprehensive assessment of methodological quality. A monitoring and reminder device has been developed (<LINK REF="REF-Boden-2006" TYPE="REFERENCE">Boden 2006</LINK>; <LINK REF="STD-Flowers-2006" TYPE="STUDY">Flowers 2006</LINK>). This is a container that houses a drop bottle and records the handle on the device being depressed to indicate drop instillation. There is also a visual and auditory function to act as a reminder for patients to instil drops. This appears to be an updated version of the device used in the <LINK REF="STD-Laster-1996" TYPE="STUDY">Laster 1996</LINK> study and, therefore, has similar issues regarding monitoring and for patients wishing to travel. The device has been designed for use with travoprost drops only, however the software for this device has been withdrawn from the UK and is no longer available.</P>
<P>Another device (<LINK REF="REF-Hermann-2006" TYPE="REFERENCE">Hermann 2006</LINK>) fitted with a microprocessor is designed to attach to a normal size bottle to record tilting and squeezing of the bottle. The advantages this has over the previous designs are that it is smaller; the microprocessor has increased data safety, data can be downloaded onto a personal computer and patients can carry the device around easily. The device is hidden under a drop bottle creating a normal bottle appearance, thereby increasing the likelihood of patients being unaware of monitoring. This device does appear to be promising, but until more accurate, cost-effective monitoring devices like this are available, methods of self report and prescription refill used independently, or in combination, will continue to be the standard assessment tools for measuring drop usage.</P>
<P>Another device available is the Medication Events Monitoring System (MEMS, <A HREF="http://www.aardexgroup.com">http://www.aardexgroup.com</A>), a white plastic container with a screw top in which the eye drop bottle is stored until needed for drop instillation, that is, it is a bottle in a bottle and therefore it is easy to tip out the drop bottle when there is a need to instil eye drops.  An electronic record is made every time the top is unscrewed. The battery is reported to last for 36 months. There are various sizes of the MEMS so it is quite probable it will store all types of glaucoma eye drop bottles. The MEMS has been used successfully to measure adherence to glaucoma treatment (<LINK REF="REF-Sleath-2012" TYPE="REFERENCE">Sleath 2012</LINK>). The device is relatively cheap to purchase and it is easy to train patients in its use. The drawbacks of the MEMS include, on the one hand, that it may act as a reminder to patients and on the other that it could be a barrier to taking medicines as prescribed. This is because it requires an additional action (unscrewing the bottle) which could be sufficient to put off some people. Also, there is no way of knowing whether the patient actually instils the eye drops once unscrewed and, vice versa, patients could leave off the screw top but still be putting in eye drops. To date no RCT has reported using the MEMS to measure adherence to ocular hypotensive medication, however its potential is worthy of exploration in future studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Co-morbidity</HEADING>
<P>We stated in the protocol that we would include studies that reported involuntary non-adherence, e.g. due to co-morbidity. Three studies (<LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK>; <LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK>; <LINK REF="STD-Sheppard-2003" TYPE="STUDY">Sheppard 2003</LINK>) reported that they asked participants what problems they had instilling drops.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Clinical outcomes</HEADING>
<P>Most of the studies measuring education or reminder interventions did not assess clinical outcomes. As these studies were short-term it is unlikely that changes in clinical outcomes such as intraocular pressure, visual field defects or optic nerve head changes would have been significantly different between groups. A study (<LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK>) that did assess clinical outcomes found evidence that one drug was more efficacious in terms of reducing intraocular pressure. This study, however, did not find a significant difference between the groups regarding adherence to therapy and, therefore, as previously discussed the difference in pressures was likely to be unrelated to the adherence level and more related to the drug, whilst the adherence results may be due to the measuring tool used. The remaining four studies (<LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>; <LINK REF="STD-Schenker-1999" TYPE="STUDY">Schenker 1999</LINK>; <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>; <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>) found no evidence that patients' intraocular pressures were significantly reduced in the groups with better reported adherence levels. <LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK> report no difference in intraocular pressure between the intervention and control group but did find a statistical difference in intraocular pressure fluctuations at 24 months in that it was lower in the intervention group.</P>
<P>
<LINK REF="STD-Sakai-2005" TYPE="STUDY">Sakai 2005</LINK> had sufficiently robust data with which to identify that there were no differences in visual field defects between the two groups. As mentioned above, the data from the remaining three studies could not be analysed (<LINK REF="STD-Laibovitz-1996" TYPE="STUDY">Laibovitz 1996</LINK>, <LINK REF="STD-Sverrisson-1999-Europe" TYPE="STUDY">Sverrisson 1999 Europe</LINK>; <LINK REF="STD-Sverrisson-1999-USA" TYPE="STUDY">Sverrisson 1999 USA</LINK>). Only one study (<LINK REF="STD-Okeke-2009" TYPE="STUDY">Okeke 2009</LINK>) measured the optic disc but the categories were not exclusive.</P>
</SUBSECTION>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>The overall quality of the evidence for the different outcomes is summarised for the main comparisons in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> and <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>.</P>
<P>In general we graded the evidence as 'low' or 'very low' (<LINK REF="REF-Gordon-2008" TYPE="REFERENCE">Gordon 2008</LINK>). This is because we considered the included trials to be at risk of bias in one or more parameters, there was inconsistency in the findings between trials, and in some cases sufficiently sparse data such that the findings were imprecise. This means that future research is likely to have an important impact on the estimates of effect and in some cases we are very uncertain about the estimates of effect.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2012-06-25 13:49:59 +0100" MODIFIED_BY="Anupa Shah">
<P>It is possible that unfavourable findings did not reach publication. A failure to publish unfavourable results leads to an accumulation of literature favouring benefits. Bias distorts systematic reviews and meta-analyses and encourages the use of questionable treatments (<LINK REF="REF-Dwan-2008" TYPE="REFERENCE">Dwan 2008</LINK>). This is less of an issue for our review since we have not found sufficient evidence yet to make definitive recommendations. For completeness, we invite readers to send us any published or unpublished studies that meet our inclusion criteria, that we may have missed.</P>
<P>Publication bias may be less of a problem in the future with the use of trial registries. For this update we searched the clinical trial registries and have a total of 16 unpublished and ongoing studies that will be included in future updates of this review.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>A systematic review by <LINK REF="REF-Olthoff-2005" TYPE="REFERENCE">Olthoff 2005</LINK> found the quality of experimental studies to be poor, as did the first version of our review (<LINK REF="REF-Gray-2009" TYPE="REFERENCE">Gray 2009</LINK>). However since then the quality of some studies appears to have improved, albeit no definitive trial has yet been published. Five intervention studies were included; three of these were RCTs (<LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK>; <LINK REF="STD-Norell-1979" TYPE="STUDY">Norell 1979</LINK>; <LINK REF="STD-Ring-2011" TYPE="STUDY">Ring 2011</LINK>) and, therefore, are included in our review. <LINK REF="STD-Norell-1979" TYPE="STUDY">Norell 1979</LINK> was the only one to be judged as good quality by <LINK REF="REF-Olthoff-2005" TYPE="REFERENCE">Olthoff 2005</LINK> who also found the education and tailoring intervention to be the most convincing. Unfortunately, Norell was the only author amongst our included studies that we could not contact for more information regarding missing methodology information and, therefore, we could not judge the study as good quality.</P>
<P>A recent update of a Cochrane review (<LINK REF="REF-Haynes-2008" TYPE="REFERENCE">Haynes 2008</LINK>) found that interventions for chronic health conditions were mostly complex and not very effective; even the most effective did not lead to large improvements in adherence and clinical outcomes. <LINK REF="REF-Haynes-2008" TYPE="REFERENCE">Haynes 2008</LINK> also found a plethora of interventions which could not be combined into a meta-analysis. As for our review, most of the studies suffered from low power due to small sample size. <LINK REF="REF-Haynes-2008" TYPE="REFERENCE">Haynes 2008</LINK> recommended that high priority should be given to fundamental and applied research, concerning innovations to assist patients in following prescriptions for long-term medical disorders.</P>
<P>We found only limited evidence to support the effectiveness of simplifying medication regimes, in contrast to <LINK REF="REF-van-Dulmen-2007" TYPE="REFERENCE">van Dulmen 2007</LINK> who found that simplification of the medication regimen led to better adherence following a review of 36 systematic adherence reviews in specialities other than ophthalmology. The difference may be accounted for by the larger number of studies and resulting higher number of patients involved, or that the method of administration may have had an effect (oral versus eye drop).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Although the findings of this review suggest that patient education combined with more complex behavioural change interventions may improve adherence to ocular hypotensive therapy, there is insufficient evidence to advocate any particular intervention at present. Educating patients about their condition, teaching them how to instil eye drops, providing reminders and working individually with patients to help them manage their eye drop routines are all aspects of care which have provided positive findings for improving adherence levels. In addition to the above, simplifying drop regimes may also be beneficial, but until there are more convincing results, we are unable to make more substantial clinical recommendations. However, in the absence of robust estimates of effectiveness, and in particular any evidence of effect on progression of the disease, it is not possible to address the issue as to whether investment in improving adherence is warranted, although in theory it would seem to be a sensible strategy.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>This review identified three problems with the published literature on this topic:</P>
<OL>
<LI>Generally, published studies are too short, although more recent studies have had longer follow-up of outcomes: they do not provide useful information on whether interventions to improve and maintain adherence to therapy are effective over the long term. Glaucoma and ocular hypertension are chronic conditions: adherence to therapy needs to be maintained over the long term. We suggest that patients should be followed up for at least one year.</LI>
<LI>Standardised outcomes are needed: this review has been limited by the fact that a wide range of outcomes were reported. This has meant that it was not possible to pool data between studies and produce reliable estimates of treatment effect. Ideally a core outcome set should be developed that would include the views of people who take these medications on a regular basis.</LI>
<LI>Better reporting of studies is needed: we encountered difficulties with the reporting and interpretation of the cross-over studies in particular. We recommend that authors follow standard reporting guidelines, for example, CONSORT guidance has been produced to assist in the writing of RCTs (<LINK REF="REF-Schulz-2010" TYPE="REFERENCE">Schulz 2010</LINK>).</LI>
</OL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>We thank the Cochrane Eyes and Vision Group editorial team, particularly Richard Wormald and Anupa Shah, for their ongoing advice and Iris Gordon for assistance with electronic searches. We are grateful to Kinjiro Amano, Vincent Nourrit, Stefan Panzeri, Louise Porter and Ingo Schiessl for translation services. We appreciate the time taken by Ingrid Adamsons, Karen Glanz, Kate Kelley, Shane Laster, Hiroshi Sakai and Donna Taraborelli to search for and provide unpublished study details and data. We value the statistical support provided by Helen Worthington, Co-ordinating Editor and statistician for the Cochrane Oral Health Group, and we also thank David Broadway, Catey Bunce, Heidi Cate, Scott Fraser, Tianjing Li and Roberta Scherer for their peer review comments. We thank Lois Orton for contributing to previous versions of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-05-22 13:15:46 +0100" MODIFIED_BY="[Empty name]">
<P>The authors of this review (with the exception of Jennifer Evans) were involved in one included study (<LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK>). </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-05-22 13:13:58 +0100" MODIFIED_BY="Anupa Shah">
<P>Conceiving the review: HW, DH<BR/>Designing the review: TG<BR/>Co-ordinating the review: TG, JE<BR/>Undertaking manual searches: TG<BR/>Screening search results: TG, LO, HW, JE<BR/>Organising retrieval of papers: TG<BR/>Screening retrieved papers against inclusion criteria: TG, HG, DH, RH, HW, JE<BR/>Appraising quality of papers: TG, HW, DH, RH, JE<BR/>Extracting data from papers: TG, HW, DH, RH, JE<BR/>Writing to authors of papers for additional information: TG, JE<BR/>Obtaining and screening data on unpublished studies: TG<BR/>Data management for the review: TG, JE<BR/>Entering data into RevMan: TG, JE<BR/>Analysis of data: TG, JE<BR/>Interpretation of data: TG, JE<BR/>Writing the review: TG, JE<BR/>Securing funding for the review: DH, HW</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>The Cochrane Collaboration's new tool for assessing the risk of bias has been used in updates of this review. In the update in 2012, two new outcomes were added: patient's knowledge about glaucoma and costs.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-02-11 12:27:48 +0000" MODIFIED_BY="Anupa Shah">
<STUDIES MODIFIED="2013-02-11 12:27:48 +0000" MODIFIED_BY="Anupa Shah">
<INCLUDED_STUDIES MODIFIED="2013-02-11 12:27:48 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Gray-2011" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" NAME="Gray 2011" YEAR="2006">
<REFERENCE MODIFIED="2012-07-16 13:51:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gray TA, Fenerty C, Harper R, Spencer AF, Campbell M, Henson DB, et al</AU>
<TI>Individualised patient care as an adjunct to standard care for promoting adherence to ocular hypotensive therapy: an exploratory randomised controlled trial</TI>
<SO>Eye</SO>
<YR>2012</YR>
<VL>26</VL>
<NO>3</NO>
<PG>407-17</PG>
<IDENTIFIERS MODIFIED="2012-07-16 13:51:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Henson D</AU>
<TI>The impact of an individualised programme of care on persistence of and adherence to therapy in newly treated cases of glaucoma or ocular hypertension</TI>
<SO>Ocular Health and Special Senses, North West Regional Office, ongoing</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="ISRCTN" VALUE="13706134"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hermann-2011a" MODIFIED="2012-07-16 13:54:37 +0100" MODIFIED_BY="[Empty name]" NAME="Hermann 2011a" YEAR="2011">
<REFERENCE MODIFIED="2012-07-16 13:53:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herman MM, Papaconstantinou D, Muether PS, Georgopolous G, Diestelhorst M</AU>
<TI>Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring</TI>
<SO>Acta Ophthalmologica</SO>
<YR>2011</YR>
<VL>89</VL>
<NO>4</NO>
<PG>300-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hermann-2011b" MODIFIED="2012-07-16 13:54:22 +0100" MODIFIED_BY="[Empty name]" NAME="Hermann 2011b" YEAR="2011">
<REFERENCE MODIFIED="2012-07-16 13:53:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hermann MM, Bron AM, Creuzot-Garcher CP, Diestelhorst M</AU>
<TI>Measurement of adherence to brimonidine therapy for glaucoma using electronic monitoring</TI>
<SO>Journal of Glaucoma</SO>
<YR>2011</YR>
<VL>20</VL>
<NO>8</NO>
<PG>502-8</PG>
<IDENTIFIERS MODIFIED="2012-07-16 13:53:47 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-I_x002d_SIGHT" MODIFIED="2013-02-04 12:07:07 +0000" MODIFIED_BY="[Empty name]" NAME="I-SIGHT" YEAR="2012">
<REFERENCE MODIFIED="2013-02-04 12:07:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glanz K, Beck AD, Bundy L, Primo S, Lynn MJ, Cleveland J, et al</AU>
<TI>Impact of a health communication intervention to improve glaucoma treatment adherence: results of the Interactive Study to Increase Glaucoma Adherence to Treatment Trial results of the I-SIGHT Trial</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2012</YR>
<VL>130</VL>
<NO>10</NO>
<PG>1252-8</PG>
<IDENTIFIERS MODIFIED="2012-06-18 13:25:13 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-06-18 13:22:19 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-06-18 13:22:19 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00794170"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laibovitz-1996" MODIFIED="2008-06-05 13:27:20 +0100" MODIFIED_BY="Anupa Shah" NAME="Laibovitz 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-06-05 13:27:20 +0100" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laibovitz R, Boyle J, Snyder E, Strohmaier K, Adamsons I</AU>
<TI>Dorzolamide versus pilocarpine as adjunctive therapies to timolol: a comparison of patient preference and impact on daily life</TI>
<SO>Clinical Therapeutics</SO>
<YR>1996</YR>
<VL>18</VL>
<NO>5</NO>
<PG>821-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laster-1996" MODIFIED="2008-06-05 13:27:20 +0100" MODIFIED_BY="Anupa Shah" NAME="Laster 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-06-05 13:27:20 +0100" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laster SF, Martin JL, Fleming JB</AU>
<TI>The effect of a medication alarm device on patient compliance with topical pilocarpine</TI>
<SO>Journal of the American Optometric Association</SO>
<YR>1996</YR>
<VL>67</VL>
<NO>11</NO>
<PG>654-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muir-2012" MODIFIED="2012-07-16 14:03:39 +0100" MODIFIED_BY="[Empty name]" NAME="Muir 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-07-16 14:03:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muir KW, Ventura A, Stinnett SS, Enfiedjian A, Allingham RR, Lee PP</AU>
<TI>The influence of health literacy level on an educational intervention to improve glaucoma medication adherence</TI>
<SO>Patient Education and Counseling</SO>
<YR>2012</YR>
<VL>87</VL>
<NO>2</NO>
<PG>160-4</PG>
<IDENTIFIERS MODIFIED="2012-07-16 14:02:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nakakura-2012" MODIFIED="2013-02-04 13:43:06 +0000" MODIFIED_BY="[Empty name]" NAME="Nakakura 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-02-04 13:43:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakakura S, Tabuchi H, Baba Y, Maruiwa F, Ando N, Kanamoto T, et al</AU>
<TI>Comparison of the latanoprost 0.005%/ timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/ timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial</TI>
<SO>Clinical Ophthalmology</SO>
<YR>2012</YR>
<VL>6</VL>
<PG>369-75</PG>
<IDENTIFIERS MODIFIED="2012-07-16 14:03:56 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Norell-1979" MODIFIED="2009-02-16 20:20:05 +0000" MODIFIED_BY=" Iris Gordon" NAME="Norell 1979" YEAR="1979">
<REFERENCE MODIFIED="2009-02-16 20:20:05 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Norell SE</AU>
<TI>Improving medication compliance: a randomised clinical trial</TI>
<SO>British Medical Journal</SO>
<YR>1979</YR>
<VL>2</VL>
<NO>6197</NO>
<PG>1031-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okeke-2009" MODIFIED="2012-07-16 14:09:23 +0100" MODIFIED_BY="[Empty name]" NAME="Okeke 2009" YEAR="2007">
<REFERENCE MODIFIED="2012-07-16 14:09:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00333463</AU>
<TI>Compliance with once daily glaucoma medication</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00333463</SO>
<YR>(accessed 7 October 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-16 14:09:23 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ring-2011" MODIFIED="2013-02-11 12:27:48 +0000" MODIFIED_BY="[Empty name]" NAME="Ring 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-02-11 12:27:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK">
<AU>Ring L</AU>
<SO>A Quasi Experimental Study of Adherence to Ocular Hypotensive Treatment: a Patient Education Perspective [MSc dissertation]</SO>
<YR>2011</YR>
<PB>University of London</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sakai-2005" MODIFIED="2012-07-16 14:20:06 +0100" MODIFIED_BY=" Iris Gordon" NAME="Sakai 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-16 14:20:06 +0100" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sakai H, Shinjyo S, Nakamura Y, Nakamura Y, Ishikawa S, Sawaguchi S</AU>
<TI>Comparison of latanoprost monotherapy and combined therapy of 0.5% timolol and 1% dorzolamide in chronic primary angle-closure glaucoma (CACG) in Japanese patients</TI>
<SO>Journal of Ocular Pharmacology and Therapeutics</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>6</NO>
<PG>483-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schenker-1999" MODIFIED="2009-02-16 20:34:07 +0000" MODIFIED_BY=" Iris Gordon" NAME="Schenker 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-02-16 20:34:07 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="OTHER">
<AU>Schenker H, Maloney S, Liss C, Gormley G, Hartenbaum D</AU>
<TI>Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma</TI>
<SO>Clinical Therapeutics</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>1</NO>
<PG>138-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheppard-2003" MODIFIED="2012-07-16 14:20:53 +0100" MODIFIED_BY=" Iris Gordon" NAME="Sheppard 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-07-16 14:20:53 +0100" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheppard J, Warner J, Kelley K</AU>
<TI>An evaluation of the effectiveness of a nurse-led glaucoma monitoring clinic</TI>
<SO>Ophthalmic Nursing</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>2</NO>
<PG>15-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-25 15:10:56 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-25 15:10:56 +0000" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="48112269"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sverrisson-1999-Europe" MODIFIED="2012-03-28 09:50:17 +0100" MODIFIED_BY="[Empty name]" NAME="Sverrisson 1999 Europe" YEAR="1999">
<REFERENCE MODIFIED="2009-02-18 11:55:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sverrisson T, Gross R, Pearson J, Rusk C, Adamsons I</AU>
<TI>The dorzolamide/timolol combination versus timolol plus pilocarpine: patient preference and impact on daily life. United States Patient Preference Study Group. International Patient Preference Study Group</TI>
<SO>Journal of Glaucoma</SO>
<YR>1999</YR>
<VL>8</VL>
<NO>5</NO>
<PG>315-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sverrisson-1999-USA" MODIFIED="2012-03-28 09:49:33 +0100" MODIFIED_BY="[Empty name]" NAME="Sverrisson 1999 USA" YEAR="1999">
<REFERENCE MODIFIED="2009-02-18 11:55:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sverrisson T, Gross R, Pearson J, Rusk C, Adamsons I</AU>
<TI>The dorzolamide/timolol combination versus timolol plus pilocarpine: patient preference and impact on daily life. United States Patient Preference Study Group. International Patient Preference Study Group</TI>
<SO>Journal of Glaucoma</SO>
<YR>1999</YR>
<VL>8</VL>
<NO>5</NO>
<PG>315-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-08-09 12:59:36 +0100" MODIFIED_BY="Trish Gray"/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<STUDY DATA_SOURCE="PUB" ID="STD-Akafo-1995" MODIFIED="2012-07-16 14:37:30 +0100" MODIFIED_BY=" Iris Gordon" NAME="Akafo 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-07-16 14:37:30 +0100" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="OTHER">
<AU>Akafo SK, Thompson JR, Rosenthal AR</AU>
<TI>A cross-over trial comparing once daily levobunolol with once and twice daily timolol</TI>
<SO>European Journal of Ophthalmology</SO>
<YR>1995</YR>
<VL>5</VL>
<NO>3</NO>
<PG>172-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amon-1990" MODIFIED="2012-07-16 14:37:51 +0100" MODIFIED_BY="Anupa Shah" NAME="Amon 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-07-16 14:37:51 +0100" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="OTHER">
<AU>Amon A, Menapace R, Wedrich A, Radax U</AU>
<TI>Aspects of glaucoma patient care and its impact on compliance</TI>
<SO>Spektrum der Augenheilkunde</SO>
<YR>1990</YR>
<VL>4</VL>
<NO>1</NO>
<PG>5-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bayer-2004" MODIFIED="2012-07-16 14:38:45 +0100" MODIFIED_BY=" Iris Gordon" NAME="Bayer 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-07-16 14:38:45 +0100" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bayer A, Weiler W, Oeverhaus U, Skrotzki FE, Stewart WC</AU>
<TI>Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies</TI>
<SO>Journal of Ocular Pharmacology and Therapeutics</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>6</NO>
<PG>470-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bhojwani-1981" MODIFIED="2009-02-16 20:57:04 +0000" MODIFIED_BY=" Iris Gordon" NAME="Bhojwani 1981" YEAR="1981">
<REFERENCE MODIFIED="2009-02-16 20:57:04 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="OTHER">
<AU>Bhojwani SC, Jones DK</AU>
<TI>Comparative study of aqueous and oily pilocarpine in the production of ocular hypotension</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1981</YR>
<VL>65</VL>
<NO>8</NO>
<PG>530-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blair-2001" MODIFIED="2012-07-16 14:39:24 +0100" MODIFIED_BY=" Iris Gordon" NAME="Blair 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-07-16 14:39:24 +0100" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blair DJ, Cantor LB, Janes B, Hoop JS, Knotts SL, Abel SR</AU>
<TI>Subjective vs objective assessment of patient compliance with glaucoma medical therapy</TI>
<SO>Investigative Ophthalmology and Visual Science</SO>
<YR>2001</YR>
<VL>42</VL>
<NO>4</NO>
<PG>S417</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blair-2004" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY=" Iris Gordon" NAME="Blair 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blair DJ, Cantor L, WuDunn D, Hoop J, Malinovsky V</AU>
<TI>Glaucoma and compliance: comparison of objective patient compliance information with respect to "QD" dosing versus "BID" dosing on patient medication compliance</TI>
<SO>Investigative Ophthalmology and Visual Science</SO>
<YR>2004</YR>
<VL>45</VL>
<PG>U457</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bron-2004" MODIFIED="2012-07-16 14:41:08 +0100" MODIFIED_BY=" Iris Gordon" NAME="Bron 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-07-16 14:41:08 +0100" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="OTHER">
<AU>Bron A, Velasque L, Rebica H, Pouliquen P, Elena PP, Rouland JF</AU>
<TI>Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost</TI>
<SO>Journal Français d'Ophtalmologie</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>9 Pt 1</NO>
<PG>971-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-1991" MODIFIED="2009-02-16 21:13:42 +0000" MODIFIED_BY=" Iris Gordon" NAME="Chang 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-02-16 21:13:42 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="OTHER">
<AU>Chang JS, Lee DA, Petursson G, Spaeth G, Zimmerman TJ, Hoskins HD, et al</AU>
<TI>The effect of a glaucoma medication reminder cap on patient compliance and intraocular pressure</TI>
<SO>Journal of Ocular Pharmacology</SO>
<YR>1991</YR>
<VL>7</VL>
<NO>2</NO>
<PG>117-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Derick-1992" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY=" Iris Gordon" NAME="Derick 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Derick RJ, Robin AL, Tielsch J, Wexler JL, Kelley EP, Stoecker JF, et al</AU>
<TI>Once-daily versus twice-daily levobunolol (0.5%) therapy: a crossover study</TI>
<SO>Ophthalmology</SO>
<YR>1992</YR>
<VL>99</VL>
<NO>3</NO>
<PG>424-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dunker-2007" MODIFIED="2009-02-16 21:27:21 +0000" MODIFIED_BY=" Iris Gordon" NAME="Dunker 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-02-16 21:27:21 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="OTHER">
<AU>Dunker S, Schmucker A, Maier H. Latanoprost/Timolol Fixed Combination Study Group</AU>
<TI>Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol</TI>
<SO>Advances in Therapy</SO>
<YR>2007</YR>
<VL>24</VL>
<NO>2</NO>
<PG>376-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flowers-2006" MODIFIED="2013-02-04 11:58:47 +0000" MODIFIED_BY="[Empty name]" NAME="Flowers 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-02-04 11:58:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flowers B, Wand M, Piltz-Seymour J, Berke SJ, Day D, Teague J, et al</AU>
<TI>Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension</TI>
<SO>Clinical Therapeutics</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>11</NO>
<PG>1803-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghinato-1996" MODIFIED="2009-02-16 21:24:08 +0000" MODIFIED_BY=" Iris Gordon" NAME="Ghinato 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-02-16 21:24:08 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghinato U, Morgante A, Perinotto U, Pasek M, Polito D</AU>
<TI>Compliance and glaucoma: utility of a simplified therapy</TI>
<TO>Compliance e glaucoma: utilita di una terapia semplificata</TO>
<SO>Bollettino D Oculistica</SO>
<YR>1996</YR>
<VL>75</VL>
<NO>2</NO>
<PG>303-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goni-2005" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" NAME="Goni 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="OTHER">
<AU>Goni FJ. Brimonidine/Timolol Fixed Combination Study Group</AU>
<TI>12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension</TI>
<SO>European Journal of Ophthalmology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>5</NO>
<PG>581-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Granstrom-1982" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" NAME="Granstrom 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Granstrom PA</AU>
<TI>Glaucoma patients not compliant with their drug therapy: clinical and behavioral aspects</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1982</YR>
<VL>66</VL>
<NO>7</NO>
<PG>464-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gulkilik-2011" MODIFIED="2013-02-04 11:57:09 +0000" MODIFIED_BY="[Empty name]" NAME="Gulkilik 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-02-04 11:57:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gulkilik G, Oba E, Odabasi M</AU>
<TI>Comparison of fixed combinations of dorzolamide/timolol and brimonidine/timolol in patients with primary open-angle glaucoma</TI>
<SO>International Ophthalmology</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>6</NO>
<PG>447-51</PG>
<IDENTIFIERS MODIFIED="2013-02-04 11:57:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hasegawa-2005" MODIFIED="2009-02-16 21:31:06 +0000" MODIFIED_BY=" Iris Gordon" NAME="Hasegawa 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-16 21:31:06 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hasegawa K, Takahashi T, Kawase K</AU>
<TI>Evaluation of topical brinzolamide switched from dorzolamide for glaucoma</TI>
<SO>Japanese Journal of Clinical Ophthalmology</SO>
<YR>2005</YR>
<VL>59</VL>
<NO>2</NO>
<PG>215-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hughes-2005" MODIFIED="2013-02-04 11:56:35 +0000" MODIFIED_BY=" Iris Gordon" NAME="Hughes 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-02-04 11:56:35 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="OTHER">
<AU>Hughes BA, Bacharach J, Craven ER, Kaback MB, Mallick S, Landry TA, et al</AU>
<TI>A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/ timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension</TI>
<SO>Journal of Glaucoma</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>5</NO>
<PG>392-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hunter-1999" MODIFIED="2009-02-18 16:46:48 +0000" MODIFIED_BY="[Empty name]" NAME="Hunter 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-02-18 16:46:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Hunter, F</AU>
<TI>Evaluation of compliance in patients with glaucoma</TI>
<SO>National Research Register. NHS Lothian - University Hospitals Division</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inoue-2011" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" NAME="Inoue 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inoue K, Okayama R, Higa R, Sawada H, Wakakura M, Tomita G</AU>
<TI>Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination</TI>
<SO>Journal of Ocular Pharmacology and Therapeutics</SO>
<YR>2011</YR>
<VL>27</VL>
<NO>6</NO>
<PG>581-7</PG>
<IDENTIFIERS MODIFIED="2013-02-04 11:55:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inoue-2012" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" NAME="Inoue 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inoue K, Setogawa A, Higa R, Moriyama R, Wakakura M, Tomita G</AU>
<TI>Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from beta-blockers and prostaglandin analogs</TI>
<SO>Clinical Ophthalmology</SO>
<YR>2012</YR>
<VL>6</VL>
<PG>231-5</PG>
<IDENTIFIERS MODIFIED="2013-02-04 11:50:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kass-1987" MODIFIED="2009-02-16 21:41:44 +0000" MODIFIED_BY=" Iris Gordon" NAME="Kass 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-02-16 21:41:44 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kass MA, Gordon M, Morley Jr RE, Meltzer DW, Goldberg JJ</AU>
<TI>Compliance with topical timolol treatment</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1987</YR>
<VL>103</VL>
<NO>2</NO>
<PG>188-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klein-2003" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" NAME="Klein 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klein, T</AU>
<TI>Canadian study of Travatan as replacement therapy (CSTART): switching to Travatan can improve long-term care</TI>
<SO>Clinical and Surgical Ophthalmology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>10</NO>
<PG>426-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konstas-2001" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" NAME="Konstas 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" NOTES="Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial" NOTES_MODIFIED="2013-02-06 13:18:58 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Konstas AG, Lake S, Maltezos AC, Holmes KT, Stewart WC</AU>
<TI>Twenty-four hour intraocular pressure reduction with latanoprost compared with pilocarpine as third-line therapy in exfoliation glaucoma</TI>
<SO>Eye</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>Pt 1</NO>
<PG>59-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurtz-2004" MODIFIED="2013-02-04 11:49:52 +0000" MODIFIED_BY="[Empty name]" NAME="Kurtz 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-02-04 11:49:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kurtz S , Shemesh G</AU>
<TI>The efficacy and safety of once-daily versus once-weekly latanoprost treatment for increased intraocular pressure</TI>
<SO>Journal of Ocular Pharmacology and Therapeutics</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>4</NO>
<PG>321-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lorenz-2011" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" NAME="Lorenz 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lorenz K, Rosbach K, Matt A, Pfeiffer N</AU>
<TI>Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension</TI>
<SO>Clinical Ophthalmology</SO>
<YR>2011</YR>
<VL>5</VL>
<PG>1745-50</PG>
<IDENTIFIERS MODIFIED="2012-07-16 12:41:12 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-March-2000" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" NAME="March 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>March WF, Ochsner KI. Brinzolamide Long-Term Therapy Study Group</AU>
<TI>The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2000</YR>
<VL>129</VL>
<NO>2</NO>
<PG>136-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00230763" MODIFIED="2012-07-16 13:36:31 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00230763" YEAR="2007">
<REFERENCE MODIFIED="2012-07-16 13:36:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Determination of predictive factors allowing to an additional 10% reduction of intra-ocular pressure (PREDICOM)</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00230763</SO>
<YR>(accessed 7 October 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-16 12:40:58 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00262626" MODIFIED="2012-07-17 10:08:08 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00262626" YEAR="2626">
<REFERENCE MODIFIED="2012-07-17 10:08:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00262626</AU>
<TI>The Canadian glaucoma study</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00262626</SO>
<YR>(accessed 4 October 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00328835" MODIFIED="2012-07-17 10:08:18 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00328835" YEAR="2006">
<REFERENCE MODIFIED="2012-07-17 10:08:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00328835</AU>
<TI>Optic nerve compliance study</TI>
<SO>clinicaltrials.gov/ct2/show/study/NCT00328835</SO>
<YR>(accessed 4 October 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-16 13:43:08 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00329095" MODIFIED="2012-07-16 13:48:10 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00329095" YEAR="2006">
<REFERENCE MODIFIED="2012-07-16 13:48:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00329095</AU>
<TI>An evaluation of use of topical ocular hypotensive medication by compliance</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00329095</SO>
<YR>(accessed 7 October 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-16 13:45:40 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00348062" MODIFIED="2012-07-16 13:48:29 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00348062" YEAR="8062">
<REFERENCE MODIFIED="2012-07-16 13:48:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00348062</AU>
<TI>A multicenter evaluation of methods to reduce hyperemia associated with bimatoprost therapy for glaucoma or ocular hypertension</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00348062</SO>
<YR>(accessed 7 October 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-16 13:48:29 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01415401" MODIFIED="2012-07-17 10:08:34 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01415401" YEAR="5401">
<REFERENCE MODIFIED="2012-07-17 10:08:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01415401</AU>
<TI>Efficacy and tolerability of AZARGA® as replacement therapy in patients on COMBIGAN® therapy in Canada</TI>
<SO>clinicaltrials.gov/ct2/show/NCT01415401</SO>
<YR>(accessed 4 October 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Novack-1988" MODIFIED="2009-02-18 14:04:06 +0000" MODIFIED_BY="[Empty name]" NAME="Novack 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-02-18 14:04:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Novack GD, David R, Lee PF, Freeman MI, Duzman E, Batoosingh AL</AU>
<TI>Effect of changing medication regimens in glaucoma patients</TI>
<SO>Ophthalmologica</SO>
<YR>1988</YR>
<VL>196</VL>
<NO>1</NO>
<PG>23-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rolle-2012" MODIFIED="2012-07-16 15:50:05 +0100" MODIFIED_BY="[Empty name]" NAME="Rolle 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-07-16 15:50:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rolle T, Curto D, Alovisi C, Franzone M, Brogliatti B, Grignolo FM</AU>
<TI>Timogel(R) vs timolol 0.5% ophthalmic solution: efficacy, safety, and acceptance</TI>
<SO>European Journal of Ophthalmology</SO>
<YR>2012</YR>
<VL>22</VL>
<NO>1</NO>
<PG>28-33</PG>
<IDENTIFIERS MODIFIED="2012-07-16 15:49:56 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rossi-2011" MODIFIED="2012-07-16 15:50:44 +0100" MODIFIED_BY="[Empty name]" NAME="Rossi 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-07-16 15:50:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossi GC, Pasinetti GM, Sandolo F, Bordin M, Bianchi PE</AU>
<TI>From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch study</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2011</YR>
<VL>12</VL>
<NO>16</NO>
<PG>2425-31</PG>
<IDENTIFIERS MODIFIED="2012-07-16 15:50:35 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanchez_x002d_Pulgarin-2011" MODIFIED="2013-02-04 11:48:48 +0000" MODIFIED_BY="[Empty name]" NAME="Sanchez-Pulgarin 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-02-04 11:48:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez-Pulgarin M, Martinez-de-la-Casa JM, Escalada A, Saenz-Frances F, Garcia-Feijoo J, Garcia Sanchez J</AU>
<TI>The influence of the Travalert (R) dosing aid on medical treatment compliance and the quality of life of glaucoma patients</TI>
<TO>Estudio de la influencia del dispositivo de ayuda a la dosificacion Travalert (R) sobre el cumplimiento del tratamiento medico y calidad de vida de los pacientes con glaucoma</TO>
<SO>Archivos de la Sociedad Espanola de Oftalmologia</SO>
<YR>2011</YR>
<VL>86</VL>
<NO>9</NO>
<PG>282-6</PG>
<IDENTIFIERS MODIFIED="2012-07-16 15:52:21 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sclar-1991" MODIFIED="2009-02-18 14:06:57 +0000" MODIFIED_BY="[Empty name]" NAME="Sclar 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-02-18 14:06:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sclar DA, Skaer TL, Chin A, Okamoto MP, Nakahiro RK, Gill MA</AU>
<TI>Effectiveness of the C Cap in promoting prescription refill compliance among patients with glaucoma</TI>
<SO>Clinical Therapeutics</SO>
<YR>1991</YR>
<VL>13</VL>
<NO>3</NO>
<PG>396-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shibuya-2003" MODIFIED="2009-02-18 14:11:24 +0000" MODIFIED_BY="[Empty name]" NAME="Shibuya 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-02-18 14:11:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Shibuya T, Kashiwagi K, Tsukahara S</AU>
<TI>Comparison of efficacy and tolerability between two gel-forming timolol maleate ophthalmic solutions in patients with glaucoma or ocular hypertension</TI>
<SO>Ophthalmologica</SO>
<YR>2003</YR>
<VL>217</VL>
<NO>1</NO>
<PG>31-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wandel-1986" MODIFIED="2009-02-18 14:13:06 +0000" MODIFIED_BY="[Empty name]" NAME="Wandel 1986" YEAR="1986">
<REFERENCE MODIFIED="2009-02-18 14:13:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wandel T, Charap AD, Lewis RA, Partamian L, Cobb S, Lue JC, et al</AU>
<TI>Glaucoma treatment with once-daily levobunolol</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1986</YR>
<VL>101</VL>
<NO>3</NO>
<PG>298-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yie-2000" MODIFIED="2009-02-18 14:14:46 +0000" MODIFIED_BY="[Empty name]" NAME="Yie 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-02-18 14:14:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yie T, Liang L, Chen X</AU>
<TI>Clinical observation on the effect of 4% pilocarpine gel used one dose per day in the treatment of glaucoma</TI>
<SO>Yen Ko Hsueh Pao [Eye Science]</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>2</NO>
<PG>77-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-06-25 13:37:40 +0100" MODIFIED_BY="Trish Gray"/>
<ONGOING_STUDIES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN25754048" MODIFIED="2012-07-17 12:08:45 +0100" MODIFIED_BY="[Empty name]" NAME="ISRCTN25754048" YEAR="2007">
<REFERENCE MODIFIED="2012-07-17 12:08:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN25754048</AU>
<TI>Glaucoma compliance aids research project</TI>
<SO>controlled-trials.com/ISRCTN25754048/</SO>
<YR>(accessed 8 December 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-16 16:07:10 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN31673586" MODIFIED="2012-07-16 16:10:01 +0100" MODIFIED_BY="[Empty name]" NAME="ISRCTN31673586" YEAR="2010">
<REFERENCE MODIFIED="2012-07-16 16:09:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN31673586</AU>
<TI>Comparing the after-use sensation and safety of long acting (LA) carteolol 2 % versus timolol LA 0.5 % in simple intra-ocular hypertension and glaucoma</TI>
<SO>controlled-trials.com/ISRCTN31673586/</SO>
<YR>(accessed 7 October 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-16 16:07:21 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN89683704" MODIFIED="2013-02-04 13:18:32 +0000" MODIFIED_BY="[Empty name]" NAME="ISRCTN89683704" YEAR="2009">
<REFERENCE MODIFIED="2013-02-04 13:18:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN89683704</AU>
<TI>Helping adherence with glaucoma treatment: a randomised trial</TI>
<SO>controlled-trials.com/ISRCTN89683704/</SO>
<YR>(accessed 8 December 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-16 16:10:18 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00376974" MODIFIED="2013-02-06 12:32:33 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00376974" YEAR="2006">
<REFERENCE MODIFIED="2013-02-06 12:32:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00376974</AU>
<TI>The effect of education on patient compliance</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00376974</SO>
<YR>(accessed 29 November 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-16 16:14:54 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00454922" MODIFIED="2012-07-16 16:27:37 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00454922" YEAR="2008">
<REFERENCE MODIFIED="2012-07-16 16:27:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00454922</AU>
<TI>Effect of glaucoma educators on adherence to prescribed therapeutic regimens in glaucoma patients</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00454922</SO>
<YR>(accessed 6 December 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00465803" MODIFIED="2012-07-16 16:30:08 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00465803" YEAR="2010">
<REFERENCE MODIFIED="2012-07-16 16:30:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00465803</AU>
<TI>A phase IIIb study of DuoTrav to treat glaucoma or ocular hypertension</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00465803</SO>
<YR>(accessed 29 October 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-16 16:27:52 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00508469" MODIFIED="2012-07-16 16:34:17 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00508469" YEAR="2010">
<REFERENCE MODIFIED="2012-07-16 16:34:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00508469</AU>
<TI>Adherence assessment with Travalert dosing aid</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00508469</SO>
<YR>(accessed 4 October 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-16 16:34:17 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00573638" MODIFIED="2012-07-16 16:36:19 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00573638" YEAR="2009">
<REFERENCE MODIFIED="2012-07-16 16:36:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00573638</AU>
<TI>Effects of Xal-Ease on patient compliance with Xalatan</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00573638</SO>
<YR>(accessed 29 October 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-16 16:35:03 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00626067" MODIFIED="2012-07-16 16:39:35 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00626067" YEAR="2007">
<REFERENCE MODIFIED="2012-07-16 16:39:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00626067</AU>
<TI>Study of patient use and perception of the Travatan dosing aid</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00626067</SO>
<YR>(accessed 4 October 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-16 16:37:55 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00676637" MODIFIED="2013-02-06 12:34:54 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00676637" YEAR="2010">
<REFERENCE MODIFIED="2013-02-06 12:34:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00676637</AU>
<TI>Glaucoma Adherence Study (GAS)</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00676637</SO>
<YR>(accessed 29 November 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-16 16:40:02 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00756184" MODIFIED="2013-02-04 13:19:25 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00756184" YEAR="2009">
<REFERENCE MODIFIED="2013-02-04 13:19:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00756184</AU>
<TI>Value of an intervention to enhance adherence in glaucoma patients</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00756184</SO>
<YR>(accessed 29 October 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-16 16:42:10 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00767793" MODIFIED="2012-07-17 11:18:24 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00767793" YEAR="2009">
<REFERENCE MODIFIED="2012-07-17 10:14:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00767793</AU>
<TI>A placebo-controlled study of INS117548 ophthalmic solution in subjects with glaucoma</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00767793</SO>
<YR>(accessed 7 October 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-17 10:10:32 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00887029" MODIFIED="2013-02-06 12:35:06 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00887029" YEAR="2009">
<REFERENCE MODIFIED="2013-02-06 12:35:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00887029</AU>
<TI>A 12 week comparison of DuoTrav and Xalacom in open-angle glaucoma (DVX)</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00887029</SO>
<YR>(accessed 29 November 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-17 11:22:13 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01125306" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" NAME="NCT01125306" YEAR="2011">
<REFERENCE MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01125306</AU>
<TI>Efficiency of Xal-Ease device in glaucoma and/or ocular hypertension (OHT) patients, treated with Xalatan or Xalacom</TI>
<SO>clinicaltrials.gov/ct2/show/NCT01125306</SO>
<YR>(accessed 4 October 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-17 11:22:22 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01409421" MODIFIED="2013-02-06 12:35:23 +0000" MODIFIED_BY="[Empty name]" NAME="NCT01409421" YEAR="2013">
<REFERENCE MODIFIED="2013-02-06 12:35:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01409421</AU>
<TI>Glaucoma treatment adherence and persistence</TI>
<SO>clinicaltrials.gov/ct2/show/NCT01409421</SO>
<YR>(29 November 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-17 11:40:25 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01417689" MODIFIED="2012-07-17 11:42:44 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01417689" YEAR="2012">
<REFERENCE MODIFIED="2012-07-17 11:42:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01417689</AU>
<TI>Eyedrop instillation technique</TI>
<SO>clinicaltrials.gov/ct2/show/NCT01417689</SO>
<YR>(accessed 4 October 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-17 11:41:46 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<ADDITIONAL_REFERENCES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<REFERENCE ID="REF-Ajit-2010" MODIFIED="2013-02-04 10:25:02 +0000" MODIFIED_BY="Heather Waterman" NAME="Ajit 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ajit R, Fenerty C, Henson D</AU>
<TI>Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid</TI>
<SO>Eye</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>8</NO>
<PG>1338-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barber-1997" MODIFIED="2009-02-11 20:14:57 +0000" MODIFIED_BY="[Empty name]" NAME="Barber 1997" TYPE="JOURNAL_ARTICLE">
<AU>Barber BL, Strahlman ER, Laibovitz R, Guess HA, Reines SA</AU>
<TI>Validation of a questionnaire for comparing the tolerability of ophthalmic medications</TI>
<SO>Ophthalmology</SO>
<YR>1997</YR>
<VL>104</VL>
<NO>2</NO>
<PG>334-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bissell-2004" MODIFIED="2013-02-04 10:26:47 +0000" MODIFIED_BY="Trish Gray" NAME="Bissell 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bissell P, May CR, Noyce PR</AU>
<TI>From compliance to concordance: barriers to accomplishing a re-framed model of health care interactions</TI>
<SO>Social Science and Medicine</SO>
<YR>2004</YR>
<VL>58</VL>
<NO>4</NO>
<PG>851-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boden-2006" MODIFIED="2008-11-26 14:28:25 +0000" MODIFIED_BY="Trish Gray" NAME="Boden 2006" TYPE="JOURNAL_ARTICLE">
<AU>Boden C, Sit A, Weinreb RN</AU>
<TI>Accuracy of an electronic monitoring and reminder device for use with travoprost eye drops</TI>
<SO>Journal of Glaucoma</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>1</NO>
<PG>30-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-1997" MODIFIED="2009-01-06 14:38:10 +0000" MODIFIED_BY="[Empty name]" NAME="Brown 1997" TYPE="JOURNAL_ARTICLE">
<AU>Brown BG, Bardsley J, Poulin D, Hillger LA, Dowdy A, Maher VM, et al</AU>
<TI>Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease</TI>
<SO>American Journal of Cardiology</SO>
<YR>1997</YR>
<VL>80</VL>
<NO>2</NO>
<PG>111-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burr-2012" MODIFIED="2013-02-04 13:11:06 +0000" MODIFIED_BY="[Empty name]" NAME="Burr 2012" TYPE="COCHRANE_REVIEW">
<AU>Burr J, Azuara-Blanco A, Avenell A, Tuulonen A</AU>
<TI>Medical versus surgical interventions for open angle glaucoma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2013-02-04 10:29:25 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-02-04 10:29:25 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004399.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Deokule-2004" MODIFIED="2013-02-04 10:31:18 +0000" MODIFIED_BY="Trish Gray" NAME="Deokule 2004" TYPE="JOURNAL_ARTICLE">
<AU>Deokule S, Sadiq S, Shah S</AU>
<TI>Chronic open angle glaucoma: patient awareness of the nature of the disease, topical medication, compliance and the prevalence of systemic symptoms</TI>
<SO>Ophthalmic and Physiological Optics</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>1</NO>
<PG>9-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Diggory-1995" MODIFIED="2008-11-26 14:28:25 +0000" MODIFIED_BY="Trish Gray" NAME="Diggory 1995" TYPE="JOURNAL_ARTICLE">
<AU>Diggory P, Cassels-Brown A, Vail A, Abbey LM, Hillman JS</AU>
<TI>Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents</TI>
<SO>Lancet</SO>
<YR>1995</YR>
<VL>345</VL>
<NO>8965</NO>
<PG>1604-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DiMatteo-1993" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" NAME="DiMatteo 1993" TYPE="JOURNAL_ARTICLE">
<AU>DiMatteo MR, Hays RD, Gritz ER, Bastani R, Crane L, Elashoff R, et al</AU>
<TI>Patient adherence to cancer control regimens: scale development and initial validation</TI>
<SO>Psychological Assessment</SO>
<YR>1993</YR>
<VL>5</VL>
<NO>1</NO>
<PG>102-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dwan-2008" MODIFIED="2013-02-06 12:37:02 +0000" MODIFIED_BY="Heather Waterman" NAME="Dwan 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, et al</AU>
<TI>Systematic review of the empirical evidence of study publication bias and outcome reporting bias</TI>
<SO>PLoS Hub for Clinical Trials</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>8</NO>
<PG>e3081</PG>
<IDENTIFIERS MODIFIED="2013-02-04 13:39:55 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Fraser-1999" MODIFIED="2013-02-04 10:34:43 +0000" MODIFIED_BY="Trish Gray" NAME="Fraser 1999" TYPE="JOURNAL_ARTICLE">
<AU>Fraser S, Bunce C, Wormald R</AU>
<TI>Risk factors for late presentation in chronic glaucoma</TI>
<SO>Investigative Ophthalmology and Visual Science</SO>
<YR>1999</YR>
<VL>40</VL>
<NO>10</NO>
<PG>2251-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Friedman-2007" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" NAME="Friedman 2007" TYPE="JOURNAL_ARTICLE">
<AU>Friedman DS, Jampel HD, Congdon NG, Miller R, Quigley HA</AU>
<TI>The Travatan dosing aid accurately records when drops are taken</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2007</YR>
<VL>143</VL>
<NO>4</NO>
<PG>699-701</PG>
<IDENTIFIERS MODIFIED="2013-02-04 10:35:06 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Glanville-2006" MODIFIED="2009-02-18 14:57:08 +0000" MODIFIED_BY="[Empty name]" NAME="Glanville 2006" TYPE="JOURNAL_ARTICLE">
<AU>Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J</AU>
<TI>How to identify randomized controlled trials in MEDLINE: ten years on</TI>
<SO>Journal of the Medical Library Association</SO>
<YR>2006</YR>
<VL>94</VL>
<NO>2</NO>
<PG>130-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gordon-2008" MODIFIED="2013-02-04 10:41:36 +0000" MODIFIED_BY="[Empty name]" NAME="Gordon 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gray-2010" MODIFIED="2013-02-04 10:42:01 +0000" MODIFIED_BY="[Empty name]" NAME="Gray 2010" TYPE="JOURNAL_ARTICLE">
<AU>Gray TA, Fenerty C, Harper R, Lee A, Spencer AF, Campbell M, et al</AU>
<TI>Preliminary survey of educational support for patients prescribed ocular hypotensive therapy</TI>
<SO>Eye</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>12</NO>
<PG>1777-86</PG>
<IDENTIFIERS MODIFIED="2013-02-04 10:41:57 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Haynes-1979" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" NAME="Haynes 1979" TYPE="BOOK">
<AU>Haynes RB, Sacket DL, Taylor DW</AU>
<SO>Compliance in Healthcare</SO>
<YR>1979</YR>
<PB>Johns Hopkins University Press</PB>
<CY>Baltimore, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haynes-2008" MODIFIED="2013-02-04 10:44:48 +0000" MODIFIED_BY="[Empty name]" NAME="Haynes 2008" TYPE="COCHRANE_REVIEW">
<AU>Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X</AU>
<TI>Interventions for enhancing medication adherence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-02-04 10:44:48 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-02-04 10:44:48 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000011.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heijl-2002" MODIFIED="2008-11-26 14:28:25 +0000" MODIFIED_BY="Trish Gray" NAME="Heijl 2002" TYPE="JOURNAL_ARTICLE">
<AU>Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M</AU>
<TI>Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2002</YR>
<VL>120</VL>
<NO>10</NO>
<PG>1268-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herman-2010" MODIFIED="2013-02-04 10:46:57 +0000" MODIFIED_BY="Heather Waterman" NAME="Herman 2010" TYPE="JOURNAL_ARTICLE">
<AU>Hermann MM, Ustündag C, Diestelhorst M</AU>
<TI>Electronic monitoring of topical treatment after ophthalmic surgery</TI>
<SO>International Ophthalmology</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>4</NO>
<PG>385-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hermann-2006" MODIFIED="2009-02-18 15:32:43 +0000" MODIFIED_BY="[Empty name]" NAME="Hermann 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hermann MM, Diestelhorst M</AU>
<TI>Microprocessor controlled compliance monitor for eye drop medication</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>2006</YR>
<VL>90</VL>
<NO>7</NO>
<PG>830-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-04-20 14:20:32 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)</SO>
<YR>2011</YR>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horne-1999" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" NAME="Horne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Horne R, Weinman J, Hankins M</AU>
<TI>The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication</TI>
<SO>Psychology and Health</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>1</NO>
<PG>1-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horne-2006" MODIFIED="2013-02-04 10:50:29 +0000" MODIFIED_BY="[Empty name]" NAME="Horne 2006" TYPE="JOURNAL_ARTICLE">
<AU>Horne, R</AU>
<TI>Compliance, adherence, and concordance: implications for asthma treatment</TI>
<SO>Chest</SO>
<YR>2006</YR>
<VL>130</VL>
<NO>Suppl 1</NO>
<PG>65S-72S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Howie-1998" MODIFIED="2013-02-04 10:50:51 +0000" MODIFIED_BY="[Empty name]" NAME="Howie 1998" TYPE="JOURNAL_ARTICLE">
<AU>Howie JG, Heaney DJ, Maxwell M, Walker JJ</AU>
<TI>A comparison of a Patient Enablement Instrument (PEI) against two established satisfaction scales as an outcome measure of primary care consultations</TI>
<SO>Family Practice</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>2</NO>
<PG>165-71</PG>
<IDENTIFIERS MODIFIED="2013-02-04 10:50:46 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Iester-2002" MODIFIED="2008-11-26 14:28:25 +0000" MODIFIED_BY="Trish Gray" NAME="Iester 2002" TYPE="JOURNAL_ARTICLE">
<AU>Iester M, Zingirian M</AU>
<TI>Quality of life in patients with early, moderate and advanced glaucoma</TI>
<SO>Eye</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>1</NO>
<PG>44-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kholdebarin-2008" MODIFIED="2013-02-04 10:52:26 +0000" MODIFIED_BY="Heather Waterman" NAME="Kholdebarin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Kholdebarin R, Campbell RJ, Jin YP, Buys YM</AU>
<TI>Mulitcenter study of compliance and drop administration in glaucoma</TI>
<SO>Canadian Journal of Ophthalmology</SO>
<YR>2008</YR>
<VL>43</VL>
<NO>4</NO>
<PG>454-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lacey-2009" MODIFIED="2013-02-04 10:54:20 +0000" MODIFIED_BY="[Empty name]" NAME="Lacey 2009" TYPE="JOURNAL_ARTICLE">
<AU>Lacey J, Cate H, Broadway DC</AU>
<TI>Barriers to adherence with glaucoma medications: a qualitative research study</TI>
<SO>Eye</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>4</NO>
<PG>924-32</PG>
<IDENTIFIERS MODIFIED="2009-02-11 20:54:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Leonard-2006" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" NAME="Leonard 2006" TYPE="JOURNAL_ARTICLE">
<AU>Leonard K, Masatu MC</AU>
<TI>Outpatient process quality evaluation and the Hawthorne effect</TI>
<SO>Social Science and Medicine</SO>
<YR>2006</YR>
<VL>63</VL>
<NO>9</NO>
<PG>2330-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leonard-2008" MODIFIED="2009-02-18 15:54:27 +0000" MODIFIED_BY="[Empty name]" NAME="Leonard 2008" TYPE="JOURNAL_ARTICLE">
<AU>Leonard KL</AU>
<TI>Is patient satisfaction sensitive to changes in the quality of care? An exploitation of the Hawthorne effect</TI>
<SO>Journal of Health Economics</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>2</NO>
<PG>444-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lu-2010" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Heather Waterman" NAME="Lu 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lu VH, Goldberg I, Lu CY</AU>
<TI>Use of glaucoma medications: state of the science and directions for observational research</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2010</YR>
<VL>550</VL>
<NO>4</NO>
<PG>568-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lunnela-2010" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Heather Waterman" NAME="Lunnela 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lunnela J, Kaariainen M, Kyngas H</AU>
<TI>The views of compliant glaucoma patients on counselling and support</TI>
<SO>Scandinavian Journal of Caring Science</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>3</NO>
<PG>490-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maier-2005" MODIFIED="2013-02-04 10:58:06 +0000" MODIFIED_BY="Trish Gray" NAME="Maier 2005" TYPE="JOURNAL_ARTICLE">
<AU>Maier PC, Funk J, Schwarzer G, Antes G, Falck-Ytter YT</AU>
<TI>Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials</TI>
<SO>BMJ</SO>
<YR>2005</YR>
<VL>331</VL>
<NO>7509</NO>
<PG>134</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mangione-2001" MODIFIED="2008-11-26 14:28:25 +0000" MODIFIED_BY="Trish Gray" NAME="Mangione 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD, et al</AU>
<TI>Development of the 25-Item National Eye Institute Visual Function Questionnaire</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2001</YR>
<VL>119</VL>
<NO>7</NO>
<PG>1050-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mangione_x002d_Smith-2002" MODIFIED="2009-02-18 15:57:36 +0000" MODIFIED_BY="[Empty name]" NAME="Mangione-Smith 2002" TYPE="JOURNAL_ARTICLE">
<AU>Mangione-Smith R, Elliott MN, McDonald L, McGlynn EA</AU>
<TI>An observational study of antibiotic prescribing behavior and the Hawthorne effect</TI>
<SO>Health Services Research</SO>
<YR>2002</YR>
<VL>37</VL>
<NO>6</NO>
<PG>1603-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moss_x002d_Morris-2002" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" NAME="Moss-Morris 2002" TYPE="JOURNAL_ARTICLE">
<AU>Moss-Morris R, Weinman J, Petrie K, Horne R, Cameron L, Buick D</AU>
<TI>The revised IIlness Perception Questionnaire (IPQ-R)</TI>
<SO>Psychology and Health</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-2006" MODIFIED="2009-02-18 16:00:58 +0000" MODIFIED_BY="[Empty name]" NAME="Nelson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Nelson MR, Reid CM, Ryan P, Willson K, Yelland L</AU>
<TI>Self-reported adherence with medication and cardiovascular disease outcomes in the Second Australian National Blood Pressure Study (ANBP2)</TI>
<SO>Medical Journal of Australia</SO>
<YR>2006</YR>
<VL>185</VL>
<NO>9</NO>
<PG>487-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2009" MODIFIED="2013-02-04 11:06:15 +0000" MODIFIED_BY="Heather Waterman" NAME="NICE 2009" TYPE="OTHER">
<AU>NICE</AU>
<TI>Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension</TI>
<SO>www.nice.org.uk/nicemedia/live/12145/43839/43839.pdf</SO>
<YR>(accessed 7 November 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Hare-2009" MODIFIED="2013-02-04 11:07:22 +0000" MODIFIED_BY="Heather Waterman" NAME="O'Hare 2009" TYPE="JOURNAL_ARTICLE">
<AU>O'Hare F, Jeganathan VS, Rokhar CG, Rogers SL, Crowston JG</AU>
<TI>Readability of prescription labels and medication refill in a population of tertiary referral glaucoma patients</TI>
<SO>Clinical and Experimental Ophthalmology</SO>
<YR>2009</YR>
<VL>37</VL>
<NO>9</NO>
<PG>849-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olthoff-2005" MODIFIED="2008-11-26 14:28:25 +0000" MODIFIED_BY="Trish Gray" NAME="Olthoff 2005" TYPE="JOURNAL_ARTICLE">
<AU>Olthoff CM, Schouten JS, van de Borne BW, Webers CA</AU>
<TI>Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review</TI>
<SO>Ophthalmology</SO>
<YR>2005</YR>
<VL>112</VL>
<NO>6</NO>
<PG>953-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parker-1995" MODIFIED="2013-02-04 11:08:19 +0000" MODIFIED_BY="[Empty name]" NAME="Parker 1995" TYPE="JOURNAL_ARTICLE">
<AU>Parker RM, Baker DW, Williams MV, Nurss JR</AU>
<TI>The test of functional health literacy in adults: a new instrument for measuring patients' literacy skills</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>10</NO>
<PG>537-41</PG>
<IDENTIFIERS MODIFIED="2013-02-04 11:08:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Patel-1995" MODIFIED="2008-11-26 14:28:25 +0000" MODIFIED_BY="Trish Gray" NAME="Patel 1995" TYPE="JOURNAL_ARTICLE">
<AU>Patel SC, Spaeth GL</AU>
<TI>Compliance in patients prescribed eyedrops for glaucoma</TI>
<SO>Ophthalmic Surgery</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>3</NO>
<PG>233-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quigley-2006" MODIFIED="2009-02-18 22:36:55 +0000" MODIFIED_BY="Anupa Shah" NAME="Quigley 2006" TYPE="JOURNAL_ARTICLE">
<AU>Quigley HA, Broman AT</AU>
<TI>The number of people with glaucoma worldwide in 2010 and 2020</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>2006</YR>
<VL>90</VL>
<NO>3</NO>
<PG>262-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reardon-2004" MODIFIED="2013-02-04 11:09:26 +0000" MODIFIED_BY="Trish Gray" NAME="Reardon 2004" TYPE="JOURNAL_ARTICLE">
<AU>Reardon G, Schwartz GF, Mozaffari E</AU>
<TI>Patient persistency with topical ocular hypotensive therapy in a managed care population</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2004</YR>
<VL>137</VL>
<NO>Suppl 1</NO>
<PG>S3-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reardon-2011" MODIFIED="2013-02-04 13:37:52 +0000" MODIFIED_BY="Heather Waterman" NAME="Reardon 2011" TYPE="JOURNAL_ARTICLE">
<AU>Reardon G, Kotak S, Schwatz GF</AU>
<TI>Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review</TI>
<SO>Patient Preference and Adherence</SO>
<YR>2011</YR>
<VL>5</VL>
<PG>451-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reidy-1998" MODIFIED="2013-02-04 11:12:18 +0000" MODIFIED_BY="[Empty name]" NAME="Reidy 1998" TYPE="JOURNAL_ARTICLE">
<AU>Reidy A, Minassian DC, Vafidis G, Joseph J, Farrow S, Wu J, et al</AU>
<TI>Prevalence of serious eye disease and visual impairment in a north London population: population based, cross sectional study</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>316</VL>
<NO>7145</NO>
<PG>1643-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ross-2004" MODIFIED="2009-02-18 16:09:58 +0000" MODIFIED_BY="[Empty name]" NAME="Ross 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ross S, Walker A, MacLeod MJ</AU>
<TI>Patient compliance in hypertension: role of illness perceptions and treatment beliefs</TI>
<SO>Journal of Human Hypertension</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>9</NO>
<PG>607-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rotchford-1998" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" NAME="Rotchford 1998" TYPE="JOURNAL_ARTICLE">
<AU>Rotchford AP, Murphy KM</AU>
<TI>Compliance with timolol treatment in glaucoma</TI>
<SO>Eye</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>Pt 2</NO>
<PG>234-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royal-Pharmaceutical-Society-of-Great-Britain-1997" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" NAME="Royal Pharmaceutical Society of Great Britain 1997" TYPE="CONFERENCE_PROC">
<AU>Royal Pharmaceutical Society of Great Britain</AU>
<SO>From compliance to concordance: achieving shared goals in medicine taking</SO>
<YR>1997</YR>
<PB>RPS</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rudnicka-2006" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" NAME="Rudnicka 2006" TYPE="JOURNAL_ARTICLE">
<AU>Rudnicka AR, Shahrul M, Owen CG, Cook DG, Ashby D</AU>
<TI>Variations in primary open angle glaucoma prevalence by age, gender and race: a Bayesian meta-analysis</TI>
<SO>Investigative Ophthalmology and Visual Science</SO>
<YR>2006</YR>
<VL>47</VL>
<NO>10</NO>
<PG>4254-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-2010" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Heather Waterman" NAME="Schulz 2010" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Altman DG, Moher D, for the CONSORT group</AU>
<TI>CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c332</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwartz-2008" MODIFIED="2013-02-06 12:43:45 +0000" MODIFIED_BY="Heather Waterman" NAME="Schwartz 2008" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz GF, Plake KS, Mychaskiw MA</AU>
<TI>An assessment of readiness for behaviour change in patients prescribed ocular hypotensive therapy</TI>
<SO>Eye</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>8</NO>
<PG>1668-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Senior-2004" MODIFIED="2013-02-04 11:39:34 +0000" MODIFIED_BY="[Empty name]" NAME="Senior 2004" TYPE="JOURNAL_ARTICLE">
<AU>Senior V, Marteau TM, Weinman J. Genetic Risk Assessment for FH Trial (GRAFT) Study Group</AU>
<TI>Self-reported adherence to cholesterol-lowering medication in patients with familial hypercholesterolaemia: the role of illness perceptions</TI>
<SO>Cardiovascular Drugs and Therapy</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>6</NO>
<PG>475-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sleath-2012" MODIFIED="2013-02-04 11:40:54 +0000" MODIFIED_BY="Heather Waterman" NAME="Sleath 2012" TYPE="JOURNAL_ARTICLE">
<AU>Sleath B, Blalock SJ, Stone JL, Cockrell-Skinner A, Covert D, Muir K, et al</AU>
<TI>Validation of a short version of the glaucoma self-efficacy questionnaire </TI>
<SO>British Journal of Ophthalmology</SO>
<YR>2012</YR>
<VL>96</VL>
<NO>2</NO>
<PG>258-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spaeth-2006" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" NAME="Spaeth 2006" TYPE="JOURNAL_ARTICLE">
<AU>Spaeth G, Walt J, Keener J, Spaeth G, Walt J, Keener J</AU>
<TI>Evaluation of quality of life for patients with glaucoma</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2006</YR>
<VL>141</VL>
<NO>Suppl 1</NO>
<PG>S3-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spry-2005" MODIFIED="2008-11-26 14:28:25 +0000" MODIFIED_BY="Trish Gray" NAME="Spry 2005" TYPE="JOURNAL_ARTICLE">
<AU>Spry PG, Sparrow JM, Diamond JP, Harris HS</AU>
<TI>Risk factors for progressive visual field loss in primary open angle glaucoma</TI>
<SO>Eye</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>6</NO>
<PG>643-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taylor-2002" MODIFIED="2013-02-04 11:41:53 +0000" MODIFIED_BY="[Empty name]" NAME="Taylor 2002" TYPE="JOURNAL_ARTICLE">
<AU>Taylor SA, Gailbraith SM, Mills RP</AU>
<TI>Causes of non-compliance with drug regimes in glaucoma patients: a qualitative study</TI>
<SO>Journal of Ocular Pharmacology and Therapeutics</SO>
<YR>2002</YR>
<VL>18</VL>
<NO>5</NO>
<PG>401-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Treharne-2004" MODIFIED="2013-02-04 11:42:36 +0000" MODIFIED_BY="[Empty name]" NAME="Treharne 2004" TYPE="JOURNAL_ARTICLE">
<AU>Treharne GJ, Lyons AC, Kitas GD</AU>
<TI>Medication adherence in rheumatoid arthritis: effects of psychosocial factors</TI>
<SO>Psychology, Health and Medicine</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>3</NO>
<PG>337-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsai-2003" MODIFIED="2008-11-26 14:28:25 +0000" MODIFIED_BY="Trish Gray" NAME="Tsai 2003" TYPE="JOURNAL_ARTICLE">
<AU>Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW</AU>
<TI>Compliance barriers in glaucoma: a systematic classification</TI>
<SO>Journal of Glaucoma</SO>
<YR>2003</YR>
<VL>12</VL>
<NO>5</NO>
<PG>393-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ulrik-2006" MODIFIED="2013-02-04 11:43:07 +0000" MODIFIED_BY="[Empty name]" NAME="Ulrik 2006" TYPE="JOURNAL_ARTICLE">
<AU>Ulrik CS, Backer V, Soes-Petersen U, Lange P, Harving H, Plaschke PP</AU>
<TI>The patient's perspective: adherence or non-adherence to asthma controller therapy?</TI>
<SO>Journal of Asthma</SO>
<YR>2006</YR>
<VL>43</VL>
<NO>9</NO>
<PG>701-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Urquhart-1999" MODIFIED="2008-11-26 14:28:25 +0000" MODIFIED_BY="Trish Gray" NAME="Urquhart 1999" TYPE="JOURNAL_ARTICLE">
<AU>Urquhart J</AU>
<TI>Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens</TI>
<SO>Pharmacoeconomics</SO>
<YR>1999</YR>
<VL>15</VL>
<NO>3</NO>
<PG>217-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Dulmen-2007" MODIFIED="2009-02-18 22:21:34 +0000" MODIFIED_BY="Anupa Shah" NAME="van Dulmen 2007" TYPE="JOURNAL_ARTICLE">
<AU>van Dulmen S, Sluijs E, van Dijk L, de Ridder D, Heerdink R, Bensing J</AU>
<TI>Patient adherence to medical treatment: a review of reviews</TI>
<SO>BMC Health Services Research</SO>
<YR>2007</YR>
<VL>7</VL>
<PG>55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vanelli-2009" MODIFIED="2013-02-04 11:43:41 +0000" MODIFIED_BY="Heather Waterman" NAME="Vanelli 2009" TYPE="JOURNAL_ARTICLE">
<AU>Vanelli M, Pedan A, Hoar J, Messier D, Kiarsis K</AU>
<TI>The role of patient inexperience in medication discontinuation: a retrospective analysis of medication non-persistence in seven chronic diseases</TI>
<SO>Clinical Therapeutics</SO>
<YR>2009</YR>
<VL>31</VL>
<NO>11</NO>
<PG>2628-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vrijens-2012" MODIFIED="2013-02-04 11:45:10 +0000" MODIFIED_BY="Heather Waterman" NAME="Vrijens 2012" TYPE="JOURNAL_ARTICLE">
<AU>Vrijens B, De Geest S, Hughes DA, Kardas P, Demonceau J, Ruppar T, et al</AU>
<TI>A new taxonomy for describing and defining adherence to medication</TI>
<SO>British Journal of Pharmacology</SO>
<YR>2012</YR>
<VL>73</VL>
<NO>5</NO>
<PG>691-705</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weis-2003" MODIFIED="2013-02-04 11:45:30 +0000" MODIFIED_BY="[Empty name]" NAME="Weis 2003" TYPE="JOURNAL_ARTICLE">
<AU>Weis M, Britten B</AU>
<TI>What is concordance?</TI>
<SO>Pharmaceutical Journal</SO>
<YR>2003</YR>
<VL>271</VL>
<NO>7270</NO>
<PG>493</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetzels-2006" MODIFIED="2009-02-18 16:39:52 +0000" MODIFIED_BY="[Empty name]" NAME="Wetzels 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wetzels G, Nelemans P, van Wijk B, Broers N, Schouten J, Prins M</AU>
<TI>Determinants of poor adherence in hypertensive patients: development and validation of the "Maastricht Utrecht Adherence in Hypertension (MUAH)-questionnaire"</TI>
<SO>Patient Education and Counseling</SO>
<YR>2006</YR>
<VL>64</VL>
<NO>1-3</NO>
<PG>151-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilensky-2006" MODIFIED="2013-02-04 11:46:09 +0000" MODIFIED_BY="Trish Gray" NAME="Wilensky 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wilensky J, Fiscella RG, Carlson AM, Morris LS, Walt J</AU>
<TI>Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2006</YR>
<VL>141</VL>
<NO>Suppl 1</NO>
<PG>S28-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yu-2005" MODIFIED="2009-02-16 21:43:54 +0000" MODIFIED_BY=" Iris Gordon" NAME="Yu 2005" TYPE="JOURNAL_ARTICLE">
<AU>Yu YF, Nichol MB, Yu AP, Ahn J</AU>
<TI>Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California medicaid program</TI>
<SO>Value Health</SO>
<YR>2005</YR>
<VL>8</VL>
<NO>4</NO>
<PG>495-505</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-02-04 13:23:30 +0000" MODIFIED_BY="Heather Waterman">
<REFERENCE ID="REF-Gray-2009" MODIFIED="2013-02-04 13:23:30 +0000" MODIFIED_BY="Heather Waterman" NAME="Gray 2009" TYPE="COCHRANE_REVIEW">
<AU>Gray T, Orton LC, Henson D, Harper R, Waterman H</AU>
<TI>Interventions for improving adherence to ocular hypotensive therapy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-02-04 13:22:40 +0000" MODIFIED_BY="Heather Waterman">
<IDENTIFIER MODIFIED="2013-02-04 13:22:40 +0000" MODIFIED_BY="Heather Waterman" TYPE="DOI" VALUE="10.1002/14651858.CD006132.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-02-26 12:40:37 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-02-26 12:40:37 +0000" MODIFIED_BY="Anupa Shah" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gray-2011">
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, single-centre, observer masked, parallel-group study</P>
<P>Duration: 24 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Country: UK</P>
<P>Setting: hospital outpatient clinic</P>
<P>Target number of participants: 127</P>
<P>Gender: 64 men, 63 women</P>
<P>Age range: 30 to 91, mean age 66 years</P>
<P>Ethnicity: 114 (90%) white, 8 (6%) black, 5 (4%) other</P>
<P>Inclusion criteria: patients newly prescribed ocular hypotensive eye drops with a diagnosis of OAG, normal tension glaucoma, pseudo-exfoliation glaucoma, pigment dispersion glaucoma or OHT</P>
<P>Exclusion criteria: patients unable to give informed consent or patients already prescribed a complicated drop regime for another eye condition</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention group: individualised programme of care carried out by an ophthalmic-trained nurse based on an assessment that takes into account factors such as other medical conditions, additional medications, independence with daily living activities, potential problems managing an eye drop regime and beliefs about medications. Patients also continue to receive the information, advice and training they would normally be given within the outpatients department.<BR/>
</P>
<P>Control group: usual care; patients receive the information, advice and training they would normally be given within the outpatients department</P>
<P>Follow-up: 1 year<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Persistence of therapy measured by counting prescription and dispensing data</P>
<P>Adherence to therapy assessed through self report via interviewer-administered questionnaire</P>
<P>Beliefs about illness and medicines assessed through self report via previously validated, interviewer-administered questionnaires</P>
<P>Patient enablement assessed through self report via previously validated, interviewer-administered questionnaires</P>
<P>Intraocular pressure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Funding sources: part-funded by Pfizer</P>
<P>http://www.controlled-trials.com/ISRCTN13706134</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hermann-2011a">
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, single-centre, observer masked, parallel-group study</P>
<P>Duration: 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Greece</P>
<P>Setting: hospital outpatient clinic</P>
<P>Number of participants: 36</P>
<P>Gender: 11 men, 25 women</P>
<P>Age range: 26 to 76, mean age 55.1 +/- 14</P>
<P>Ethnicity: Caucasian</P>
<P>61% ocular hypertension</P>
<P>Inclusion criteria: age more than 18 years; diagnosis of primary open-angle glaucoma or ocular hypertension; established topical hypotensive therapy with brimonidine; no history of ocular surgery in the past 6 months</P>
<P>Exclusion criteria: none</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Open or masked monitoring and brimonidine twice daily or 3 times daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-28 12:55:55 +0000" MODIFIED_BY="[Empty name]">
<P>Dosing interval, applications per day, adherence rate, coverage. Assessed using an electronic monitoring device. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Funding sources: not reported. This statement was included in the published paper <I>"The authors did not receive support from a for-profit organization."</I>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hermann-2011b">
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, single-centre, observer masked, parallel-group study</P>
<P>Duration: 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Country: France</P>
<P>Setting: hospital outpatient clinic</P>
<P>Number of participants: 75</P>
<P>Gender: 44 men, 31 women</P>
<P>Age range: 42 to 89 years, mean age 70.0 +/- 11.2 years</P>
<P>Ethnicity: 100% white</P>
<P>Inclusion criteria: 18 years of age or older taking topical therapy for open-angle glaucoma, chronic angle-closure glaucoma, or ocular hypertension; no history of ocular surgery in the past 3 months; minimum of 12 months experience with topical glaucoma therapy</P>
<P>Exclusion criteria: none</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Brimonidine twice daily and 3 times daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Electronic monitoring</P>
<P>Dosing interval</P>
<P>Applications per day</P>
<P>Adherence rate %</P>
<P>Coverage %</P>
<P>Medication used per dosing</P>
<P>Drops per dosing</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Funding sources: <I>"The authors did not receive support from a for-profit organization."</I>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-I_x002d_SIGHT">
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, multi-centre, observer masked, parallel-group study</P>
<P>Duration: 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Country: USA</P>
<P>Setting: outpatient clinic</P>
<P>Number of participants: 312</P>
<P>Gender: 195 men, 117 women</P>
<P>Age range: 18 to 80 years, mean age 62.6 years</P>
<P>Study participants were patients with glaucoma considered to non-adherent <I>"because they did not take their medication, refill their medication, and/or keep their appointments"</I>
</P>
<P>Inclusion criteria: receive treatment for their eye condition at 1 of the 2 participating eye clinics; be between the ages of 18 and 80 years; be white or black/African American; have a home or cellular telephone; speak and understand English; be diagnosed with glaucoma or ocular hypertension for at least 1 year; be prescribed daily doses of topical glaucoma treatments for at least the past year; not have had eye surgery within the past 3 months; have better than 20/200 vision in at least 1 eye; and be able to read or have someone who can help them with reading printed materials</P>
<P>Patients also had to acknowledge non-adherence in the past year with medication taking, obtaining refills or clinic appointments</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention group: 12 telephone calls over 9 months delivered automatically including tailored information on adherence and glaucoma. The intervention was <I>"individually tailored to a participant&#8217;s knowledge, attitudes, and behaviors; psychosocial predictors of adherence; health literacy; race and culture; and prescribed medication regimen."</I>
</P>
<P>Control group: usual care</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Adherence (self report of missed doses)</P>
<P>Prescription refills (pharmacy records)</P>
<P>Appointment keeping<BR/>Sources of information: interviews, medical record review, appointment records and pharmacy data</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-18 13:30:54 +0100" MODIFIED_BY="[Empty name]">
<P>http://clinicaltrials.gov/ct2/show/NCT00794170</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Laibovitz-1996">
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Randomised, single-centre, observer masked, 2-period cross-over study</P>
<P>Duration: 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Country: USA</P>
<P>Setting: outpatient clinic</P>
<P>Number of participants: 75</P>
<P>Gender: 36 men, 39 women</P>
<P>Age range: 24 to 88 years, mean age 55.7 years</P>
<P>Ethnicity: white: 29/312 (9.3%), black 283/312 (90.7%)</P>
<P>Inclusion criteria: men and women aged 18 years or older with OAG or OHT who were clinically suitable for adjunctive therapy. Patients treated with an ophthalmic beta-blocker for at least 3 weeks prior to randomisation.</P>
<P>Exclusion criteria: patients prescribed dorzolamide or pilocarpine in the past, visual acuity of worse than 20/80 in both eyes, history or evidence of acute or chronic ACG, insufficient pupillary dilation for an adequate retinal examination, history or presence of uveitis or retinal detachment. Patients with asthma or chronic obstructive pulmonary disease, clinically significant renal disease, severe physical disability or any contraindication to the use of dorzolamide, timolol or pilocarpine ophthalmic solution.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" NOTES="&lt;p&gt;kkkkkkkkkkkkkk&lt;/p&gt;" NOTES_MODIFIED="2013-02-06 13:18:58 +0000" NOTES_MODIFIED_BY="Trish Gray">
<P>Group A: 2% dorzolamide 3 times daily during period 1 and 2% pilocarpine 4 times daily during period 2</P>
<P>Group B: 2% pilocarpine 4 times daily during period 1 and 2% dorzolamide 3 times daily during period 2</P>
<P>Both groups continued to receive 0.5% timolol twice daily throughout the study</P>
<P>Follow-up: short-term; 14 days per period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Adherence assessed through self report via interviewer-administered questionnaire using previously validated tool (COMTol). Patients were asked how often they missed eye drops. Responses were marked on a scale of 0 to 6: 0 = never, 6 = always.</P>
<P>Quality of life assessed via interviewer-administered questionnaire (COMTol). Patients asked whether quality of life was interfered with by side effects or activity limitations. Responses were marked on a scale of 0 to 5: 0 = not at all, 5 = extremely.</P>
<P>IOP reduction assessed with Goldmann applanation tonometer</P>
<P>Visual field defects assessed with Humphrey Field Analyser 24-2 programme</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray">
<P>Funding Sources: Sponsored by Merck &amp; Co</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Laster-1996">
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Randomised, single-centre, 2-period cross-over study</P>
<P>Duration: 60 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Country: USA</P>
<P>Setting: university-based glaucoma clinic</P>
<P>Number of participants: 13</P>
<P>Gender: 2 men, 11 women</P>
<P>Age range and mean age: data unavailable</P>
<P>Ethnicity: data unavailable</P>
<P>Inclusion criteria: patients diagnosed with OAG who were prescribed pilocarpine solution 4 times a day</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray">
<P>Group 1: pre-weighed bottle of pilocarpine of appropriate concentration (according to prescription) in a medication vial fitted with the Prescript TimeCap in period 1 and pre-weighed bottle of pilocarpine of appropriate concentration (according to prescription) without the vial or cap in period 2</P>
<P>Group 2: pre-weighed bottle of pilocarpine of appropriate concentration (according to prescription) without the vial or cap in period 1 and pre-weighed bottle of pilocarpine of appropriate concentration (according to prescription) in a medication vial fitted with the TimeCap in period 2</P>
<P>Follow-up: short-term; 30 days per period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray">
<P>Adherence assessed by weighing the drop bottle at the end of each 30-day period and also through self report via a patient questionnaire completed at the end of each period</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Funding sources: non-commercially funded</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muir-2012">
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, single-centre, parallel-group study</P>
<P>Duration: 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Country: USA</P>
<P>Setting: medical centre</P>
<P>Number of participants: 127 (131 enrolled, 4 withdrew)</P>
<P>Gender: 126 men, 1 woman</P>
<P>Age range 43 to 87 years; mean age: 66 years (SD 9.6)</P>
<P>Ethnicity: 29% white, 80% African American, 1% other</P>
<P>Inclusion criteria: score of 18 or higher on Mini Mental State Examination patients diagnosed with OAG who were prescribed pilocarpine solution 4 times a day</P>
<P>Exclusion criteria: best-corrected visual acuity in the better seeing eye &lt; 20/200; eye surgery in the past month</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-29 15:54:32 +0100" MODIFIED_BY="[Empty name]">
<P>Educational intervention lasting 20 minutes (one-on-one session) including "informational video". Language of video varied according to participants' tested health literacy level. </P>
<P>Standard care </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Number of days without medication</P>
<P>Medication possession ratio</P>
<P>Self reported disease knowledge</P>
<P>Satisfaction with care</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Funding sources: non-commercially funded</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nakakura-2012">
<CHAR_METHODS MODIFIED="2012-07-02 10:18:35 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, multi-centre, parallel-group study</P>
<P>Duration: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Japan</P>
<P>Setting: hospital</P>
<P>Number of participants: 36 (39 enrolled, 3 withdrew)</P>
<P>Gender: 19 men, 17 women</P>
<P>Average age: 71 years</P>
<P>Ethnicity: not reported, assumed Japanese</P>
<P>Inclusion criteria: primary open-angle glaucoma; exhibition of a stable intraocular pressure for more than 3 months; no history of fixed-combination therapy; treated with 3 antiglaucoma eye drops (various preparations of prostaglandin F2-alpha analogues + beta-blockers + carbonic anhydrase inhibitors)<BR/>Exclusion criteria: congenital or narrow-angle glaucoma; ocular surgery including laser surgery within the previous 6 months; any previous glaucoma surgery; ocular inflammation, neovascular glaucoma or steroid-induced glaucoma; any other conditions that prevent use of the Goldmann applanation tonometer; at risk of visual acuity and visual fields worsening during this study; allergy to preservatives</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Latanoprost 0.005%/timolol 0.5% plus brinzolamide 1%<BR/>Dorzolamide 1%/timolol 0.5% plus latanoprost 0.005%</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 11:16:39 +0000" MODIFIED_BY="[Empty name]">
<P>Intraocular pressure</P>
<P>Questionnaire including question <I>"How often do you forget administration per week?"</I>
</P>
<P>Adverse effects</P>
<P>If both eyes included, right eye analysed</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-02 10:24:26 +0100" MODIFIED_BY="[Empty name]">
<P>Funding not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Norell-1979">
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Randomised, single-centre, 2-period, parallel-group study. Randomisation stratified by age.</P>
<P>Duration: 40 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Country: Sweden</P>
<P>Setting: hospital outpatient clinic</P>
<P>Number of participants: 73 (82 recruited, 9 excluded from analysis)</P>
<P>Gender: 45 men, 37 women</P>
<P>Age range: 50 to 90 years, median age 73 years</P>
<P>Ethnicity: not stated</P>
<P>Inclusion criteria: patients with chronic simple glaucoma, glaucomatous visual field defect, cupping of optic disc, raised IOP and prescribed pilocarpine eye drops 3 times a day in an eye with visual acuity of least 2/60</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray">
<P>Experimental group: no intervention for the first 20-day monitoring period, then 30-minute education and tailoring programme implemented at clinic appointment and monitoring continued for a further 20 days. Education involved basic information on glaucoma and its treatment, supplied by a tape-slide show and leaflet. Patients' knowledge and understanding was then checked by ophthalmology assistant and insufficiently mastered information re-emphasised. Patients were encouraged to ask questions and discuss problems with medication. Tailoring involved patient interview with an ophthalmology assistant to ascertain daily routine and to advise on best times to instil eye drops within daily routine. Advice given re: storage of drops. Times and drop routine written for each patient.</P>
<P>Control group: monitoring for 2 x 20-day periods, no intervention</P>
<P>Follow-up: short-term; 20 days per period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray">
<P>Adherence to therapy assessed with a medication monitor which recorded the date and hour each time the medication bottle was opened</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray">
<P>Funding sources: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-06 14:12:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Okeke-2009">
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, 2-centre, 2-period, parallel-group study</P>
<P>Duration: 3 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 14:12:38 +0000" MODIFIED_BY="[Empty name]">
<P>Country: USA</P>
<P>Setting: Glaucoma Services of the Wilmer Eye Institute and the Scheie Eye Institute</P>
<P>Number of participants: 66</P>
<P>Gender:3 6 men, 30 women</P>
<P>Age range: mean age 66.1 in intervention group; 63.8 in the control group</P>
<P>Ethnicity: 40 black, 25 white, 1 Asian</P>
<P>Inclusion criteria: people with glaucoma being treated with a prostaglandin analogue in 1 or both eyes</P>
<P>Exclusion criteria: people were excluded if they were unable to understand the study, they did not put in their own drops, or they could not use the dosing aid</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>The intervention consisted of the following:</P>
<UL>
<LI>10-minute educational video</LI>
<LI>structured discussion</LI>
<LI>reminder telephone calls</LI>
<LI>activation of the audible and visible alarms on the dosing aid</LI>
</UL>
<P>People in the control group received usual care, i.e. were told that it is important to take their eye drops as prescribed but had no other intervention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Adherence rate as measured by a dosing aid device and a questionnaire</P>
<P>Intraocular pressure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Funding sources: supported in part by the National Institutes of Health, charitable grants and Alcon</P>
<P>http://clinicaltrials.gov/ct2/show/NCT00333463</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ring-2011">
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Quasi-experimental, single-centre study</P>
<P>Duration: 3 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Country: UK</P>
<P>Setting: hospital outpatient clinic</P>
<P>Number of participants: 124 (127 recruited, 2 withdrew and 1 died)</P>
<P>Gender: 47 men, 77 women</P>
<P>Age range: 40 to over 80, mean age = 71 years (calculated from frequencies on table 5, page 32), median age 73 years</P>
<P>Ethnicity: 101 white, 12 Asian, 8 black, 3 other</P>
<P>Inclusion criteria: people diagnosed with open-angle glaucoma, ocular hypertension, normal tension glaucoma on ocular hypotensive drops</P>
<P>Exclusion criteria: people who were unable to understand and sign and informed consent form, people who could not see the film clearly</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-02-28 13:48:23 +0000" MODIFIED_BY="[Empty name]">
<P>Educational intervention: specially developed film</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-30 11:46:50 +0100" MODIFIED_BY="[Empty name]">
<P>Questionnaire</P>
<P>Weight of eye drop bottles </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Funding Sources: International Glaucoma Association</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" NOTES="&lt;p&gt;PAC needs adding to footnotes.&lt;/p&gt;" NOTES_MODIFIED="2013-02-06 13:18:58 +0000" NOTES_MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Sakai-2005">
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray">
<P>Quasi-randomised, single-centre, parallel-group study</P>
<P>Duration: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Country: Japan</P>
<P>Setting: university-based ophthalmology clinic</P>
<P>Number of participants: 36 (40 recruited, 2 withdrew after randomisation, 2 excluded after washout period as IOP &lt; 20 mmHg and, therefore, no longer met criteria)</P>
<P>Gender: 14 men, 22 women</P>
<P>Age range: 45 to 75 years, mean age 64 years</P>
<P>Ethnicity: Asian 100%</P>
<P>Inclusion criteria: patients with primary ACG diagnosed by indentation gonioscopy and UBM, existence of synechial angle closure, released pupillary block by LPI at least 3 months before the study and a history of elevated IOP &gt; 21 mmHg without any treatment with antiglaucoma medications</P>
<P>Exclusion criteria: previous ocular surgery other than LPI, acute PAC, use of oral acetazolamide because of poor IOP control, suspected secondary angle closure related to uveal effusion, uveitis, lens subtractions or trauma. Patients who were already scheduled for surgery that would affect IOP such as trabeculectomy or phacoemulsification. Patients prescribed medicines for hypertension, cardiovascular disease, bronchial asthma and allergy to any of the study medication.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Latanoprost (L) group: monotherapy with latanoprost once daily</P>
<P>Timolol/dorzolamide (T/D) group: unfixed combination therapy with 0.5% timolol maleate twice daily and 1% dorzolamide 3 times daily</P>
<P>Follow-up: short-term; 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray">
<P>Adherence assessed though self report via patient questionnaire at 12 weeks. Patients were asked how many times they had forgotten to apply their drops. Pre-defined responses were; less than once a week, once a week, 2 or 3 times a week and 4 or more times a week.</P>
<P>IOP reduction assessed with Goldmann applanation tonometer</P>
<P>Visual field defects assessed with Humphrey Field Analyser, automated perimetry full-threshold 30-2 programme</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray">
<P>Funding sources: none</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Schenker-1999">
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Randomised, multi-centre, 2-period, cross-over study</P>
<P>Duration: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Country: USA</P>
<P>Setting: hospital outpatient clinic</P>
<P>Number of participants: 202</P>
<P>Gender: 77 men, 125 women</P>
<P>Mean age: 59.4 years</P>
<P>Ethnicity: white 142 (70%), black 47 (23%), Hispanic 13 (6%)</P>
<P>Inclusion criteria: patients with a diagnosis of OAG or OHT. IOP &#8805; 22 mmHg in at least 1 eye after a 3-week washout period</P>
<P>Exclusion criteria: contact lens use within 3 weeks of study start, a history of acute or chronic ACG, occludable angles, a history of recent ocular inflammation or foreign body, a history of uveitis, concomitant use of systemic medications known to affect IOP, contraindications to beta-blockers and existing renal disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Group A: timolol gel once daily during period 1 followed by timolol solution twice daily during period 2</P>
<P>Group B: timolol solution twice daily during period 1 followed by timolol gel once daily during period 2</P>
<P>Follow-up: short-term; 6 weeks per period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Adherence assessed through self report via interviewer-administered questionnaire. Patients were asked how often they missed 1 or 2 doses of test medication during the last 2 weeks. Pre-defined responses were scored on a scale of 1 to 5: never = 1, rarely = 2, occasionally = 3, frequently = 4, always = 5.</P>
<P>IOP reduction assessed with Goldmann applanation tonometer</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray">
<P>Funding sources: sponsored by Merck &amp; Co.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Sheppard-2003">
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray">
<P>Randomised, single-centre, parallel-group study</P>
<P>Duration: 3 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Country: UK</P>
<P>Setting: hospital outpatient clinic</P>
<P>Number of participants: 73 (92 recruited, 19 withdrew)</P>
<P>Gender: not stated</P>
<P>Mean age 73 years (SD 11.6)</P>
<P>Ethnicity: not stated</P>
<P>Inclusion criteria: patients with a diagnosis of long-term chronic stable glaucoma</P>
<P>Exclusion criteria: no telephone access, difficulties using the phone, diagnosis of cognitive impairment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Intervention: glaucoma monitoring nurse-led clinic involving consultations of 15 minutes duration divided into 2 parts. The first part was a standard assessment designed to monitor and record health details, such as current health status and recent ocular history. Eye examinations included visual acuity, visual field test and IOP test using Goldmann's applanation tonometry. The second part was a semi-structure educational session tailored to individual patient needs.</P>
<P>Control: general ophthalmic clinic involving consultations of 10 minutes duration which included the standard assessment, a fundus examination and remainder of time utilised according to each individual clinician</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray">
<P>Adherence assessed through self report patient questionnaire during a structured telephone interview</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Funding sources: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Sverrisson-1999-Europe">
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Randomised, multi-centre, observer masked, 2-period, cross-over study</P>
<P>Duration: 38 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Countries: 8 sites in 5 European countries: Belgium, Denmark, Iceland, Sweden and Switzerland</P>
<P>Setting: outpatient clinics</P>
<P>Number of participants: 93</P>
<P>Gender: 35 men, 58 women</P>
<P>Age range: 44 to 87 years, mean age: 69.5</P>
<P>Ethnicity: white 92 (98.9%), other 1 (1.1%)</P>
<P>Inclusion criteria: patients 18+<SUP> </SUP>years with a diagnosis of OAG or OHT in both eyes. IOP of &#8805; 22 mmHg 2 hrs after the morning dose of timolol maleate on study day 1 after run-in</P>
<P>Exclusion criteria: patients previously treated with dorzolamide or pilocarpine. Visual acuity of worse than 20/80 in both eyes, evidence of ACG, current use of contact lenses, intraocular surgery or significant trauma within 6 months or intraocular laser surgery within 3 months of initiation of the study, history or presence of retinal detachment or other conditions for which pilocarpine might be appropriate. Asthma, chronic obstructive pulmonary disease, renal disease, severe physical disabilities or any contraindications to the use of pilocarpine, dorzolamide or timolol ophthalmic solutions.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Group A: 2% dorzolamide/0.5% timolol combination twice daily during period 1 and 2% pilocarpine 4 times daily plus 0.5% timolol twice daily during period 2</P>
<P>Group B: 2% pilocarpine 4 times daily plus 0.5% timolol twice daily during period 1 and 2% dorzolamide/0.5% timolol combination twice daily during period 2</P>
<P>Follow-up: short-term; 14 days per period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Adherence assessed through self report via interviewer-administered questionnaire using previously validated tool (COMTol). Patients were asked how often they missed their drops. Responses were marked on a scale of 0 to 6: 0 = never, 6 = always.</P>
<P>Quality of life assessed via interviewer-administered questionnaire (COMTol). Patients asked whether quality of life was interfered with by side effects or activity limitations. Responses were marked on a scale of 0 to 5: 0 = not at all, 5 = extremely.</P>
<P>IOP reduction assessed with Goldman applanation tonometer</P>
<P>Visual field defects assessed with Humphrey Field Analyser at all US sites and some European sites. The other European sites used an Octopus perimeter.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray">
<P>Funding sources: sponsored by Merck &amp; Co.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Sverrisson-1999-USA">
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Randomised, multi-centre, observer masked, 2-period cross-over study</P>
<P>Duration: 38 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Countries: USA (10 sites)</P>
<P>Setting: outpatient clinics</P>
<P>Number of participants: 97</P>
<P>Gender: 41 men, 56 women</P>
<P>Age range: 27 to 83 years, mean age 60.4 years</P>
<P>Ethnicity: white 70 (72.2%), black 18 (18.6%), other 9 (9.3%)</P>
<P>Inclusion criteria: patients 18+<SUP> </SUP>years with a diagnosis of OAG or OHT in both eyes. IOP of &#8805; 22 mmHg 2 hours after the morning dose of timolol maleate on study day 1 after run-in.</P>
<P>Exclusion criteria: patients previously treated with dorzolamide or pilocarpine. Visual acuity of worse than 20/80 in both eyes, evidence of ACG, current use of contact lenses, intraocular surgery or significant trauma within 6 months or intraocular laser surgery within 3 months of initiation of the study, history or presence of retinal detachment or other conditions for which pilocarpine might be appropriate. Asthma, chronic obstructive pulmonary disease, renal disease, severe physical disabilities or any contraindications to the use of pilocarpine, dorzolamide or timolol ophthalmic solutions.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Group A: 2% dorzolamide/0.5% timolol combination twice daily during period 1 and 2% pilocarpine 4 times daily plus 0.5% timolol twice daily during period 2</P>
<P>Group B: 2% pilocarpine 4 times daily plus 0.5% timolol twice daily during period 1 and 2% dorzolamide/0.5% timolol combination twice daily during period 2</P>
<P>Follow-up: short-term; 14 days per period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Adherence assessed through self report via interviewer-administered questionnaire using previously validated tool (COMTol). Patients were asked how often they missed their drops. Responses were marked on a scale of 0 to 6: 0 = never, 6 = always.</P>
<P>Quality of life assessed via interviewer-administered questionnaire (COMTol). Patients asked whether quality of life was interfered with by side effects or activity limitations. Responses were marked on a scale of 0 to 5: 0 = not at all, 5 = extremely.</P>
<P>IOP reduction assessed with Goldman applanation tonometer</P>
<P>Visual field defects assessed with Humphrey Field Analyser at all US sites and some European sites. The other European sites used an Octopus perimeter.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray">
<P>Funding sources: sponsored by Merck &amp; Co.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACG: angle closure glaucoma<BR/>COMTol: Comparison of Ophthalmic Medications for Tolerability<BR/>IOP: intraocular pressure<BR/>LPI: laser peripheral iridotomy<BR/>OAG: open-angle glaucoma<BR/>OHT: ocular hypertension<BR/>SD: standard deviation<BR/>UBM: ultrasound biomicroscopy</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-02-04 13:48:31 +0000" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Akafo-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-04 13:48:31 +0000" MODIFIED_BY="Trish Gray">
<P>Did not measure adherence</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-28 13:32:13 +0100" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Amon-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-28 13:32:13 +0100" MODIFIED_BY="Trish Gray">
<P>Not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-28 13:32:14 +0100" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Bayer-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-28 13:32:14 +0100" MODIFIED_BY="Trish Gray">
<P>Not a randomised study, adherence not measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-28 13:32:16 +0100" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Bhojwani-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-28 13:32:16 +0100" MODIFIED_BY="Trish Gray">
<P>Not a randomised study, adherence not measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-28 13:32:17 +0100" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Blair-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-28 13:32:17 +0100" MODIFIED_BY="Trish Gray">
<P>Not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-28 13:32:18 +0100" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Blair-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-28 13:32:18 +0100" MODIFIED_BY="Trish Gray">
<P>Not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-06 11:34:57 +0000" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Bron-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-06 11:34:57 +0000" MODIFIED_BY="Trish Gray">
<P>Measured adherence but did not publish results. Author contacted and gave reason, <I>"such an evaluation of compliance is not reliable"</I>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-28 13:32:22 +0100" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Chang-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-28 13:32:22 +0100" MODIFIED_BY="Trish Gray">
<P>Not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-28 13:32:23 +0100" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Derick-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-28 13:32:23 +0100" MODIFIED_BY="Trish Gray">
<P>Adherence not measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-28 13:32:23 +0100" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Dunker-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-28 13:32:23 +0100" MODIFIED_BY="Trish Gray">
<P>Not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flowers-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Single-arm study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Ghinato-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray">
<P>Unclear whether participants were randomised to 1 of 2 groups. No reply from author.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-04 13:48:38 +0000" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Goni-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-04 13:48:38 +0000" MODIFIED_BY="Trish Gray">
<P>Did not measure adherence</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-28 13:32:30 +0100" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Granstrom-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-28 13:32:30 +0100" MODIFIED_BY="Trish Gray">
<P>Not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-04 13:48:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gulkilik-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-04 13:48:40 +0000" MODIFIED_BY="[Empty name]">
<P>Did not measure adherence</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-28 13:32:34 +0100" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Hasegawa-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-28 13:32:34 +0100" MODIFIED_BY="Trish Gray">
<P>Not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Hughes-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray">
<P>Did not measure adherence</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-08 15:48:13 +0100" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Hunter-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-08 15:48:13 +0100" MODIFIED_BY="Trish Gray">
<P>Very little information available, no paper, no other evidence of study found. Several attempts made to contact author without success.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-04 13:48:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Inoue-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-04 13:48:43 +0000" MODIFIED_BY="[Empty name]">
<P>Not a controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-04 13:48:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Inoue-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-04 13:48:44 +0000" MODIFIED_BY="[Empty name]">
<P>Not a controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-28 13:32:37 +0100" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Kass-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-28 13:32:37 +0100" MODIFIED_BY="Trish Gray">
<P>Not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-28 13:32:39 +0100" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Klein-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-28 13:32:39 +0100" MODIFIED_BY="Trish Gray">
<P>Not a randomised study, adherence not measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-04 13:48:46 +0000" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Konstas-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-04 13:48:46 +0000" MODIFIED_BY="Trish Gray">
<P>Did not measure adherence</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-04 13:48:47 +0000" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Kurtz-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-04 13:48:47 +0000" MODIFIED_BY="Trish Gray">
<P>Did not measure adherence</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-04 13:48:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lorenz-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-04 13:48:48 +0000" MODIFIED_BY="[Empty name]">
<P>Did not measure adherence</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-04 13:48:50 +0000" MODIFIED_BY="Trish Gray" STUDY_ID="STD-March-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-04 13:48:50 +0000" MODIFIED_BY="Trish Gray">
<P>Did not measure adherence</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-29 14:10:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00230763">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-29 14:10:20 +0100" MODIFIED_BY="[Empty name]">
<P>Non-randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-25 16:52:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00262626">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-25 16:52:45 +0000" MODIFIED_BY="[Empty name]">
<P>Non-randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-28 13:32:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00328835">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-28 13:32:50 +0100" MODIFIED_BY="[Empty name]">
<P>Non-randomised study not assessing adherence</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-29 14:10:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00329095">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-29 14:10:28 +0100" MODIFIED_BY="[Empty name]">
<P>Non-randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-28 13:32:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00348062">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-28 13:32:53 +0100" MODIFIED_BY="[Empty name]">
<P>Non-randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-25 16:52:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01415401">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-25 16:52:00 +0000" MODIFIED_BY="[Empty name]">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-04 13:48:53 +0000" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Novack-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-04 13:48:53 +0000" MODIFIED_BY="Trish Gray">
<P>Did not measure adherence</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-04 13:48:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rolle-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-04 13:48:55 +0000" MODIFIED_BY="[Empty name]">
<P>Not a controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-04 13:48:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rossi-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-04 13:48:55 +0000" MODIFIED_BY="[Empty name]">
<P>Not a controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-04 13:48:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanchez_x002d_Pulgarin-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-04 13:48:56 +0000" MODIFIED_BY="[Empty name]">
<P>Not a controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-28 13:32:56 +0100" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Sclar-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-28 13:32:56 +0100" MODIFIED_BY="Trish Gray">
<P>Not a randomised study, adherence not measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Shibuya-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray">
<P>Adherence measured although the 2 types of drops being compared were instilled with the same dosage frequency of once daily</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-28 13:33:00 +0100" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Wandel-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-28 13:33:00 +0100" MODIFIED_BY="Trish Gray">
<P>Not a randomised study, adherence not measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-28 13:33:01 +0100" MODIFIED_BY="Trish Gray" STUDY_ID="STD-Yie-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-28 13:33:01 +0100" MODIFIED_BY="Trish Gray">
<P>Not a randomised study, adherence not measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-06-25 13:37:40 +0100" MODIFIED_BY="Trish Gray" NOTES="&lt;p&gt;I put studies in here if they have been completed &amp;gt;2 years ago but either I cannot find the PI details, or there is no response from investigators. &lt;/p&gt;" NOTES_MODIFIED="2012-06-25 13:37:40 +0100" NOTES_MODIFIED_BY="Trish Gray" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-02-06 14:13:43 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;ADD TRIAL INTO ONGOING IF: &lt;/p&gt;&lt;p&gt;(1) COMPLETION DATE LESS THAN TWO YEARS AGO&lt;/p&gt;&lt;p&gt;(2) IF COMPLETION DATE MORE THAN TWO YEARS AGO AND INVESTIGATORS INDICATE THAT THEY ARE WRITING UP THE TRIAL. &lt;/p&gt;&lt;p&gt;(3) AT NEXT UPDATE ALL TRIALS IN CATEGORY (2) ASK INVESTIGATORS IF THEY CAN PROVIDE UNPUBLISHED DATA&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-02-06 14:13:43 +0000" NOTES_MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" NOTES="&lt;p&gt;Spoke to Carol Lomas on the telephone 4/10/11&lt;/p&gt;&lt;p&gt;Trial completed but not yet written up. &lt;/p&gt;&lt;p&gt;I said we would contact her when the next update happens. &lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-02-06 13:18:58 +0000" NOTES_MODIFIED_BY="Anupa Shah" STUDY_ID="STD-ISRCTN25754048">
<CHAR_STUDY_NAME MODIFIED="2008-08-06 16:25:59 +0100" MODIFIED_BY="Trish Gray">
<P>Glaucoma compliance aids research project</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Randomised, single-centre, parallel-group study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Country: UK</P>
<P>Setting: hospital outpatient clinic</P>
<P>Target number of participants: 100</P>
<P>Inclusion criteria: patients with a diagnosis of OAG, using anti-glaucoma eye drops, able to instil drops independently</P>
<P>Exclusion criteria: patients prescribed more than 1 eye drop, patients with other eye problems, patients unable to give informed consent, patients &lt; 40 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray">
<P>Intervention group: adherence aid and usual care which involves glaucoma assessment followed by assessment for appropriate adherence aid with instruction on how to use it; patients also continue to receive the usual care normally provided within the outpatients department</P>
<P>Control group: glaucoma assessment and usual care normally provided within the outpatients department</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Adherence to therapy assessed through self report via patient questionnaire</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-06-27 19:01:22 +0100" MODIFIED_BY="Trish Gray">
<P>September 2006 </P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-27 19:01:18 +0100" MODIFIED_BY="[Empty name]">
<P>See trial register entry</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-11-25 15:15:51 +0000" MODIFIED_BY="Trish Gray">
<P>http://www.controlled-trials.com/ISRCTN25754048</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Not quite sure if eligible: emailed Heather&lt;/p&gt;&lt;p&gt;Heather thinks may be eligible&lt;/p&gt;&lt;p&gt;However, not published&lt;/p&gt;&lt;p&gt;emailed investigator: fchiambaretta@chu-clermontferrand.fr&lt;/p&gt;&lt;p&gt;7/10/2011&lt;/p&gt;&lt;p&gt;Dear Professor Chiambaretta&lt;/p&gt;&lt;p&gt;We are currently updating the Cochrane systematic review on &lt;b&gt;Interventions for improving adherence to ocular hypotensive therapy. &lt;/b&gt;During our searches we identified the trial &amp;#8220;Comparing the after-use sensation and safety of long acting carteolol 2% versus timolol 0.5% in simple intra-ocular hypertension and glaucoma&amp;#8221;. &amp;#160;&lt;a href=&quot;http://www.controlled-trials.com/ISRCTN31673586/&quot; protected=&quot;true&quot;&gt;http://www.controlled-trials.com/ISRCTN31673586/&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;We think this trial might be relevant for inclusion in our review but we have been unable to find any publications relating to this study. We would be very grateful if you could send us a copy of the relevant publication(s), if available, so that we can assess whether or not the trial is eligible for inclusion, and if it is, include the relevant data from the trial in the review.&lt;/p&gt;&lt;p&gt;With many thanks for your help&lt;/p&gt;&lt;p&gt;Yours sincerely&lt;/p&gt;&lt;p&gt;Jennifer Evans&lt;/p&gt;&lt;p&gt;---------------------------------------&lt;/p&gt;&lt;p&gt;Jennifer Evans PhD&lt;/p&gt;&lt;p&gt;Lecturer&lt;/p&gt;&lt;p&gt;International Centre for Eye Health&lt;/p&gt;&lt;p&gt;London School of Hygiene and Tropical Medicine&lt;/p&gt;&lt;p&gt;UK&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-02-06 13:18:58 +0000" NOTES_MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN31673586">
<CHAR_STUDY_NAME MODIFIED="2013-02-06 11:36:53 +0000" MODIFIED_BY="[Empty name]">
<P>Comparing the after-use sensation and safety of long acting (LA) carteolol 2 % versus timolol LA 0.5 % in simple intra-ocular hypertension and glaucoma</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, parallel-group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>People with unilateral or bilateral ocular hypertension or primary open-angle glaucoma and intra-ocular pressure controlled with beta-blocker monotherapy: pressure &lt; 21mmHg and visual field stable<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Carteolol long-acting 2%: daily, 1 drop at 8 am in the eye(s) to be treated over 3 months<BR/>Timolol long-acting 0.5%: daily, 1 drop at 8 am in the eye(s) to be treated over 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Compliance, reported at 1 and 3 months was one of the secondary outcomes for this study</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-06-27 19:01:09 +0100" MODIFIED_BY="[Empty name]">
<P>December 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-27 18:53:22 +0100" MODIFIED_BY="[Empty name]">
<P>See trial register entry </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-25 13:37:33 +0100" MODIFIED_BY="[Empty name]">
<P>http://www.controlled-trials.com/ISRCTN31673586</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN89683704">
<CHAR_STUDY_NAME MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Helping adherence with glaucoma treatment</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Randomised, single-centre, parallel-group study</P>
<P>Duration: 2 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Country: UK</P>
<P>Setting: hospital outpatient clinic</P>
<P>Target number of patients: 200</P>
<P>Inclusion criteria: newly diagnosed or previously untreated glaucoma patients (using established standard criteria as documented in the European Glaucoma Society Guidelines), prescribed travoprost only, male or female, &gt; 18 years of age</P>
<P>Exclusion criteria: those who cannot speak English fluently (to eliminate any potential bias by poor interpretation of information by a translator), those whose drops will be applied by care home staff/carers/home-helpers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention group: the intervention group will spend time with a Glaucoma Support Assistant (GSA) who will discuss/provide general aspects relating to glaucoma and anti-glaucomatous therapy, advice and practical help with drop application techniques, advice on taking eye drops within their own schedule/routine and an invitation for the participant to ask any questions about anything they are unsure of. In addition, patients will be asked to discuss their normal routine and a mutually agreeable time and place will be decided upon for patients to administer their drops. Patients will be advised to take their drops before a given point in their routine, to leave their drops where this "event" normally happens (e.g. by their toothbrush holder). A helpline number will also be given so that participants or their carers can call the on-call GSA at any time during clinic hours for additional information about glaucoma and drop application. The initial intervention group appointment is expected to last about 30 minutes.</P>
<P>Standard care group/control group: the control group will receive information in the form of our expected standard care and a leaflet about glaucoma with their ophthalmologist. Expected standard care consists of a brief explanation about glaucoma and the degree to which the particular patient has the condition, a summary of the proposed future management for that patient, including how frequently and when drop administration should be carried out and the importance of the condition with respect to driving and future vision. In addition, they will receive a contact telephone number for the glaucoma research unit in case of any problems with the electronic device or adverse events.</P>
<P>Follow-up: 32 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Patient adherence, measured by an electronic dosing monitor to give a % adherence and persistence score</P>
<P>Self perception of adherence will be measured using self rating questionnaires</P>
<P>Level of knowledge about glaucoma will be measured using self rating questionnaires</P>
<P>The individual components of the intervention will be assessed using questionnaires so as to identify which components are in most demand for a given population</P>
<P>A cost-effectiveness approach will determine the additional cost associated with the additional benefits. In this way, the 'fixed' (staff, overheads etc) and 'variable' costs of the intervention protocol will be estimated per patient. Resource utilisation and variance by individual patient will be monitored prospectively. </P>
<P>Social demographic and medical history data recorded will be used in the socio-economic and health analyses</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-06-27 19:02:01 +0100" MODIFIED_BY="[Empty name]">
<P>November 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-27 18:53:39 +0100" MODIFIED_BY="[Empty name]">
<P>See trial register entry</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-09-13 11:42:59 +0100" MODIFIED_BY="[Empty name]">
<P>http://www.controlled-trials.com/ISRCTN89683704</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Silvia Orengo-Nania Baylor College of Medicine Glaucoma-trials@bcm.edu&lt;/p&gt;&lt;p&gt;Email sent 29th September 2011&lt;/p&gt;&lt;p&gt;Dear Sir/Madam&lt;/p&gt;&lt;p&gt;We are currently updating the Cochrane systematic review on &lt;b&gt;Interventions for improving adherence to ocular hypotensive therapy. &lt;/b&gt;During our searches of ClinicalTrials.gov we identified the trial &amp;#8220;The Effect of Education on Patient Compliance: NCT00376974&amp;#8221;. &lt;a href=&quot;http://clinicaltrials.gov/ct2/show/NCT00376974&quot; protected=&quot;true&quot;&gt;http://clinicaltrials.gov/ct2/show/NCT00376974&lt;/a&gt;. The principal investigator for this study was: Silvia Orengo-Nania, Baylor College of Medicine.&lt;/p&gt;&lt;p&gt;We think this trial might be relevant for inclusion in our review but we have not found any publications relating to this study. We would be very grateful if you could send us a copy of the relevant publication(s) so that we can assess whether or not the trial is eligible for inclusion in our review, and if so include the data.&lt;/p&gt;&lt;p&gt;With many thanks and best wishes&lt;/p&gt;&lt;p&gt;Jennifer&lt;/p&gt;&lt;p&gt;---------------------------------------&lt;/p&gt;&lt;p&gt;Jennifer Evans PhD&lt;/p&gt;&lt;p&gt;Lecturer&lt;/p&gt;&lt;p&gt;International Centre for Eye Health&lt;/p&gt;&lt;p&gt;London School of Hygiene and Tropical Medicine&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;" NOTES_MODIFIED="2013-02-06 13:18:58 +0000" NOTES_MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00376974">
<CHAR_STUDY_NAME MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>The effect of education on patient compliance</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, parallel-group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-25 13:37:35 +0100" MODIFIED_BY="[Empty name]">
<P>People with glaucoma attending for routine examination</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-25 13:37:35 +0100" MODIFIED_BY="[Empty name]">
<P>Educational video</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-25 13:37:35 +0100" MODIFIED_BY="[Empty name]">
<P>Intraocular pressure</P>
<P>Score on glaucoma educational test</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-06-27 18:54:12 +0100" MODIFIED_BY="[Empty name]">
<P>March 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-27 18:54:23 +0100" MODIFIED_BY="[Empty name]">
<P>See trial register entry</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-25 13:37:35 +0100" MODIFIED_BY="[Empty name]">
<P>http://clinicaltrials.gov/ct2/show/NCT00376974</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-02-06 14:04:36 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;from paul.cook@ucdencer.edu&lt;/p&gt;&lt;p&gt;6/12/2011&lt;/p&gt;&lt;p&gt;Hi, Jennifer. Our study evaluating the &amp;#8220;Effect of Glaucoma Educators on Adherence to Prescribed Therapeutic Regimens in Glaucoma Patients&amp;#8221; (http://clinicaltrials.gov/show/NCT00454922) just started a few months ago and is still recruiting participants. We won&amp;#8217;t have outcomes to report for another 12-18 months.&lt;br&gt;&lt;br&gt;We did publish an earlier pilot study of the same intervention (Cook, P. F., Bremer, R. W., Ayala, A. J., &amp;amp; Kahook, M. Y. (2010). Feasibility of motivational interviewing delivered by a glaucoma educator to improve medication adherence. Clinical Ophthalmology, 4, 1091-1101), and although our published report didn&amp;#8217;t include between-group comparisons due to the small sample size, I did later calculate those based on a request for another meta-analysis project:&lt;br&gt;&lt;br&gt;Mean_pre&lt;br&gt;SD_pre&lt;br&gt;Mean_post&lt;br&gt;SD_post&lt;br&gt;N&lt;br&gt;&lt;br&gt;Intervention&lt;br&gt;0.76&lt;br&gt;0.15&lt;br&gt;0.95&lt;br&gt;0.12&lt;br&gt;6.00&lt;br&gt;&lt;br&gt;Control&lt;br&gt;0.82&lt;br&gt;0.18&lt;br&gt;0.71&lt;br&gt;0.26&lt;br&gt;4.00&lt;br&gt;&lt;br&gt;A few notes about how I calculated these numbers: All adherence estimates are based on MEMS. Pretreatment means are based on the first 1-week sample of adherence behavior after a 2-month run-in phase. Posttreatment means are based on the last 1-week sample of adherence behavior available for the participant, at the end of the intervention phase. Numbers are percentages based on the number of doses that should have been taken per the patient's glaucoma medication regimen (i.e., .76 = 76% of prescribed doses taken over the 1-week timeframe). One participant in the intervention group was on a twice-daily medication regimen; the others were all prescribed eye drops once daily.&lt;br&gt;&lt;br&gt;If you have other questions, please let me know. Thanks for your interest in our research.&lt;br&gt;&lt;br&gt;Paul Cook, PhD&lt;br&gt;Assistant Professor&lt;br&gt;University of Colorado College of Nursing&lt;br&gt;&lt;br&gt;25/11/2011&lt;/p&gt;&lt;p&gt;Dear Dr Preston&amp;#160;&lt;/p&gt;&lt;p&gt;We are currently updating the Cochrane systematic review on Interventions for improving adherence to ocular hypotensive therapy. During our searches we identified the trial &amp;quot;Effect of Glaucoma Educators on Adherence to Prescribed Therapeutic Regimens in Glaucoma Patients&amp;quot; &lt;a href=&quot;http://clinicaltrials.gov/show/NCT00454922&quot; protected=&quot;true&quot;&gt;http://clinicaltrials.gov/show/NCT00454922&lt;/a&gt; &amp;#160;We think this trial might be relevant for inclusion in our review but we have been unable to find any publications relating to this study. We would be very grateful if you could send us a copy of the relevant publication(s), if available, so that we can assess whether or not the trial is eligible for inclusion, and if it is, include the relevant data from the trial in the review.&amp;#160;With many thanks for your help&amp;#160;&lt;/p&gt;&lt;p&gt;Yours sincerely&amp;#160;&lt;/p&gt;&lt;p&gt;Jennifer Evans&lt;/p&gt;&lt;p&gt;&amp;#160;---------------------------------------&lt;/p&gt;&lt;p&gt;Jennifer Evans PhDLecturerInternational Centre for Eye HealthLondon School of Hygiene and Tropical MedicineUK&lt;/p&gt;" NOTES_MODIFIED="2013-02-06 14:04:36 +0000" NOTES_MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00454922">
<CHAR_STUDY_NAME MODIFIED="2013-02-06 11:40:25 +0000" MODIFIED_BY="[Empty name]">
<P>Effect of glaucoma educators on adherence to prescribed therapeutic regimens in glaucoma patients<BR/>
</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-02-06 14:04:28 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised<BR/>Endpoint classification: efficacy study<BR/>Intervention model: parallel assignment<BR/>Masking: single-blind (outcomes assessor)<BR/>Primary purpose: prevention</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-06 12:42:44 +0000" MODIFIED_BY="[Empty name]">
<P>100</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-12-06 12:42:44 +0000" MODIFIED_BY="[Empty name]">
<P>Education versus standard care</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome measures: primary outcome is adherence (time frame: 6 months)<BR/>Secondary outcome measures: differences between patients randomised to standard of care and education intervention (time frame: 6 months)<BR/>Differences between dropouts and non-dropouts (time frame: 6 months)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-02-06 14:04:36 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>From clinical trals.gov</I>
</P>
<P>Start date: October 2007; end date: May 2008</P>
<P>
<I>From contact with investigators December 2011</I>
</P>
<P>
<I>"Our study evaluating the &#8220;Effect of Glaucoma Educators on Adherence to Prescribed Therapeutic Regimens in Glaucoma Patients&#8221; (http://clinicaltrials.gov/show/NCT00454922) just started a few months ago and is still recruiting participants. We won't have outcomes to report for another 12-18 months."</I>
</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-27 19:00:53 +0100" MODIFIED_BY="[Empty name]">
<P>See trial register entry</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-12-06 12:42:44 +0000" MODIFIED_BY="[Empty name]">
<P>http://clinicaltrials.gov/show/NCT00454922</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Submitted query to &lt;/p&gt;&lt;p&gt;http://www.alcon.com/en/contact-alcon/other-general.aspx&lt;/p&gt;&lt;p&gt;29/9/2011&lt;/p&gt;" NOTES_MODIFIED="2013-02-06 13:18:58 +0000" NOTES_MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00465803">
<CHAR_STUDY_NAME MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Compliance study comparing DuoTrav to TRAVATAN plus timolol using the dosing aid</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, parallel-group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>People with open-angle glaucoma or ocular hypertension</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>DuoTrav</P>
<P>Travatan/timolol</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-25 13:37:37 +0100" MODIFIED_BY="[Empty name]">
<P>Patient compliance</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-06-27 18:55:10 +0100" MODIFIED_BY="[Empty name]">
<P>March 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-27 18:55:35 +0100" MODIFIED_BY="[Empty name]">
<P>See trial register entry</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-25 13:37:37 +0100" MODIFIED_BY="[Empty name]">
<P>http://clinicaltrials.gov/ct2/show/NCT00465803</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-02-06 14:05:03 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Could not find email address for PI&lt;/p&gt;" NOTES_MODIFIED="2013-02-06 14:05:03 +0000" NOTES_MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00508469">
<CHAR_STUDY_NAME MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Adherence assessment with Travalert dosing aid</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Parallel-group randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-25 19:06:16 +0000" MODIFIED_BY="[Empty name]">
<P>People diagnosed with glaucoma or ocular hypertension</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-25 19:06:16 +0000" MODIFIED_BY="[Empty name]">
<P>Dosing aid device</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 14:05:03 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>From ClinicalTrials.gov</I>
</P>
<P>Primary outcome measures: the primary objective is to compare patients adherence using Travalert® device in the different treatment groups (time frame: use) (designated as safety issue: no)<BR/>Secondary outcome measures: safety and satisfaction (time frame: use) (designated as safety issue: no)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-06-27 19:00:43 +0100" MODIFIED_BY="[Empty name]">
<P>July 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-27 18:55:37 +0100" MODIFIED_BY="[Empty name]">
<P>See trial register entry</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-11-25 19:06:16 +0000" MODIFIED_BY="[Empty name]">
<P>http://clinicaltrials.gov/ct2/show/NCT00508469</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-02-06 14:13:43 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;email response from PI 29/9/2011&lt;/p&gt;&lt;p&gt;I have started this manuscript and can send the data to you.&lt;/p&gt;&lt;p&gt;&amp;#160;SMJ&lt;/p&gt;&lt;p&gt;&amp;#160;Associate Professor&lt;br&gt;Residency Program Director&lt;br&gt;Glaucoma Service&lt;br&gt;UVA Ophthalmology&lt;/p&gt;&lt;p&gt;***&lt;/p&gt;&lt;p&gt;Email sent to PI Dr Nilson 29/9/2011 'cnilson@mail.mcg.edu'&lt;/p&gt;&lt;p&gt;email bounced&lt;/p&gt;&lt;p&gt;sent again to other investigator sandra johnson&lt;/p&gt;&lt;p&gt;email bounced&lt;/p&gt;&lt;p&gt;found another email address for sandra johnson&lt;/p&gt;&lt;p&gt;smj3a@virginia.edu&lt;/p&gt;&lt;p&gt;***&lt;/p&gt;&lt;p&gt;Dear Professor Johnson&lt;/p&gt;&lt;p&gt;&amp;#160;We are currently updating the Cochrane systematic review on &lt;b&gt;Interventions for improving adherence to ocular hypotensive therapy. &lt;/b&gt;During our searches of ClinicalTrials.gov we identified the trial &amp;#8220;Effects of Xal-Ease on Patient Compliance With Xalatan&amp;#8221;. &lt;a href=&quot;http://clinicaltrials.gov/ct2/show/NCT00333463&quot; protected=&quot;true&quot;&gt;http://clinicaltrials.gov/ct2/show/ NCT00573638&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;&amp;#160;We think this trial might be relevant for inclusion in our review but we have been unable to find any publications relating to this study. We would be very grateful if you could send us a copy of the relevant publication(s), if available, so that we can assess whether or not the trial is eligible for inclusion, and if it is, include the relevant data from the trial in the review.&lt;/p&gt;&lt;p&gt;&amp;#160;With many thanks for your help&lt;/p&gt;&lt;p&gt;Yours sincerely&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;Jennifer Evans&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;---------------------------------------&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;Jennifer Evans PhD&lt;/p&gt;&lt;p&gt;Lecturer&lt;/p&gt;&lt;p&gt;International Centre for Eye Health&lt;/p&gt;&lt;p&gt;London School of Hygiene and Tropical Medicine&lt;/p&gt;&lt;p&gt;UK&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;" NOTES_MODIFIED="2013-02-06 14:13:43 +0000" NOTES_MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00573638">
<CHAR_STUDY_NAME MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Effects of Xal-Ease on patient compliance with Xalatan</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-02-06 11:44:58 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention model: single group assignment<BR/>Masking: open label<BR/>Primary purpose: treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-25 19:12:04 +0000" MODIFIED_BY="[Empty name]">
<P>50</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-25 19:12:16 +0000" MODIFIED_BY="[Empty name]">
<P>Device: Xal-Ease device to be used with Xalatan eye drops</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 14:13:43 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome measures: the primary outcome measure is compliance with the medication Xalatan using and not using the Xal-Ease delivery aid for their glaucoma treatment (time frame: 6 months)<BR/>Secondary outcome measures: to determine if any of the other factors mentioned in the survey affect compliance to their medical regimen (time frame: 6 months)<BR/>To see whether or not the Xal-Ease device helps patients conserve medication, i.e. - aids in drops not distilled in the eye (time frame: 6 months)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-06-27 19:00:38 +0100" MODIFIED_BY="[Empty name]">
<P>February 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-27 18:55:40 +0100" MODIFIED_BY="[Empty name]">
<P>See trial register entry</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-11-25 19:13:14 +0000" MODIFIED_BY="[Empty name]">
<P>http://clinicaltrials.gov/ct2/show/NCT00573638</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-02-06 11:49:57 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Many thanks for the prompt reply. Hopefully we can include the study in the next update.&lt;br&gt;With all best wishes&lt;br&gt;Jennifer&lt;br&gt;&lt;br&gt;&amp;gt;&amp;gt;&amp;gt; &amp;quot;Jonathan S. Myers&amp;quot; 06/10/11 1:10 PM &amp;gt;&amp;gt;&amp;gt;&lt;/p&gt;&lt;p&gt;Unfortunately we haven?t published this study (yet).&lt;/p&gt;&lt;p&gt;I appreciate your interest.&lt;/p&gt;&lt;p&gt;Good luck in your review-&lt;/p&gt;&lt;p&gt;Jonathan&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;4/10/11&lt;/p&gt;&lt;p&gt;Dear Professor Myers&lt;/p&gt;&lt;p&gt;We are currently updating the Cochrane systematic review on &lt;b&gt;Interventions for improving adherence to ocular hypotensive therapy. &lt;/b&gt;During our searches we identified the trial &amp;#8220;Study of Patient Use and Perception of the Travatan Dosing Aid&amp;#8221; &lt;a href=&quot;http://clinicaltrials.gov/ct2/show/NCT00626067&quot; protected=&quot;true&quot;&gt;http://clinicaltrials.gov/ct2/show/NCT00626067&lt;/a&gt;&lt;/p&gt;&lt;p&gt;We think this trial might be relevant for inclusion in our review but we have been unable to find any publications relating to this study. We would be very grateful if you could send us a copy of the relevant publication(s), if available, so that we can assess whether or not the trial is eligible for inclusion, and if it is, include the relevant data from the trial in the review.&lt;/p&gt;&lt;p&gt;With many thanks for your help&lt;/p&gt;&lt;p&gt;Yours sincerely&lt;/p&gt;&lt;p&gt;Jennifer Evans&lt;/p&gt;&lt;p&gt;---------------------------------------&lt;/p&gt;&lt;p&gt;Jennifer Evans PhD&lt;/p&gt;&lt;p&gt;Lecturer&lt;/p&gt;&lt;p&gt;International Centre for Eye Health&lt;/p&gt;&lt;p&gt;London School of Hygiene and Tropical Medicine&lt;/p&gt;&lt;p&gt;UK&lt;/p&gt;" NOTES_MODIFIED="2013-02-06 11:49:57 +0000" NOTES_MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00626067">
<CHAR_STUDY_NAME MODIFIED="2013-02-06 11:47:42 +0000" MODIFIED_BY="[Empty name]">
<P>Study of patient use and perception of the Travatan dosing aid</P>
<P>Pilot study of patient acceptance and impact of the new Travatan&#8482; compliance monitoring dispenser (Travatan&#8482; dosing aid)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-02-06 11:48:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised<BR/>Endpoint classification: efficacy study<BR/>Intervention model: single group assignment (but has 3 interventions)<BR/>Masking: double-blind (subject, investigator)<BR/>Primary purpose: supportive care</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-25 17:03:31 +0000" MODIFIED_BY="[Empty name]">
<P>45</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 11:48:24 +0000" MODIFIED_BY="[Empty name]">
<P>Travatan compliance monitoring dispenser</P>
<P>Fully functioning, partially functioning and non-functioning</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 11:49:57 +0000" MODIFIED_BY="[Empty name]">
<P>From clinicatrials.gov</P>
<P>Primary outcome measures: assess patients' opinions regarding new Travatan compliance monitoring dispenser (time frame: 6 weeks) (designated as safety issue: no)<BR/>Secondary outcome measures: pilot study of the impact of physician monitoring of compliance on patient compliance (time frame: 6 weeks) (designated as safety issue: no) </P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-06-27 19:02:52 +0100" MODIFIED_BY="[Empty name]">
<P>September 2006</P>
<P>Investigator indicates manuscript in preparation</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-27 18:55:45 +0100" MODIFIED_BY="[Empty name]">
<P>See trial register entry</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-11-25 17:02:51 +0000" MODIFIED_BY="[Empty name]">
<P>http://clinicaltrials.gov/show/NCT00626067</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-02-06 11:50:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00676637">
<CHAR_STUDY_NAME MODIFIED="2011-11-25 19:03:05 +0000" MODIFIED_BY="[Empty name]">
<P>GAS - Glaucoma Adherence Study</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-02-06 11:50:17 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: non-randomised<BR/>Intervention model: single group assignment<BR/>Masking: open-label</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-25 19:03:25 +0000" MODIFIED_BY="[Empty name]">
<P>100</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 11:50:27 +0000" MODIFIED_BY="[Empty name]">
<P>TravAlert dosing aid</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 11:50:38 +0000" MODIFIED_BY="[Empty name]">
<P>Mean change from baseline in intraocular pressure at 4 months</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-06-27 19:00:04 +0100" MODIFIED_BY="[Empty name]">
<P>May 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-27 18:55:49 +0100" MODIFIED_BY="[Empty name]">
<P>See trial register entry</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-11-25 19:04:49 +0000" MODIFIED_BY="[Empty name]">
<P>http://clinicaltrials.gov/show/NCT00676637%20%C2%A0</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-02-06 11:51:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;4/10/11&lt;/p&gt;&lt;p&gt;Dear Ms Evans,&lt;/p&gt;&lt;p&gt;I believe out trial may be of interest to your review.&amp;#160; As yet no publication from our study (still work under progress), but I attach the relevant ARVO poster with the results.&amp;#160; I will send you the paper when it is ready.&lt;/p&gt;&lt;p&gt;Best regards,&lt;/p&gt;&lt;p&gt;Professor A G Konstas &amp;#160;&lt;/p&gt;&lt;p&gt;******************************************&lt;/p&gt;&lt;p&gt;29/9/2011&lt;/p&gt;&lt;p&gt;Dear Professor Konstas&lt;/p&gt;&lt;p&gt;We are currently updating the Cochrane systematic review on &lt;b&gt;Interventions for improving adherence to ocular hypotensive therapy. &lt;/b&gt;During our searches of ClinicalTrials.gov we identified the trial &amp;#8220;Value of an Intervention to Enhance Adherence in Glaucoma Patients&amp;#8221; &amp;#160;&lt;a href=&quot;http://clinicaltrials.gov/ct2/show/%20NCT00756184&quot; protected=&quot;true&quot;&gt;http://clinicaltrials.gov/ct2/show/ NCT00756184&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;We think this trial might be relevant for inclusion in our review but we have been unable to find any publications relating to this study. We would be very grateful if you could let us know whether or not the trial has been published yet. If it has, we would be grateful if you could send us a copy of the relevant publication(s) so that we can assess whether or not the trial is eligible for inclusion and include the relevant data from the trial in the review.&lt;/p&gt;&lt;p&gt;With many thanks for your help&lt;/p&gt;&lt;p&gt;Yours sincerely&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;Jennifer Evans&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;---------------------------------------&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;Jennifer Evans PhD&lt;/p&gt;&lt;p&gt;Lecturer&lt;/p&gt;&lt;p&gt;International Centre for Eye Health&lt;/p&gt;&lt;p&gt;London School of Hygiene and Tropical Medicine&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-02-06 11:51:19 +0000" NOTES_MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00756184">
<CHAR_STUDY_NAME MODIFIED="2013-02-06 11:50:52 +0000" MODIFIED_BY="[Empty name]">
<P>1-year randomized control trial investigating the value of an intervention to enhance adherence in glaucoma patients receiving prostaglandin monotherapy and in patients who are candidates for adjunctive therapy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-02-06 11:50:58 +0000" MODIFIED_BY="[Empty name]">
<P>Parallel-group randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 11:51:04 +0000" MODIFIED_BY="[Empty name]">
<P>People with newly diagnosed open-angle glaucoma, or ocular hypertensive subjects naive to medical therapy and people who have failed monotherapy with any prostaglandin analogue</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 11:51:10 +0000" MODIFIED_BY="[Empty name]">
<P>Intensive glaucoma adherence and education during the course of 1 year compared to intensive, equal-time eye care education without any direct adherence or glaucoma specific education</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 11:51:19 +0000" MODIFIED_BY="[Empty name]">
<P>Adherence rate (% of days patient used the medication) as monitored by a dosing aid electronic device, intraocular pressure (morning) and persistency to therapy<BR/>Follow-up time: 1, 3, 6, 9 and 12 months</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-06-27 18:59:02 +0100" MODIFIED_BY="[Empty name]">
<P>September 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-27 18:55:51 +0100" MODIFIED_BY="[Empty name]">
<P>See trial register entry</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-27 18:59:26 +0100" MODIFIED_BY="[Empty name]">
<P>http://clinicaltrials.gov/ct2/show/NCT00756184</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-02-06 11:51:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00767793">
<CHAR_STUDY_NAME MODIFIED="2013-02-06 11:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>A multi-center, double-masked, randomized, placebo-controlled, ascending dose study of INS117548 ophthalmic solution in subjects with bilateral ocular hypertension or early primary open angle glaucoma</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-02-06 11:51:46 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, parallel-group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 11:51:49 +0000" MODIFIED_BY="[Empty name]">
<P>People with primary open-angle glaucoma or ocular hypertension</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-25 13:37:38 +0100" MODIFIED_BY="[Empty name]">
<P>INS117548 at various concentrations</P>
<P>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-25 13:37:38 +0100" MODIFIED_BY="[Empty name]">
<P>Include compliance and rate of discontinuation</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-06-27 18:58:16 +0100" MODIFIED_BY="[Empty name]">
<P>September 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-27 18:55:54 +0100" MODIFIED_BY="[Empty name]">
<P>See trial register entry</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-25 13:37:38 +0100" MODIFIED_BY="[Empty name]">
<P>http://clinicaltrials.gov/ct2/show/NCT00767793</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-02-06 11:52:21 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;29/9/2011&lt;/p&gt;&lt;p&gt;Dear Dr Yan&lt;/p&gt;&lt;p&gt;We are currently updating the Cochrane systematic review on &lt;b&gt;Interventions for improving adherence to ocular hypotensive therapy. &lt;/b&gt;During our searches of ClinicalTrials.gov we identified the trial &amp;#8220;A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma (DVX) NCT00887029&amp;#8221;.&lt;/p&gt;&lt;p&gt;We think this trial might be relevant for inclusion in our review and would be grateful if you could let us know whether or not the trial has been published. If it has, we would be very grateful if you could send us a copy of the relevant publication(s) so that we can assess whether or not the trial is eligible for inclusion, and include the relevant data from the trial in the review.&lt;/p&gt;&lt;p&gt;With many thanks for your help&lt;/p&gt;&lt;p&gt;Yours sincerely&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;Jennifer Evans&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;---------------------------------------&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;Jennifer Evans PhD&lt;/p&gt;&lt;p&gt;Lecturer&lt;/p&gt;&lt;p&gt;International Centre for Eye Health&lt;/p&gt;&lt;p&gt;London School of Hygiene and Tropical Medicine&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;" NOTES_MODIFIED="2013-02-06 11:52:21 +0000" NOTES_MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00887029">
<CHAR_STUDY_NAME MODIFIED="2013-02-06 11:52:17 +0000" MODIFIED_BY="[Empty name]">
<P>A 12 week comparison of DuoTrav and Xalacom at 24 hours post-dose in the treatment of open-angle glaucoma (the DVX study)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-06-25 13:37:40 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, cross-over</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-06 11:52:21 +0000" MODIFIED_BY="[Empty name]">
<P>People with primary open-angle glaucoma or ocular hypertension</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-25 13:37:40 +0100" MODIFIED_BY="[Empty name]">
<P>DuoTrav</P>
<P>Xalacom</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-25 13:37:40 +0100" MODIFIED_BY="[Empty name]">
<P>Intraocular pressure</P>
<P>Compliance and patient preference</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-06-27 18:57:25 +0100" MODIFIED_BY="[Empty name]">
<P>January 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-27 18:55:57 +0100" MODIFIED_BY="[Empty name]">
<P>See trial register entry</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-27 18:57:35 +0100" MODIFIED_BY="[Empty name]">
<P>http://clinicaltrials.gov/ct2/show/NCT00887029</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-02-06 14:05:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01125306">
<CHAR_STUDY_NAME MODIFIED="2013-02-06 14:05:47 +0000" MODIFIED_BY="[Empty name]">
<P>Efficiency of Xal-Ease device in glaucoma and/or ocular hypertension (OHT) patients, treated with Xalatan or Xalacom</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-02-06 11:52:57 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention model: single group assignment<BR/>Masking: open-label<BR/>Primary purpose: supportive care</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-25 19:08:36 +0000" MODIFIED_BY="[Empty name]">
<P>50</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-25 19:08:47 +0000" MODIFIED_BY="[Empty name]">
<P>Device: Xal-Ease</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 14:05:59 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome measures: consumption of Xalatan/Xalacom bottles per year per patient (time frame: 12 months)<BR/>Secondary outcome measures: evaluating cost of Xalatan/Xalacom eye drops use per year with Xal-Ease (time frame: 12 months)<BR/>Characterising the optimal conditions for proper usage of the Xal-Ease device (time frame: 12 months)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-06-27 18:56:28 +0100" MODIFIED_BY="[Empty name]">
<P>June 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-27 18:56:04 +0100" MODIFIED_BY="[Empty name]">
<P>See trial register entry</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-11-25 19:09:45 +0000" MODIFIED_BY="[Empty name]">
<P>http://clinicaltrials.gov/ct2/show/NCT01125306</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-02-06 14:09:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01409421">
<CHAR_STUDY_NAME MODIFIED="2013-02-06 11:54:00 +0000" MODIFIED_BY="[Empty name]">
<P>Research protocol: glaucoma treatment adherence and persistence</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-02-06 11:54:02 +0000" MODIFIED_BY="[Empty name]">
<P>Parallel-group randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-29 21:40:49 +0100" MODIFIED_BY="[Empty name]">
<P>People with glaucoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-29 21:41:10 +0100" MODIFIED_BY="[Empty name]">
<P>Motivational interviewing, reminder calls and standard care</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 14:09:49 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>From ClinicalTrials.gov</I>
</P>
<P>Primary outcome measures: MEMS-based medication adherence and persistence (time frame: 1 month) (designated as safety issue: no) comparing adherence and persistence between the intervention and control groups. Medication Event Monitoring Systems record the date and time a pill bottle is opened, evaluating the percentage of prescribed doses taken during one-week intervals, but will augment it by also considering a more fine-grained percentage of prescribed doses taken in required dosing window (defined as within 3 hours before or after the scheduled time) as a second primary outcome measure.<I>
<BR/>
<BR/>
</I>Secondary outcome measures: counsellor-rated medication adherence (time frame: 1 month) (designated as safety issue: no). Will supplement MEMS-based adherence metrics with a counsellor rating of adherence completed by the glaucoma educator during each in-person or telephone contact with intervention group participants. The interview also measures patients' perceived reasons for non-adherence, including treatment cost, lack of commitment based on low perceived benefits of treatment and fear of potential adverse drug events (ADEs)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-06-27 18:56:23 +0100" MODIFIED_BY="[Empty name]">
<P>April 2011 </P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-27 18:56:08 +0100" MODIFIED_BY="[Empty name]">
<P>See trial register entry</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-09-29 21:42:33 +0100" MODIFIED_BY="[Empty name]">
<P>http://clinicaltrials.gov/show/NCT01409421</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-02-06 14:10:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01417689">
<CHAR_STUDY_NAME MODIFIED="2011-09-29 13:56:41 +0100" MODIFIED_BY="[Empty name]">
<P>Eyedrop Instillation Technique</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Parallel-group randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-29 13:57:13 +0100" MODIFIED_BY="[Empty name]">
<P>People with glaucoma or suspected glaucoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-29 13:57:49 +0100" MODIFIED_BY="[Empty name]">
<P>Standard eye drop instillation compared to experimental technique of eye drop instillation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 14:10:04 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>From ClinicalTrials.gov</I>
</P>
<P>Primary outcome measures: complete success (time frame: day 1, immediately after intervention) (designated as safety issue: no). Total success is defined as: patient manages to instil 1 eye drop into the eye spending only 1 eye drop. Difference in the proportion of patients achieving successful eye drop instillation in each of the 2 groups. For the main analysis the results of the first eye (right or left randomly determined will be used) a mixed model with both eyes in the analysis will also be presented for sensitivity analysis.<BR/>
<BR/>Secondary outcome measures: qualified success (time frame: day 1, same day as intervention) (designated as safety issue: no). Qualified success is defined as: patient manages to instil 1 eye drop into the eye regardless of the amount of drops spent. Difference in the proportion of patients achieving successful eye drop instillation in each of the 2 groups. For the main analysis the results of the first eye (right or left randomly determined will be used) a mixed model with both eyes in the analysis will also be presented for sensitivity analysis.<BR/>Number of drops (time frame: day 1) (designated as safety issue: no). Number of eye drops spent on attempted instillation in the first eye (randomly assigned). The average number of drops spent on each of the groups will be compared. Mixed models with data from both eyes will also be presented for sensitivity analysis.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-06-27 18:56:20 +0100" MODIFIED_BY="[Empty name]">
<P>August 2011 </P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-27 18:56:11 +0100" MODIFIED_BY="[Empty name]">
<P>See trial register entry</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-09-29 13:58:59 +0100" MODIFIED_BY="[Empty name]">
<P>http://clinicaltrials.gov/show/NCT01417689</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>OAG: open-angle glaucoma<BR/>OHT: ocular hypertension<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-02-26 12:40:37 +0000" MODIFIED_BY="Anupa Shah">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-24 11:58:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gray-2011">
<DESCRIPTION>
<P>
<I>&#8220;Computer-generated randomisation was conducted by a statistician with no involvement in data collection.  Patients were allocated to receive either individualised patient care in addition to standard care or standard care alone.  Stratified random sampling ensured equal proportions of patients within each arm from specialist glaucoma and general ophthalmic clinics, to reduce the risk of confounding factors from potential clinical management inequalities&#8221;</I> Page 257</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 12:58:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hermann-2011a">
<DESCRIPTION>
<P>
<I>&#8220;Patients were then assigned to open or masked monitoring and to brimonidine BID or TID using permuted block randomization and randomization envelopes.&#8221; </I>Page e301</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 11:08:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hermann-2011b">
<DESCRIPTION>
<P>"<I>Patients were then randomly assigned to brimonidine bid or tid using permuted block randomization with randomization envelopes and received the study medication with attached monitoring devices free of charge</I>.<I>"</I> Page 503</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 11:09:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-I_x002d_SIGHT">
<DESCRIPTION>
<P>
<I>"After completing the baseline interview, each participant was randomized into either the control or intervention group (with a 1:1 ratio). A random number generator was used in Excel (Microsoft), and participants were randomized in blocks of 10. The sequence was generated in advance by the research project manager, and participants were assigned in the order that they were enrolled. Randomization was stratified by clinical site because of expected differences in sex, race, and educational level between the sites."</I> Page E2</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" RESULT="YES" STUDY_ID="STD-Laibovitz-1996">
<DESCRIPTION>
<P>Computerised random number generator used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laster-1996">
<DESCRIPTION>
<P>Drawing of lots (each participant was randomly given a number using a statistical table then numbers were drawn to assign to either group 1 or group 2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 11:15:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muir-2012">
<DESCRIPTION>
<P>
<I>"Subjects were randomized in a one-to-one fashion to standard care or an educational intervention."</I> Page 161</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-02 10:25:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nakakura-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 13:35:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Norell-1979">
<DESCRIPTION>
<P>
<I>&#8220;They were stratified for age and randomly allocated to an experimental group or a control group.&#8221; </I>Page 1031</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-04 13:58:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okeke-2009">
<DESCRIPTION>
<P>
<I>"To perform the randomization procedure, a string of random numbers was selected from a random numbers table...."</I> Page 2287</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ring-2011">
<DESCRIPTION>
<P>
<I>&#8220;The participants were randomly allocated to either the control group or the intervention group. The allocation can be referred to as random because the film was shown on various days and no prior knowledge of when the participants were attending their routine clinic appointment was known.&#8221; </I>Page 27</P>
<P>Further information from investigator:</P>
<P>
<I>"The participants were allocated into each group purely by attending an outpatient appointment on different days. The control or test intervention was set for different days and the participants arrived according to their outpatient appointment. This was considered random allocation as the student researcher had no influence over which participant arrived on which day."</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" RESULT="NO" STUDY_ID="STD-Sakai-2005">
<DESCRIPTION>
<P>
<I>&#8220;All but 1 of the remaining 36 patients were randomly allocated to ...&#8221;</I>
</P>
<P>Page 484</P>
<P>Assigned by rotation. 1 patient not randomised but assigned to latanoprost group to minimise possible side effects of timolol administration due to a pulse rate of 59/min at first evaluation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" RESULT="YES" STUDY_ID="STD-Schenker-1999">
<DESCRIPTION>
<P>
<I>&#8220;... were enrolled in this 12-week, randomized observer-masked, two-period cross-over study.&#8221;</I> Page 138</P>
<P> </P>
<P>
<I>&#8220;This was an open-label, multicenter, randomized, observer-masked, two-period crossover study ...&#8220;</I> Page 139</P>
<P>Correspondence with investigators: <I>"Subjects were randomized 1:1 to one of two sequences of treatment (tgel/ts or ts/tgel); randomization done within each center in blocks of 4."</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-Sheppard-2003">
<DESCRIPTION>
<P>
<I>&#8220;The patients who consented to take part were allocated [...] using a computerised randomisation table".</I> Page 17</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" RESULT="YES" STUDY_ID="STD-Sverrisson-1999-Europe">
<DESCRIPTION>
<P>Computerised random number generator used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" RESULT="YES" STUDY_ID="STD-Sverrisson-1999-USA">
<DESCRIPTION>
<P>Computerised random number generator used (contact with trialists)</P>
<P>
<I>&#8220;[...] patients who met the inclusion criteria and who had none of the exclusion criteria on study day 1 were randomly assigned to group A or group B.&#8221; </I>Page 316</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-02-26 12:36:08 +0000" MODIFIED_BY="Trish Gray" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-24 11:57:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gray-2011">
<DESCRIPTION>
<P>
<I>"Allocations were concealed in opaque sealed envelopes by personnel with no involvement in the study.  Envelopes were then passed onto a study coordinator with minimal involvement in the study.  The study coordinator was responsible for opening envelopes as patients were recruited and contacting the intervention nurse to inform her as new patients were randomised to the intervention-arm.&#8221;</I> Page 257</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hermann-2011a">
<DESCRIPTION>
<P>
<I>&#8220;Patients were then assigned to open or masked monitoring and to brimonidine BID or TID using permuted block randomization and randomization envelopes.&#8221; </I>Page e301</P>
<P>Not enough detail about the envelopes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 11:08:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hermann-2011b">
<DESCRIPTION>
<P>
<I>"Patients were then randomly assigned to brimonidine bid or tid using permuted block randomization with randomization envelopes and received the study medication with attached monitoring devices free of charge</I>.<I>"</I> Page 503</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-I_x002d_SIGHT">
<DESCRIPTION>
<P>
<I>"Research interviewers were not masked to assignment because it was necessary to determine treatment group participants&#8217; preferences for intervention delivery (eg, preferred telephone number and time of day)" </I>Page E2</P>
<P>Unclear if this applies to recruitment as well as outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" RESULT="YES" STUDY_ID="STD-Laibovitz-1996">
<DESCRIPTION>
<P>Central allocation used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" RESULT="NO" STUDY_ID="STD-Laster-1996">
<DESCRIPTION>
<P>Open random allocation schedule used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-02 10:14:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muir-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-02 10:25:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nakakura-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Norell-1979">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-04 13:58:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okeke-2009">
<DESCRIPTION>
<P>
<I>"...The numbers were placed into envelopes and then sealed and initialed across the seal. The envelopes were numbered consecutively starting with 1. When an eligible patient was identified, an envelope was opened; if the envelope contained an even number then the participant received the intervention."</I> Page 2287</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 12:36:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ring-2011">
<DESCRIPTION>
<P>Information from investigator:</P>
<P>
<I>"The person recruiting the participants was the student researcher as outlined in the dissertation.  This person was aware of which group the participant was allocated to."</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" RESULT="NO" STUDY_ID="STD-Sakai-2005">
<DESCRIPTION>
<P>Open random allocation schedule used</P>
<P>
<I>"One patient was assigned.. to the latanoprost group to eliminate the risk of side effects."</I>
</P>
<P>Correspondence with investigator: <I>"It was open labelled and allocation schedule was not concealed prior to the assignment to the subjects. Two subjects were dropped out by their own will, may be because of the allocation."</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 11:26:55 +0000" MODIFIED_BY="Trish Gray" RESULT="YES" STUDY_ID="STD-Schenker-1999">
<DESCRIPTION>
<P>Correspondence with investigators: <I>"Allocation completed by use of sealed envelopes opened at the time of enrollment"</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 14:16:20 +0000" MODIFIED_BY="Trish Gray" RESULT="UNKNOWN" STUDY_ID="STD-Sheppard-2003">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" RESULT="YES" STUDY_ID="STD-Sverrisson-1999-Europe">
<DESCRIPTION>
<P>Central allocation used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" RESULT="YES" STUDY_ID="STD-Sverrisson-1999-USA">
<DESCRIPTION>
<P>Central allocation used (contact with trialists)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-03-29 04:39:02 +0100" MODIFIED_BY="Trish Gray" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.05" NO="5">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-02-26 12:40:37 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-02-26 12:38:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gray-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hermann-2011a">
<DESCRIPTION>
<P>
<I>&#8220;Subjects received the study medication with attached monitoring devices free of charge and were familiarized with the usage of the bottles. Patients with masked monitoring were not informed about the electronic adherence monitoring. Instead, these patients were told, the electronic devices would continuously record the temperature of the medication. Patients assigned to open monitoring were fully informed about the monitoring of adherence to topical therapy.&#8221;</I> Page e301</P>
<P> </P>
<P>It is not clear if the personnel or participants were masked</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-02-06 11:08:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hermann-2011b">
<DESCRIPTION>
<P>
<I>"According to the study protocol electronic adherence monitoring was accomplished in a masked fashion. Patients were informed about the electronic monitoring only to the point that the temperature of the medication would be recorded."</I> Page 502</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-02-26 12:39:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-I_x002d_SIGHT">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-02-26 12:34:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laibovitz-1996">
<DESCRIPTION>
<P>
<I>&#8220;Because one purpose of our study was to determine patient preference between the two ophthalmic medications, and dosing regimen is an integral part of such preference, we deliberately did not mask the treatment regimens to the patients or study physician. However, the interviewer administering the COMTol questionnaire was masked to the patient&#8217;s regimen, interviews were conducted in a brightly lit room (to induce miosis in all patients), and patients were instructed not to disclose their dosing frequency to the interviewer.&#8221; </I>Page 823</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Laster-1996">
<DESCRIPTION>
<P>Participants and personnel were not masked</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-02-26 12:39:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muir-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-07-02 10:25:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nakakura-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-02-26 12:39:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Norell-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-02-26 12:39:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Okeke-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-02-26 12:39:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ring-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sakai-2005">
<DESCRIPTION>
<P>Difficult to mask participants as dosing frequency differed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-04-26 12:39:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schenker-1999">
<DESCRIPTION>
<P>Participants and care providers deliberately not masked. Difficult to mask participants as dosing frequencies were different. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-02-26 12:40:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sheppard-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-29 04:41:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sverrisson-1999-Europe">
<DESCRIPTION>
<P>
<I>&#8220;Because the purpose of the studies was to determine patient preference between two therapeutic regimes and dose regimen is an integral part of such preference, the treatment regimens were deliberately not masked to the patients or the study physician. However, the interviewer administering the COMTol questionnaire was masked to the patient&#8217;s regimen, interviews were conducted in a brightly lit room (to induce miosis in all patients), and patients were instructed not to disclose their dose frequency to the interviewer.&#8221; </I>Page 823</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-02-28 14:20:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sverrisson-1999-USA">
<DESCRIPTION>
<P>
<I>&#8220;Because the purpose of the studies was to determine patient preference between two therapeutic regimes and dose regimen is an integral part of such preference, the treatment regimens were deliberately not masked to the patients or the study physician. However, the interviewer administering the COMTol questionnaire was masked to the patient&#8217;s regimen, interviews were conducted in a brightly lit room (to induce miosis in all patients), and patients were instructed not to disclose their dose frequency to the interviewer.&#8221; </I>Page 823</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-02-26 12:40:33 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-22 10:35:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gray-2011">
<DESCRIPTION>
<P>"<I>The researcher and outcome assessor were masked to allocations until study completion.</I>" Figure 1 page 409</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hermann-2011a">
<DESCRIPTION>
<P>
<I>&#8220;Subjects received the study medication with attached monitoring devices free of charge and were familiarized with the usage of the bottles. Patients with masked monitoring were not informed about the electronic adherence monitoring. Instead, these patients were told, the electronic devices would continuously record the temperature of the medication. Patients assigned to open monitoring were fully informed about the monitoring of adherence to topical therapy.&#8221;</I> Page e301</P>
<P> </P>
<P>The above statement suggests the participants might have been masked, but not clear as to personnel or outcome assessors. However, as the outcome measures were based on electronic recording, lack of masking was considered not to be a source of bias here.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-06 11:08:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hermann-2011b">
<DESCRIPTION>
<P>
<I>"According to the study protocol electronic adherence monitoring was accomplished in a masked fashion. Patients were informed about the electronic monitoring only to the point that the temperature of the medication would be recorded." </I>Page 502</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-I_x002d_SIGHT">
<DESCRIPTION>
<P>
<I>"Adherence data from data abstractions were coded independently by 2 raters who met in cases of disagreement to resolve discrepancies"</I> Page E3</P>
<P>
<I>"Research interviewers were not masked to assignment because it was necessary to determine treatment group participants&#8217; preferences for intervention delivery (eg, preferred telephone number and time of day)" </I>Page E2</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-02-28 13:11:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laibovitz-1996">
<DESCRIPTION>
<P>
<I>&#8220;Because one purpose of our study was to determine patient preference between the two ophthalmic medications, and dosing regimen is an integral part of such preference, we deliberately did not mask the treatment regimens to the patients or study physician. However, the interviewer administering the COMTol questionnaire was masked to the patient&#8217;s regimen, interviews were conducted in a brightly lit room (to induce miosis in all patients), and patients were instructed not to disclose their dosing frequency to the interviewer.&#8221; </I>Page 823</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-29 15:46:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laster-1996">
<DESCRIPTION>
<P>Outcome assessors were not masked. The effects may vary with outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-02 10:27:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muir-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-02 10:27:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nakakura-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Norell-1979">
<DESCRIPTION>
<P>
<I>&#8220;Patients were not told the purpose of the monitor until we had finished collecting all the data.&#8221;</I> Page 1032</P>
<P>Electronic outcome monitoring considered at low risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okeke-2009">
<DESCRIPTION>
<P>Masking was not described and intervention/control group received very different interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ring-2011">
<DESCRIPTION>
<P>Not masked</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sakai-2005">
<DESCRIPTION>
<P>Correspondence with investigator: <I>"It was open labelled, and the number of the eye drop(s) was different."</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schenker-1999">
<DESCRIPTION>
<P>
<I>&#8220;A member of the clinic staff who was masked to the treatment the patient was receiving administered an anti-glaucoma patient-preference questionnaire.&#8221; </I>Page 139</P>
<P>Correspondence with investigators: <I>"Investigator office staff was blinded until after the analysis was reported."</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-26 12:40:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sheppard-2003">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-29 04:41:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sverrisson-1999-Europe">
<DESCRIPTION>
<P>
<I>&#8220;Because the purpose of the studies was to determine patient preference between two therapeutic regimes and dose regimen is an integral part of such preference, the treatment regimens were deliberately not masked to the patients or the study physician. However, the interviewer administering the COMTol questionnaire was masked to the patient&#8217;s regimen, interviews were conducted in a brightly lit room (to induce miosis in all patients), and patients were instructed not to disclose their dose frequency to the interviewer.&#8221; </I>Page 823</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-02-28 14:20:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sverrisson-1999-USA">
<DESCRIPTION>
<P>
<I>&#8220;Because the purpose of the studies was to determine patient preference between two therapeutic regimes and dose regimen is an integral part of such preference, the treatment regimens were deliberately not masked to the patients or the study physician. However, the interviewer administering the COMTol questionnaire was masked to the patient&#8217;s regimen, interviews were conducted in a brightly lit room (to induce miosis in all patients), and patients were instructed not to disclose their dose frequency to the interviewer.&#8221; </I>Page 823</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gray-2011">
<DESCRIPTION>
<P>Outcomes at 12 months: data for 63/64 of intervention group and 60/63 of control group. Reasons for incomplete outcome data supplied. Figure 2 page 412</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hermann-2011a">
<DESCRIPTION>
<P>36/37 participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hermann-2011b">
<DESCRIPTION>
<P>
<I>"A total of 75 patients [...] were enrolled in the study; 67 (89%) completed the study and were included in the statistical analysis. Seven patients (9.3%) did not complete the study owing to adverse effects (migraine, dry eye, redness, allergy). One bottle (1.3%) was not recollected."</I> Unclear which group 7 patients were in. Page 504.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-18 13:51:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-I_x002d_SIGHT">
<DESCRIPTION>
<P>Intervention group: 150/157 (96%) interviewed at 12 months </P>
<P>Intervention group: 152/155 (98%) interviewed at 12 months</P>
<P>Figure page E4</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-06 11:12:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laibovitz-1996">
<DESCRIPTION>
<P>
<I>"Of the 75 patients who entered the study, 51 completed both treatment periods (Table III). A total of 21 patients discontinued therapy due to adverse experiences while receiving pilocarpine (12 from group A and 9 from group B), whereas only 2 patients discontinued therapy due to adverse experiences while receiving dorzolamide (both from group B).[...] Only 1 patient, who was lost to follow-up during the first period, discontinued dorzolamide<BR/>and did not enter the second period." </I>Page 825</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" RESULT="UNKNOWN" STUDY_ID="STD-Laster-1996">
<DESCRIPTION>
<P>&#8220;<I>A total of 13 patients were [..] able to complete the study</I>&#8221; Page 655</P>
<P>This suggests that more people could have been enrolled and not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-02 10:16:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muir-2012">
<DESCRIPTION>
<P>131 enrolled, 4 withdrew, no other information on follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-06 11:16:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nakakura-2012">
<DESCRIPTION>
<P>20/21 participants in <I>latanoprost/timolol plus brinzolamide </I>group followed up compared to 16/18 in <I>dorzolamide/timolol plus latanoprost</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-Norell-1979">
<DESCRIPTION>
<P>73/82 (89%) participants provided complete data</P>
<P> </P>
<P>
<I>&#8220;The second monitor record was lost in nine cases-one patient suffered acute heart disease, two were admitted to hospital for long-term care, in two cases the monitor was lost or broken, and in four no record was obtained because the monitor battery was defective." </I>Page 1032</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Okeke-2009">
<DESCRIPTION>
<P>All 66 patients randomised were apparently assessed for adherence at 3 months, however the following statement implies there were some dropouts in the intervention group. <I>"For the 35 patients randomized to the intervention group, telephone calls were made at weeks 1 to 5, 7, 9, and 11. The number of patients contacted was highest at week 1 (100%), and over the remaining weeks there was a decline in the number successfully contacted (week 11, 63%). Reasons for the decline included early dropout from study, inability to contact patients, and early final visit."</I> Page 2289</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-28 13:56:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ring-2011">
<DESCRIPTION>
<P>
<I>&#8220;A total of 127 participants were enrolled into the study over a four week period; 2 participants withdrew without a specific reason and 1 participant died before the 3 month data was collected. All results are based on a cohort of responding participants (n=124). 110 participants completed the study (88.7%). 14 of the original cohort did not respond to the 3 month postal questionnaire (non-response rate of 11.3%).&#8221; </I>Page 32</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" RESULT="UNKNOWN" STUDY_ID="STD-Sakai-2005">
<DESCRIPTION>
<P>No data available for 4 patients; 2o withdrew after randomisation and 2 were excluded after washout period<BR/>Attrition rate: 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" RESULT="UNKNOWN" STUDY_ID="STD-Schenker-1999">
<DESCRIPTION>
<P>10 patients did not complete both periods, a further 8 patients were excluded from the questionnaire analysis because of other protocol violations. Attrition rate: 9%. A further 4 patients (11%) did not respond to the adherence question.</P>
<P>99/102 group A and 93/100 group B completed the study. Reasons for non-completion described well and summarised here:</P>
<P>Adverse event: n = 5, 4 probably related to medication, 1 unrelated</P>
<P>Other reason: 3 lost to follow-up, 1 withdrew consent, 1 for personal reasons</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" RESULT="UNKNOWN" STUDY_ID="STD-Sheppard-2003">
<DESCRIPTION>
<P>92 participants: 36/42 (86%) nurse-led and 37/50 (74%) doctor clinic</P>
<P> </P>
<P>
<I>&#8220;There was no difference in age, length of time diagnosed with glaucoma or the questionnaire measures between the participants who dropped out and those who remained in the study.&#8221;</I> Page 18</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Anupa Shah" RESULT="NO" STUDY_ID="STD-Sverrisson-1999-Europe">
<DESCRIPTION>
<P>Insufficient information to permit judgement. Difficult to assess attrition rate from paper and following contact with author. 18 patients (19%) were excluded from the adherence analysis, 19 (20%) from quality of life analysis concerning side effects and 22 (24%) from quality of life analysis concerning activity limitations. Numbers of patients involved in IOP and visual field test analysis were not published and could not be obtained from authors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sverrisson-1999-USA">
<DESCRIPTION>
<P>Insufficient information to permit judgement. Difficult to assess attrition rate from paper and following contact with author. 12 patients (13%) were excluded from the adherence analysis, 8 (8%) from the quality of life analysis concerning side effects and 9 (9%) from the quality of life analysis concerning activity limitations. Numbers of patients involved in IOP and visual field test analysis were not published and could not be obtained from authors.</P>
<P>See table 5. Lower follow-up in timolol plus pilocarpine group (63%) compared to combination group (97%), however, in international study good follow-up, 95% and 92%, in both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-24 12:08:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gray-2011">
<DESCRIPTION>
<P>There were some modifications from the protocol but this was additional data collection (clinical outcomes data and knowledge and self report adherence measures). All data collected were available for this review. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 13:03:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hermann-2011a">
<DESCRIPTION>
<P>Difficult to judge without access to protocol; no immediate cause for concern. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hermann-2011b">
<DESCRIPTION>
<P>Difficult to assess with information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-I_x002d_SIGHT">
<DESCRIPTION>
<P>Investigator confirmed that all outcome data specified in protocol and collected in the study were published</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laibovitz-1996">
<DESCRIPTION>
<P>Difficult to judge without access to protocol; no immediate cause for concern</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" RESULT="UNKNOWN" STUDY_ID="STD-Laster-1996">
<DESCRIPTION>
<P>Difficult to judge without access to protocol; no immediate cause for concern</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muir-2012">
<DESCRIPTION>
<P>Difficult to judge without access to protocol; no immediate cause for concern</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nakakura-2012">
<DESCRIPTION>
<P>Difficult to judge without access to protocol; no immediate cause for concern</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Norell-1979">
<DESCRIPTION>
<P>Difficult to judge without access to protocol; no immediate cause for concern</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Okeke-2009">
<DESCRIPTION>
<P>Difficult to judge without access to protocol; no immediate cause for concern</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ring-2011">
<DESCRIPTION>
<P>Investigator confirmed all data collected were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" RESULT="UNKNOWN" STUDY_ID="STD-Sakai-2005">
<DESCRIPTION>
<P>Difficult to judge without access to protocol; no immediate cause for concern</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" RESULT="UNKNOWN" STUDY_ID="STD-Schenker-1999">
<DESCRIPTION>
<P>Difficult to judge without access to protocol; no immediate cause for concern</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" RESULT="UNKNOWN" STUDY_ID="STD-Sheppard-2003">
<DESCRIPTION>
<P>Difficult to judge without access to protocol; no immediate cause for concern</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" RESULT="UNKNOWN" STUDY_ID="STD-Sverrisson-1999-Europe">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 13:18:58 +0000" MODIFIED_BY="Trish Gray" RESULT="UNKNOWN" STUDY_ID="STD-Sverrisson-1999-USA">
<DESCRIPTION>
<P>Difficult to judge without access to protocol; no immediate cause for concern</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-03-29 04:39:52 +0100" MODIFIED_BY="Trish Gray" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-03-16 11:57:02 +0000" MODIFIED_BY="Trish Gray">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-03-16 11:57:02 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-04-23 12:58:03 +0100" MODIFIED_BY="[Empty name]">Summary of findings: education and individualised care planning</TITLE>
<TABLE COLS="4" ROWS="11">
<TR>
<TD COLSPAN="4">
<P>
<B>Education and individualised care planning compared with standard care for improving adherence to ocular hypotensive therapy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Patient or population: people with glaucoma or ocular hypertension</B>
</P>
<P>
<B>Settings: outpatients</B>
</P>
<P>
<B>Intervention: education and individualised care planning </B>
</P>
<P>
<B>Comparison: standard care</B>
</P>
</TD>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>902</P>
<P>(7)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>1</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>3 studies found that people given education and individualised care planning were more adherent. Substantial improvements in adherence were observed in these studies. 4 studies did not find a difference, in these studies the intervention was less detailed. Different measures of adherence meant it was difficult to estimate overall treatment effect.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Persistence</P>
</TD>
<TD VALIGN="TOP">
<P>127<BR/>(1)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>2</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Only 1 trial reported this outcome in which 17/127 patients discontinued therapy (risk ratio for persistence 1.14, 95% CI 0.99 to 1.41)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Intraocular pressure</P>
</TD>
<TD VALIGN="TOP">
<P>193<BR/>(2)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>3</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Only 2 trials reported this outcome. One trial reported this at 12 and 24 months and found no difference between the intervention groups. 1 trial reported at 3 months follow-up which may be too short a time period to observe an effect on intraocular pressure.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Visual field defects</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>No data on this outcome</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Quality of life</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>No data on this outcome</P>
</TD>
</TR>
<TR>
<TD>
<P>Adverse effects</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>No data on this outcome</P>
</TD>
</TR>
<TR>
<TD>
<P>Patient knowledge</P>
</TD>
<TD>
<P>390</P>
<P>(4)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>low<SUP>4</SUP>
</B>
</P>
</TD>
<TD>
<P>In <LINK REF="STD-Gray-2011" TYPE="STUDY">Gray 2011</LINK> intervention improved patient knowledge (median knowledge score was 14 (range 2 to 18) for the intervention group and 6 (range 0 to 17) for the control group (Mann&#8211;Whitney P &lt; 0.001). 3 other studies reported no differences in patient knowledge between groups.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>We downgraded to low because (i) the majority of the trials were not masked , (ii) there was inconsistency in trial results.<BR/>
<SUP>2</SUP>We downgraded to low because (i) only one trial, (ii) imprecision in the estimate.<BR/>
<SUP>3</SUP>We downgraded to low because (i) only one trial measured at reasonable length of follow-up, (ii) no pooled estimate so not enough numbers to detect moderate effects.<BR/>
<SUP>4</SUP>We downgraded to low because (i) inconsistency in trial results, (ii) the majority of the trials were not masked.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2013-02-06 14:10:38 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-04-23 12:58:15 +0100" MODIFIED_BY="[Empty name]">Summary of findings: drug regimen</TITLE>
<TABLE COLS="4" ROWS="10">
<TR>
<TD COLSPAN="4">
<P>
<B>Simplified drug regimen for improving adherence to ocular hypotensive therapy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Patient or population: people with glaucoma or ocular hypertension</B>
</P>
<P>
<B>Settings: outpatients</B>
</P>
<P>
<B>Intervention: simplified drug regimen</B>
</P>
<P>
<B>Comparison: standard care</B>
</P>
</TD>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>650</P>
<P>(8)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>All studies reported a better adherence rate in the group with the simpler drug regimen; in 3 studies this difference was statistically significant. Different measures of adherence meant it was difficult to estimate overall treatment effect.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Persistence</P>
</TD>
<TD VALIGN="TOP">
<P>265</P>
<P>(3)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>2 out of 3 studies found that the people using the simpler drug regimen had a higher persistence, however all 3 studies were short-term cross-over studies and time periods were not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Intraocular pressure</P>
</TD>
<TD VALIGN="TOP">
<P>503<BR/>(5)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Overall there was little evidence of any effect on IOP</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Visual field defects</P>
</TD>
<TD VALIGN="TOP">
<P>301</P>
<P>(4)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>None of the studies found significant effects on visual fields but were of short duration</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Quality of life</P>
</TD>
<TD VALIGN="TOP">
<P>265</P>
<P>(3)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>In all 3 studies quality of life was assessed using the COMTol questionnaire. There were more reported activity limitations when the frequency of drop instillation increased.</P>
</TD>
</TR>
<TR>
<TD>
<P>Adverse effects</P>
</TD>
<TD>
<P>650</P>
<P>(8)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1</SUP>
</B>
</P>
</TD>
<TD>
<P>Interventions too different to come to a consensus as to adverse effects</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>We downgraded to very low because (i) trials were at risk of performance and other biases, (ii) data from cross-over trials had not been analysed appropriately, and (iii) there was inconsistency in trial results.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-02-06 14:17:41 +0000" MODIFIED_BY="Trish Gray">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-02-06 14:17:34 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-03-29 15:42:24 +0100" MODIFIED_BY="[Empty name]">Study design, interventions and outcomes in included studies</TITLE>
<TABLE COLS="8" ROWS="17">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Study</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>RCT type</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Intervention</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control group</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Length of follow-up</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Main outcome measures</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Gray 2011</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Parallel-group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Education and tailoring programme</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Usual care</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 months and 24 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adherence (prescription data and questionnaire)</P>
<P>Persistence (prescription and dispensing data)</P>
<P>Intraocular pressure</P>
<P>Patient knowledge</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Hermann 2011</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Parallel-group, factorial</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Brimonidine twice daily</P>
<P/>
<P>Masked monitoring</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Brimonidine 3 times daily</P>
<P> </P>
<P>Open monitoring</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 month</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adherence (electronic monitoring device)</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Herman 2011a</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Parallel-group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Brimonidine twice daily</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Brimonidine 3 times daily</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 weeks</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adherence (electronic monitoring)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I-SIGHT</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Parallel-group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Telephone automated education and tailoring programme</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Usual care</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adherence (self report of missed doses)</P>
<P>Prescription refills (pharmacy records)</P>
<P>Appointment keeping<BR/>Sources of information: interviews, medical record review, appointment records, and pharmacy data</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Laibovitz 1996</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cross-over</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2% dorzolamide three times daily</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2% pilocarpine four times daily during period 1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14 days per period</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adherence (questionnaire &#8211; COMTol)</P>
<P>Persistence (number of patients who continued treatment)</P>
<P>Quality of life (questionnaire &#8211; COMTol)</P>
<P>Intraocular pressure (Goldmann applanation tonometer)</P>
<P>Visual field defects (Humphrey Field Analyser) </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Both groups continued to receive 0.5% timolol twice daily throughout the study</P>
<P> </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Laster 1996</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cross-over</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pre-weighed bottle of pilocarpine in a medication vial fitted with the Prescript TimeCap</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pre-weighed bottle of pilocarpine in a medication vial fitted with the TimeCap</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30 days per period</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adherence (weighing the drop bottle and questionnaire)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Muir 2012</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Parallel-group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Educational intervention lasting 20 minutes (one-on-one session) including "informational video" delivered at varying literacy levels</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Standard care</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adherence (number of days without medication)</P>
<P>Self reported disease knowledge</P>
<P>Satisfaction with care</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Language of video varied according to participants' tested health literacy level</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Nakakura 2012</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Parallel-group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Latanoprost 0.005%/timolol 0.5% plus brinzolamide 1%<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dorzolamide 1%/timolol 0.5% plus latanoprost 0.005%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 weeks</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intraocular pressure</P>
<P>Adherence (self reported)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Norell 1979</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Parallel-group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Education and tailoring programme</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No intervention</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adherence (medication monitor)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Okeke 2009</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Parallel-group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Education and tailoring programme</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No intervention</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adherence rate (dosing aid device)</P>
<P>Intraocular pressure</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Ring 2011</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Quasi-experimental</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Educational intervention (film)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No intervention</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adherence (return of bottles)</P>
<P>Patient knowledge (questionnaire)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sakai 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Quasi-experimental</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Latanoprost once daily</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.5% timolol maleate twice daily and 1% dorzolamide 3 times daily</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adherence (questionnaire)</P>
<P>Intraocular pressure (Goldmann applanation tonometer)</P>
<P>Visual field defects (Humphrey Field Analyser)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Schenker 1999</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cross-over</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Timolol gel once daily</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Timolol solution twice daily</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 weeks per period</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adherence (questionnaire)</P>
<P>Intraocular pressure (Goldmann applanation tonometer)</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sheppard 2003</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Parallel-group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Education and tailoring</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Usual care</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adherence (questionnaire)</P>
<P>Patient knowledge (questionnaire)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sverrisson 1999 Europe</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cross-over</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2% dorzolamide/0.5% timolol combination twice daily</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2% pilocarpine four times daily plus 0.5% timolol twice daily</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14 days per period</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adherence (questionnaire COMTol)</P>
<P>Persistence (number of patients who completed treatment)</P>
<P>Quality of life (questionnaire COMTol)</P>
<P>Intraocular pressure (Goldman applanation tonometer)</P>
<P>Visual field defects (Humphrey Field Analyser/ Octopus perimeter)</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sverrisson USA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cross-over</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2% dorzolamide/0.5% timolol combination twice daily</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2% pilocarpine 4 times daily plus 0.5% timolol twice daily</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14 days per period</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adherence (questionnaire COMTol)</P>
<P>Persistence (number of patients who completed treatment)</P>
<P>Quality of life (questionnaire COMTol)</P>
<P>Intraocular pressure (Goldman applanation tonometer)</P>
<P>Visual field defects (Humphrey Field Analyser)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>COMTol: Comparison of Ophthalmic Medications for Tolerability<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2013-02-06 14:17:37 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-03-29 06:58:20 +0100" MODIFIED_BY="[Empty name]">Effect of education and tailoring on adherence</TITLE>
<TABLE COLS="8" ROWS="8">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Study</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Outcome measure  </P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Follow-up period</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Outcome measure variable type</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Intervention</P>
<P>n/N (%)</P>
<P>
<I>or </I>
</P>
<P>mean (SD)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
<P>n/N(%)</P>
<P>
<I>or</I>
</P>
<P>mean (SD)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Reported P value</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Gray 2011</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number of people who were adherent</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dichotomous</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>45/64 (70%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27/63 (43%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Data from page 185 of Gray PhD thesis</P>
<P>&#8220;Refill adherence&#8221; measured by contacting GPs and pharmacists for prescription and dispensing information during the 1-year follow-up. People who collected 100% of prescriptions were defined as adherent.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I-SIGHT</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Self reported medication adherence: number of people not reporting missing drops in 1 month</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>"last visit" which could be 6, 9 or 12 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dichotomous</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30.2%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27.0%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>"treatment x visit" interaction 0.18</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Also reported a number of other measures of adherence (see table 3, page E5) including self reported refill adherence, self reported appointment adherence, chart report medication adherence, chart report refill adherence, chart report appointment adherence, none of which showed statistically significant differences between groups</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Muir 2012</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Days without medication</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Continuous</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>63 (198) n = 67</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>65 (198) n = 60</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.955 (calculated from data t-test)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Norell 1979</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>% of time exceeding 8-hour dose intervals</P>
<P> </P>
<P/>
<P>% (number of missed doses)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dichotomous  (denominator not reported)</P>
<P> </P>
<P> </P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13%</P>
<P> </P>
<P> </P>
<P/>
<P>6% (120)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24%</P>
<P> </P>
<P> </P>
<P/>
<P>15% (338)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 0.001</P>
<P> </P>
<P> </P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Table page 1032</P>
<P>Measured using a medication monitor</P>
<P>Unit of analysis not same as unit of randomisation</P>
<P>Reported P value tests difference in change between first time period (before intervention) and second time period (after intervention)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Okeke 2011</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adherence rate</P>
<P> </P>
<P/>
<P/>
<P>Change between pre-intervention 3 months and post-intervention 3 months </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Continuous</P>
<P> </P>
<P> </P>
<P/>
<P>Continuous</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.73 (0.22)</P>
<P> </P>
<P> </P>
<P/>
<P>0.19 (0.20)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.51 (0.30)</P>
<P> </P>
<P> </P>
<P/>
<P>0.06 (0.30)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.001</P>
<P> </P>
<P> </P>
<P/>
<P>0.01</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Table 3 page 2289</P>
<P>Adherence rate measured using Travatan dosing aid device</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>*Ring 2011</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number of people who were adherent</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dichotomous</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18/54 (33.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19/56 (33.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.947 (calculated from data)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Page 44 of Ring MSc thesis</P>
<P>People who returned bottles within 10% of target weight were defined as adherent</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sheppard 2003</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adherence</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Continuous</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="3" VALIGN="TOP">
<P>&#8220;<I>No differences were found between the two groups on adherence using an ANCOVA with the pre-appointment score as a covariate</I>&#8221;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Page 19</P>
<P>Adherence measured by questionnaire using an 11-point response scale: 0 &#8220;I never use my eye drops&#8221; to 10 &#8220;I always use my eye drops&#8221;. Reported as a continuous variable in the paper but only pre-appointment mean (SD) reported. Also reported <I>&#8220;significantly fewer of the [intervention] group reported [specific problems with adherence] compared to [control group].&#8221;</I>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Adherence: taking medicine as prescribed</P>
<P>See text for description of education and tailoring packages in each study.</P>
<P>*Ring 2011 did not include any tailoring.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2013-02-06 14:17:41 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-04-20 14:47:05 +0100" MODIFIED_BY="[Empty name]">Effect of drug regimen on adherence</TITLE>
<TABLE COLS="8" ROWS="9">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Study</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Outcome measure  </P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Follow-up period</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Outcome measure variable type</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Intervention*</P>
<P>n/N (%)</P>
<P>
<I>or </I>
</P>
<P>mean (SD)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
<P>n/N(%)</P>
<P>
<I>or</I>
</P>
<P>mean (SD)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Reported P value</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Hermann 2011</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adherence rate (%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 weeks</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Continuous</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>73.3 (13)</P>
<P>n = 18</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>64.0 (12)</P>
<P>n = 18</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.02</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Table 3 page e302</P>
<P>Adherence rate defined as <I>&#8220;Ratio of recorded dosing events to intended dosing events for the observed time period.&#8221;</I> A recorded dosing event was application of 1 or more drops within 30 minutes following the first application.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Herman 2011a</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adherence rate (%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 weeks</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Continuous</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>72.2 (19)</P>
<P>n = 33</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>62.1 (16)</P>
<P>n = 34</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.04</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Text pages 504 and 505<BR/>Adherence rate defined as for Herman 2011 above</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Laibovitz 1996</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Reported missed doses</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 weeks</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Continuous</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.8 (SE 0.18)</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.3 (SE 0.18)</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>COMTol questionnaire: <I>&#8220;How often did you miss one or more doses?&#8221;</I> Graded 0 (never) to 6 (always). Data are from cross-over study but data from 2 time periods appear to have been pooled.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Nakakura 2012</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Forgot administration</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 weeks</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dichotomous</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2/19</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2/16</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.855 (calculated)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Question <I>"How often do you forget administration per week?"</I> Never/within 2 times per week/more than 3 times per week</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sakai 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Reported missed doses</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dichotomous</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16/18 (88.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13/18 (72.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.207 (calculated)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>&#8220;How many times patient has forgotten to apply the eye drop?&#8221;</I> Answer less than once a week defined as adherent</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Schenker 1999</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Reported never missed dose</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dichotomous</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>141/180 (78.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>123/182 (67.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.021 (calculated)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Table V Page 144</P>
<P>Frequency of missed doses: never, rarely, occasionally, frequently, always<BR/>Analysis ignores cross-over design</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sverrisson 1999 Europe</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Reported missed doses</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Continuous</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.1   (0.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.4 (0.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>COMTol questionnaire: <I>&#8220;How often did you miss one or more doses?&#8221;</I> Graded 0 (never) to 6 (always). Data are from cross-over study but data from 2 time periods appears to have been pooled.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sverrisson 1999 USA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Reported missed doses</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Continuous</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.2 (0.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.2 (0.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>COMTol: Comparison of Ophthalmic Medications for Tolerability<BR/>SE: standard error</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-05-22 11:05:28 +0100" MODIFIED_BY="[Empty name]"/>
<FIGURES MODIFIED="2013-02-26 12:40:38 +0000" MODIFIED_BY="Anupa Shah">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-02-26 12:40:38 +0000" MODIFIED_BY="Anupa Shah" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVIAAAM1CAIAAACt2e5zAAAqFUlEQVR42u3dsW4lR3rFcQIGjA0Y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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-02-26 12:40:38 +0000" MODIFIED_BY="Anupa Shah" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAADnCAMAAAD4paggAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAbpElEQVR42u1da5AcV3U+++jXzGh3unc31krB5ZUUkirlBzGRsGSt
sHctQAlgoEIVZUwAV0U2j0CloAI4VY7JD2wZbOK4bEB2lbDBSShTrsg8LCxpjD0Sj1VKqVQQocyu
JGS0s0S73bvS7vbM9Oxs7qtf89jH7MxsjzifHj197zn3nO45fe/tnvv1AUAgGoY20PEkIBoEqx3P
AaJxwPBCYHghMLwQCAwvBIYXAsMLgcDwQqwbOvEU1BcWnoLAk3oMLxwP1urxQsn+Ig6OCLzWEBhe
CASGFwLDC4Hh1TIwm66IaFB4DRHIsUzFqvU6ts1VbOuJZTysojhUWXrRwDBqeO+VSqUmpK2ROrZd
xKtKfZP9m9oU3SMt2S/Y2Ns1Y3A0zhcA+jRZIZfzUFKVyWYkptBHuE5cjju0UJEP26qUZuK2pKhp
WiclHCqp6kO8ayD/zJgSN5mCYpM6lTYpyoC1miRCToK32r1ftr12hrpV4cMQ+0PLuZRr9zm7B2xZ
0ZhtmeqA15ajDvuKMSXm+8DsaqwlgF5NVslxpWVZ7QVpfivGUTPmXlskgKvxfHyOfC6OJ8hmSM3Q
Z7o9R/JyDy3MnPh4//iVYSbdlcgdu43UjTq0buhH44FO4PqZ3FGdKUx3A9yqXbD9MoAdcqZIW7Xy
Cm0Vnj3R5bUDHeMwG89Pz5FehvUzPUd4Obh2/+4ks/0StT3N/WJt0U9J7b/nXUVdyanXez4wu5dG
ufScmY/NAwwn8sdmAU7mMY4aHV507lWYBshOgnkz2b9g0E1h1JgiO7kbYSxLtlPG4K5zhraHaShO
enuO1PWDSTbOdqMQGHAkGNRYK1S4MNZv+2UA2jneqsQ04bwxOOi1A6MG2JOg3ew29QFh+7xrd2E7
sZ3ntkUL7JOVo5Yms54PYzBa8HygsIx+Lm1r7CClXO92Ir69gHFUBfViCg2lwDaukN5rakuhuCtF
9+k/Oc82dI98FIXsHwmo5Aef7rrMhkNy/UuOJ0k3vNDdS7lTat5RHDjkCclHK6hMbVlY4D4IZSUX
sEt9orY3TAZ0AtoQUAw4DYGWzIGFwu4UTF3vtF3o5/64sPA3x0W9ESdDUz5D/r8TJq8EotcEOrc5
ZVa42ZfmHoxdJV8quSkgX/heLikeC5zihQKnmLJf9gyXpZpHPaGTvsqdcNm/OTxJbC8G7Q6a3PZs
sEmh3RZwkzo9GPLYAfPD4tZSfpWOqHMT2p3E4aexm2rC3Gv6KTJbPnHM7vGLsluhl46D22CrWiqu
po0XSOCrfaDHAU5rTPKUbdLYJ33ZYc2T7NyW0ViZzRuxt0APmUCpDhyP+c3xdihOTNo5LyrVUts/
O0sKbWZbybg6pC2dtPWzrX0qi0jqgwbbfh7yuBu0f2cfir8avY0fwffIIZ/FZSdNmdrP7DNhZm9/
oM3TebWNzrlycn6qVHrDPpmNZLacJcFzoVehktPdG79Jb/675Y/5neD0/AD5wlNJWb/K+9ycQm1M
JaWH456QaIf5sYH50LkRKtmWyUxqg8Ft/5GrQ9q6ibT1sn2FBJl8HXsA0SPb4YcQM2ofbyl2FzOQ
2KcMzwDskTGOGjz3qtcEbsUPQWy7VivmB7/dU0+vnXc/a+Dcq/LcqwO06Bzn+MLK5D77nx0LrzxZ
q5WDU3M/qafX3ZkvBvaybS3YxawNi2Wz8MDJwHdM1BW4GDqwGNrCWWmjTi0CcEEOAsMLgeGFQGB4
IZoJnNrjnWMDb28wvFp/PGi0xYVVyiONFoFzLwSGFwKB4YXA8EJgeDUa5vo3jcSy1g0vY4iu1Bqq
Sq/dvDbi7VK69/GN/egyOvetikabsDGMohNe+ZHeJeuX5rCuCb/kfZO+a3m5VdBoL+rY20UmvEzH
Knhfh8mZqo5GebAZTVaPuxxWMyZrpsfGBUbPtX0+brcmp109UdanKQoXHdKVA7atSnaAaUvlh3jH
c0bZCYYiazbj48a4M2Zcpp8ymmL7/FtZ8HJlzr+FvhjzybNly5KWBkNGGm01NH216v2JBfUfJBg4
T/8+rsxu+EoeuuXp7gL88kz7hmcK5wdStObBDXNdpGbg0utfn2NPjduZjC7NxbUcDGQu7h8qCj3d
gg2f+gkUE1dn2xdYw5d++/HO5MW/+M4CfO4YJEgdl6dNEzz/w8NQjM117RuFf3v561cebmP25iH1
x23wlUSsbUG4QGzFmK3XqS2CgdcvHrqPSQtb8dj81ecKcPxpxz++dVit2miLi6tV8FerNr33OiSD
7NECnVEYJV9N/pyUBXhRA2u3W6OOsRrBxiW4g8nkxuCcz5zlepQL+xjj77p01yljctc5Y5DsPSaB
9Zgnz3HHdoBO0x59kdjfCRpnEWmco3v3ucs5Vy5sC9iny1xa2PpywbYpjdbBbqpq5Dd3eaX5fnIt
nMoYZUxVUnXDRw7tTi3FYYWS4hC91ukt7M2lAlTcanRcSqM1/3BhsftyCY027SxPo+UFwtbILQVI
7WHcWg8W/ubYGBrtyvrNn6ZSqY6zYo8yVdtcQuLm9m9f9eREDQQLgHNiy8o4A7YbJl8oM3cyRMf1
nzsY85nElSCNln5yXIaj0C3j/va6PglbO+cn4sP4HCNCU3vKUgX1jNh76CxskwCkLQ4pLkqjdP1G
eoTWUA6rFFTkMuo22KKWlnE2bSHE33XHWMfj1tKAYaOYTAbB/Qa7C5BGwBDDHeftylsdxZX7VMgW
e6IBb+RvoBC2NMMYJ52xhstOohJehVHy3+jnxAX/obcr2YsAv84ljgHEZz9Pv3OFTaAu9rAaH1zm
fO6AM1VSNpWU3kVCaOaZ/ufLzE0lD2R9IrfEXg3wH9cBnLaluWli5VblDsHM7VYob9eyPzHtyj2Q
k5ww93dUs/lyLmHrJVtOEtHrjmAcRWTuFQGY/emd9WzPSWTWl0Yb4bnX7yPP0cjN1bO5R78YnHxh
eP2+h1dDgYuhkUbbjFOLAFyQg8DwQmB4IRAYXohmAqf2eOfYwNsbDK/mjwfLSSzU2aPk+l1hODgi
cO6FwPBCIDC8EBheCAyvpWHWSQZxbYQXTWqm9lWguA4tyU615c9WLA/yYaupb17auzXwaYWqXonm
kpa71tBkGY0Wf8VeWe+VSk1ofPFmGYt0CVpp18xXKpYH+bDV1Hc1+PDMbKVkeMMnrqyhzdJjsbLY
B69wcDSsotdf6YzBamosn+yQl8/VibNUsODmeR0a/EumYTBGalqTaJ5WIuuSUVkmWaqeZozWXlXh
2WoVQVgVjFYI6nI7gkALQzbTHInLsRHml6tjhvLFunqcOcuxVZKoZ9pIMHft0J5/DOSoZeoiR246
JqtJnt82zZi7h0PtOarIRivk0pKi9YIkIY12pXMvw2fV8nyy39Ey7lPkRZbPtUfKPMD3eZ5XkbsV
pjLqdwDeZjo0Tyt0jIvyJ7QL81x8z8SRHoDZY7npvwKW4zXJdGdjeZMPL64ut9MpT7gr3fsmaKbY
HdP5KZqHDMZhjutcr+TUb7lteXpW/kWP05Gn2aQKGXWHX97xLLXq5qjtGKfqx0WO3Lf9KM9D/dkT
pF37e90fC7X31LjGPwm5byVyL70PQL4f42gl4UUmX296yNs7zxis3+X5ZCl4WtbcOePNfD8r8rxy
FIzR73p5WmlOWI4XxvqFzGmjK0eUBkEb5Y1xfqzkMC4q+LrcjjpmnHaHI4PaUSXQKKFwzIBOrvOW
MRh9wW9L6Emw1+Md3vQaDXxjTPXLuWeu73TPz5FrD4J1Mzv0QeJj/sbL2VB7bzZErloh96+Ovf0Q
wGt/j3FUBcHF0JQm2nclF2CRhvLJigLKGS3Nzgoex9QcmNZ2pwK81SAxlQo4fV/8/K6gwMgtCzDL
OGdh3XI74DFdR95apDrlpNrSvLIixy3dljNqAzlqxb+RfW4a20pJcH0dIeck8+0bJjkx15uJ4W+O
VnUa7eXSO632MjKpVxDOMeswjunmtp5XQ9KnPJERJtBdvDE8r945n4l9gt9GhnX91k0vQ62YBO20
M7FEBa4tRYg5225y9Y5SRu2p0hy1DHvb5IBzJ82S9vpcj4ScNPc7mtPWbMNuaoVXkt5R+thhK9wQ
KlC2gH6SD46/gK2KV94L28jIUfxflqfV/3Y6t2b28/3b4AyRvnNqe0/oG9Rso+2bfLLn61I7ZzzD
OrOTdbyZIdUhm4dKubYUqgOvetTGTsoHH4Ctckk5870sPy4sciavgHymTw3pzcFZJShHc9r+NcDZ
hzCOVjb3krOvlAiczithduqU476CpLA/mOe1Tc6RuVL8Li8Z7T0sGezL9g0iY/CX5fcQ6V0bgtlq
iUz8fdLcDNuJ37UxUDV1u+K+5s1gdqxuZV70LVRnmrTVI2fLHnlMJaUHPGL2I5ST26bkL5SUl/ju
Iv7nGwNZ17WHr1ghvR+r75gKym3Q5eEPkXsWnNqvZO61Yuj5cqLgsplkh2p+KVztmmBuviINpRp7
Cp2uS6uj0f4ezb1WH14JZ7EzfrmsWM4voyfV/JqiZZte6kpwZoPvr2kEFntWSaPF8ELUfG7xFCCN
tgmnFgG4IAeB4YXA8EIgMLwQzQRO7fHOsYG3Nxhe1/54sFqP1vrcDbPRInDuhcDwQiAwvBAYXggM
rwbAXGc75jr5g+FVHZR0G8usmnRrKI+WlW1q0sEKO0bc9bOK/U2rykb7qIFh1IDeK5WakO/in8qq
qmvNxj9dVra7SQfL7Zjzry9jf/eqstHumsferiGDozF9wuuvjrOcrU78gEu6TTL+rKkpx/nlzjmv
Q3veRHeInGCkityvnG1rxjkvVleUV9OMbms+Ksf5t9erKbRtQ2YM2vQBWe0l1Z9h7djyOz6ZBpdd
O3RcUWyb+SPqh5L7D9heNlrZcP3k9mi5sONoBww3G+2U8DGpHhDZsjNajGejdX1h9nbKZzCOGjL3
0n1uxNHxGcZ9fdB95lscj88RiX/OvE/IKjlVd0m3nUcOyZ1+d5CCpNY1T2Tk3OP0a1/ITD/wzgzT
35Wf5L8xzL6U20VE5uJ5k7Q4vCt/bJZUP3hosgegO370zfuAsWuptaOZ40Y/80fUQ/HZXd2u7dt/
5/mpT+cev4GVCztJ5fF5V86QuI+L4x/q5o4+fCl2vefLnGfvd+/BOKp/eJHJ15/5z//vZTzUu8eM
C6KA55HV3u+ycLUxGPW4OXffCGNKsLHCGKWsEpnbNaar5TiLV90JGqcHZQfhozfTPLKG/SKA/Le9
24nC3RJoHwCQ7k/fnvXqiC8uL1bUkwY/usc15dien5oEH+UrrYUdh+W3FT6e4z6eZ3ltKR4wJh3P
lz2ePRuz0VZD7YuhKUMivS9bkWNbxsIFn81aysAtYdu6MmFSLI2KvgKlroo8soLBSqtP5cDR821k
z9xchK7LpeqncmFeLPXR9RNcZm6IfOu7FGDahrLR9hUKu1OuvdXSaKPehaz5N8d6ZaMdLJbf44fn
ue0h0q1nje58OPgQgLNtQzK83COxdi2+eA5YHtn4exmDVZvl1SRSpNmJH5A9w87E3lumXsrk+LAJ
5cxcYWdbONet8NFFxvWua/HyefDs4cy+Kjr8tO2rxAA5wclFh275X/ov/i/Zr20KFjhPZr82xoJQ
u1d68mobKydj4VP2oZNtcGn26pcy52E826E+kSgWgjLiX+H0kwawlyi1z3z1ISK7/38eiZ1eAPXl
P7HkIsRnO/R2B9Srj/zN0wtuXUBd1Is9Yoc09KsnbNfPQqHj8EsFWi7s3HzX1Tjbp6a5j25r5P/P
Oe88xAraZ+YCvjwJgd4r2xbBEWqVvc9aDXohlV3T3Et2xkrKpgpKeImPlVOe5zYuGkr2tDfVysl5
EjQnuvqfApb9dXr+aozLhBdMWbfIgjt7YgOTvddgDNrEPrnrCuW4ytkxymdVhk/wunjYH14vwLPM
Hil4fp7mOWhJubDzBZbflssRH53w28Fi2tutUl+IvYKE3VTd514rxuFPzEfqkM1NV+saDyN7x9c3
G22E516NDq+uDzzdMROxq9s+9Ol6Npe4HJxfYHhhNtoGAhdDI422GacWAbggB4HhhcDwQiAwvBDN
BE7t8c6xgbc3GF6RHw8iN8As91wMabQInHshMLwQCAwvBIYXAsOr2TBrqlqtihmswuWn9UKTV0ys
OIWBL6hmqwqJPJCraS2sonvpgEh5bN6VJTuVHBVlpVWrfq99q/cAyz6Y0Bt3MuqOJTi2NeSyDakE
ctWS8pv4p1Q4j245SqsKNvZ20bk0RO7YEcabdUQ+2W/Iw0aa55S1h2nOWWC82zjnuIo8tODLg0u/
7dsv2yxzLWe8KvLhNOfzejlkSd1hYKllFc6Qpflw+fVFc9V65ay9pCLaJRZGQrluKUY0wf3t1eRh
nebkplxeaR6z0Uao5y1mprsBbtUu2JxbS5mpBya+n3snK4frnlN2MLnrZ3JHOe92x+siD60nL7qR
FNg/nUvSvLh5llu2mDnx8XeNn6A5c628wjOv9cgTHwH68oH89BxPf3ssN81zItFctV45I89+NyPa
pfErbHF/KXZcmuRtzpn5/yLeDycYl7cvj3EUnfDiSWMLY/02/R9GaSdz2tDecp6Vi9yxwBgSg3yZ
sWqAxr9CV96Dc07K+blleV5ZynrNSWByBlpuzKC/A9qTINLf0ny4nBdbeC1YTnFjYNW8a4v7y6YS
hsbbpHlzyaAt5dKUy/taAeOoCmonotUEylC7h23eeg/d33sPHOxYgIF7wS0fuAgH24v0096BgYHf
MFrZW8mnC8WgPCeHec2Q/w92LlBdr3micpHNQTu/BAdJwdQ3OjvfwFScnoOvvIExy9ofgEC57xv/
69q6xyOikU+dzLj5damdKE189fDDv32Y+euh/kS0yDHbliWq1YWItjb4vNnBcIXDcsdCkEHb5rNd
PXk+F3Mzxpbllg3kkDWZ7BtgMsH3u4pdIi0kzVXrl1fwsMQ3x31ksRlkmje3Z25CuxNKmb+ICNz1
dm7LkCCXNNj283BFD8sdC+xtAIeJyEkHjo+4eWiF/EnDvI1HlbzFUcjoua00t6xKtPj7VZQzQGUL
k3aOx8zC1O0iHy7NVeuXp70bQB6zD5X51g0afzFG8VejdH6opY3vkduIs7jsJHLhNT0/QL7EVI9s
l9zot7PcsXSG3S1/7BXBcVVs3uEI+cRcP+3h5I1gZRPHyQiXK80tO5WUHuaM2qn3KFR2hmfBlTZS
Dqw4anlPsFzZ6CrL7FN5rtsZtY+7Fr+rn957xvcpwzMAe2SMo6oDe8SoLY3OHRt67rXpUs/aW5na
3FgabSs/Vo1ceDU6d2wIRn527Y0kpOAKVQyvYHhFbtrQzOiqz4+LJRFarLeTRWhd4Ky0zkAabaR7
XgSGFwKB4YXA8EJcw8CpfZ2BNFqk0UZqPLjmBpACDo4InHshMLwQCAwvBIYXAsNrvWA2QWNteogo
h5cTUw50+USN0qyvm5bMclsJ91XR0BM16VXJRpuwMYxaIby6lMyD8IWq1UvniK2EX1bWMG+yatIT
KK26qGNv1wrhVRwzjCuP0Ryxcox/Y5RJO8IosLYgt2oOOJpbTruSbtWVH7IZc5ZmvR1h7FdBhx1K
qrJBObBKknc8W09JNelBX0zjHN4+jaXKNWRJS4OhbME4aoHw6hw47tDlhPp0/kf8d4Xrf5yb3AFg
K3NuHlvpD+DbkltO0THuyfdNSD1ER80pLBwygg4LxfHEHMAONSMW5uV/UJse5H6b4H5djeemZwFm
Y465D+D7mC60FcLr9X96d1zLsByxgj/r7ARNJfHg54j9wf3wScUtpxg1PPmLxjkSnM4ojNHv+5y3
AJ7nxVXHjPN8v7C9Nj04b1zmVrOTjIn75YJtE8e2Y3hVQ8TW2psDu19cMkesuSmrZgM5almuWE9e
JIt1N1Xy4kpObXqBbLS9hb25FIzcUoDUnjA/wMLfHAvRfEOOYoIxc6JCjthT/tzZ6EgeDDJsXSmH
PU8wP8LZr5WIzX5e3HazNj3ocyW6YfIFstk5PxEfxucYLXLpZAccs1siW86fpf0M589KWxzVDTL5
xi6v3NUT8jfAFlp3FraJDH8ng6OWvRVuSPM53tna9GAe3shptIVjNmWwaYYxvkg2uOykFcLLejCx
sXCRbHmOWDorulW5IwHwa5Yj9qF+WvR/J2/3yl09Id9xoHAvqXu7kr3IK6Tg8y0/L678i9r0YFSz
L7APM8/0P0+nabacJKLXHcE4ao2511qwPAFX5MU1P/iCVIteFaw1G+21PPdq8htyGolLS9M7uxY7
f/jKk/TTwalcWy16VfCnzz0SHOHbVn+FX2MoaoGTgcS8+o7weAowG20TTi0CcEEOAsMLgeGFQGB4
ITC8EBheCASGFwLDC4HhhVgBrHXWj1YDGF4I7L0QGF4IRAlwxUTE5l7XAnDFRBPObY3hudbLPQIN
4OCIwLkXAsMLgcCpPWI97nNwat+Ie0edbfSVT5M9HbZdlao/ndZrs+1Px/UVe8CrfK+rGcXwqnt0
8ZPM/q44utwvRhd7K1cN3bDWYttXt2ClHlglR1rVKM69IvQwo/ZHApZet+uirtaw92pwR1bLuFqD
qlX6wG31tvUVe6Cv+IAxvBrVIVn0r7XiOyd3bCTb1aqCp1mj7bJ2avKgkg6GVyMHPDEzWeUYWYOq
vmbba/Wgsg7OvaIxNlprHNrWPi7ra5/NletgeEUoEmv/ObxeP6TX+wd5fKxa/1AJPiVY2ekNPHVa
rWrY6Boa0FfjfKXnXhV0LAwvRAOvNBwcEQ0EhhcCwwuB4YVAYHghMLwQ1wQCPwohxwVRJ+gVwguf
gCHqAwsHRwTOvRAYXggEhhcCwwtxbaFz6Zl/691Tou+RD6/SPq3YwkdUaCXfS7JXLeLgiEBgeCEi
Hl7WCmvL5CzLL12nH56sisatljgez/dqLkX51NeLiLbc6whaba4awePRW/DUr35wtCxxJXlXhsX+
iJrgFcclrZIrSYj50k3txlzjwaNxN1akj4fbgpD/UT/1q+69Kr2JwNLDNcF9960WHsEy/OKLpseX
7v8td8b3NZrHQ+2EjEf91Nc4OOqW+FPS7+plfXJZ36yva3+tV7Sth7fROh6r5MyXOxjdU1/HlwDo
gZdULX+6dCsSM7El5r1ROZ4VMGwje+o763se6NWzzKsJrMBLytY/vvSQTy17PFF1tdbnXjp7j4pe
y5OLwE1B086+VTZwWMs8tYjq8VhreWjU9FPfucoD06v3rH4Nj7uwpG55lbymqYNjibWgM/ST8Cny
x1PRzyif+sBLAPyru5S7XWyln4VLf3NsJd9Lf3PUl3uYFdHj0Kt8GYhof2/QYqsoMLxaCS23QKdy
eBVb+CsotLDvi9fa9dB5TVwk6HtEgQtyEBheCAwvBALDC4HhhcDwQiCWRvDBBL6BCdG48ML3LyFw
cERgeCEQGF4IDC8EhhcCgeGFwPBCIBCI5fH/kSuj+dOVr4YAAAAASUVORK5CYII=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-07-17 12:12:36 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-02-18 12:50:26 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-02-18 12:35:47 +0000" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-18 12:50:26 +0000" MODIFIED_BY="[Empty name]">
<P>#1 MeSH descriptor Glaucoma<BR/>#2 MeSH descriptor Ocular Hypertension<BR/>#3 MeSH descriptor Intraocular Pressure<BR/>#4 glaucoma*<BR/>#5 (intraocular or intra ocular) next pressure*<BR/>#6 ocular hypertensi*<BR/>#7 IOP or OHT<BR/>#8 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7)<BR/>#9 MeSH descriptor Antihypertensive Agents<BR/>#10 antihypertensi*<BR/>#11 therap* or treat* or medicat* or drug* or drop*<BR/>#12 (#9 OR #10 OR #11)<BR/>#13 MeSH descriptor Attitude to Health<BR/>#14 MeSH descriptor Patient Compliance<BR/>#15 MeSH descriptor Patient Dropouts<BR/>#16 MeSH descriptor Treatment Refusal<BR/>#17 MeSH descriptor Patient Acceptance of Health Care<BR/>#18 MeSH descriptor Patient Satisfaction<BR/>#19 adhere* or non adhere* or complian* or non complian* or concordance or persistence or acceptance or coperat* or co operat* or conform*<BR/>#20 (discontinu* or abstention or abstain* or stop* or abandon*) near/4 (treat*)<BR/>#21 (discontinu* or abstention or abstain* or stop* or abandon*) near/4 (medic*)<BR/>#22 (discontinu* or abstention or abstain* or stop* or abandon*) near/4 (therap*)<BR/>#23 (#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22)<BR/>#24 (#8 AND #12 AND #23)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-07-16 11:49:11 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-07-16 11:49:11 +0100" MODIFIED_BY="[Empty name]">MEDLINE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-18 14:59:11 +0000" MODIFIED_BY="[Empty name]">
<P>1 randomized controlled trial.pt.<BR/>2 (randomized or randomised).ab,ti.<BR/>3 placebo.ab,ti.<BR/>4 dt.fs.<BR/>5 randomly.ab,ti.<BR/>6 trial.ab,ti.<BR/>7 groups.ab,ti.<BR/>8 or/1-7<BR/>9 exp animals/<BR/>10 exp humans/<BR/>11 9 not (9 and 10)<BR/>12 8 not 11<BR/>13 exp glaucoma/<BR/>14 exp ocular hypertension/<BR/>15 exp intraocular pressure/<BR/>16 glaucom$.tw.<BR/>17 ((intraocular or intra ocular) adj1 pressure$).tw.<BR/>18 ocular hypertensi$.tw.<BR/>19 (IOP or OHT).tw.<BR/>20 or/13-19<BR/>21 exp antihypertensive agents/<BR/>22 antihypertensi$.tw.<BR/>23 (therap$ or treat$ or medicat$ or drug$ or drop$).tw.<BR/>24 or/21-23<BR/>25 exp attitude to health/<BR/>26 exp patient compliance/<BR/>27 exp patient dropouts/<BR/>28 exp treatment refusal/<BR/>29 exp patient acceptance of health care/<BR/>30 exp patient satisfaction/<BR/>31 (adhere$ or non adhere$ or complian$ or non complian$ or concordance or persistence or acceptance or coperat$ or co operat$ or conform$).tw.<BR/>32 ((discontinu$ or abstention or abstain$ or stop$ or abandon$) adj4 treat$).tw.<BR/>33 ((discontinu$ or abstention or abstain$ or stop$ or abandon$) adj4 medic$).tw.<BR/>34 ((discontinu$ or abstention or abstain$ or stop$ or abandon$) adj4 therap$).tw.<BR/>35 or/25-34<BR/>36 20 and 24 and 35<BR/>37 12 and 36</P>
<P>The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (<LINK REF="REF-Glanville-2006" TYPE="REFERENCE">Glanville 2006</LINK>).</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-07-16 11:49:32 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-07-16 11:49:32 +0100" MODIFIED_BY="[Empty name]">EMBASE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-18 12:56:12 +0000" MODIFIED_BY="[Empty name]">
<P>1 exp randomized controlled trial/ <BR/>2 exp randomization/ <BR/>3 exp double blind procedure/ <BR/>4 exp single blind procedure/ <BR/>5 random$.tw. <BR/>6 or/1-5 <BR/>7 (animal or animal experiment).sh. <BR/>8 human.sh. <BR/>9 7 and 8 <BR/>10 7 not 9 <BR/>11 6 not 10 <BR/>12 exp clinical trial/ <BR/>13 (clin$ adj3 trial$).tw. <BR/>14 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw. <BR/>15 exp placebo/ <BR/>16 placebo$.tw. <BR/>17 random$.tw. <BR/>18 exp experimental design/ <BR/>19 exp crossover procedure/ <BR/>20 exp control group/ <BR/>21 exp latin square design/ <BR/>22 or/12-21 <BR/>23 22 not 10 <BR/>24 23 not 11 <BR/>25 exp comparative study/ <BR/>26 exp evaluation/<BR/>27 exp prospective study/<BR/>28 (control$ or prospectiv$ or volunteer$).tw. <BR/>29 or/25-28 <BR/>30 29 not 10 <BR/>31 30 not (11 or 23) <BR/>32 11 or 24 or 31<BR/>33 exp glaucoma/<BR/>34 exp intraocular hypertension/ <BR/>35 exp intraocular pressure/ <BR/>36 glaucom$.tw. <BR/>37 ((intraocular or intra ocular) adj1 pressure$).tw. <BR/>38 ocular hypertensi$.tw. <BR/>39 (IOP or OHT).tw.<BR/>40 or/33-39 <BR/>41 exp antihypertensive agent/ <BR/>42 antihypertensi$.tw. (28653)<BR/>43 (therap$ or treat$ or medicat$ or drug$ or drop$).tw. <BR/>44 or/41-43 <BR/>45 exp attitude to health/ <BR/>46 exp patient compliance/ <BR/>47 exp patient/ <BR/>48 exp treatment refusal/ <BR/>49 exp patient attitude/ <BR/>50 exp patient satisfaction/ <BR/>51 (adhere$ or non adhere$ or complian$ or non complian$ or concordance or persistence or acceptance or coperat$ or co operat$ or conform$).tw. <BR/>52 ((discontinu$ or abstention or abstain$ or stop$ or abandon$) adj4 treat$).tw. <BR/>53 ((discontinu$ or abstention or abstain$ or stop$ or abandon$) adj4 medic$).tw. <BR/>54 ((discontinu$ or abstention or abstain$ or stop$ or abandon$) adj4 therap$).tw. <BR/>55 or/45-54 <BR/>56 40 and 44 and 55 <BR/>57 32 and 56 </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2012-07-16 11:51:12 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2012-07-16 11:51:12 +0100" MODIFIED_BY="[Empty name]">CINAHL (EBSCO) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-18 13:00:19 +0000" MODIFIED_BY="[Empty name]">
<P>1 Randomized Controlled Trial.pt. <BR/>2 Controlled Clinical.pt. <BR/>3 Randomized Controlled Trials.sh. <BR/>4 Random Allocation.sh. <BR/>5 Double Blind Method.sh. <BR/>6 Single Blind Method.sh. <BR/>7 1 or 2 or 3 or 4 or 5 or 6 <BR/>8 (Animals not Human).sh. <BR/>9 7 not 8 <BR/>10 Clinical Trial.pt. <BR/>11 exp Clinical Trials/ <BR/>12 (clin$ adj25 trial$).ti,ab. <BR/>13 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab. <BR/>14 placebos.sh. <BR/>15 Placebo$.ti,ab. <BR/>16 random$.ti,ab.<BR/>17 Research Design.sh. <BR/>18 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 <BR/>19 18 not 8 <BR/>20 19 not 9 <BR/>21 Comparative Study.sh. <BR/>22 exp Evaluation studies/ <BR/>23 Follow Up Studies.sh. <BR/>24 Prospectice Studies.sh. <BR/>25 (control$ or prospective$ or volunteer$).ti,ab. <BR/>26 21 or 22 or 23 or 24 or 25 <BR/>27 26 not 8 <BR/>28 27 not (9 or 20) <BR/>29 9 or 20 or 28 <BR/>30 exp GLAUCOMA/ or exp OCULAR HYPERTENSION/<BR/>31 exp INTRAOCULAR PRESSURE/ <BR/>32 glaucoma$.mp. <BR/>33 (ocular adj1 hypertension).mp. <BR/>34 (intraocular adj1 pressur$).mp. <BR/>35 OHT.mp. <BR/>36 30 or 31 or 32 or 33 or 34 or 35 <BR/>37 exp ATTITUDE TO HEALTH/ or exp PATIENT COMPLIANCE/ or exp TREATMENT REFUSAL/ <BR/>38 exp PATIENT CARE PLANNING/ or exp PATIENT EDUCATION/<BR/>39 ((patient$ or user$) adj3 (acceptance or complian$ or non-complian$ or concordance or persisten$ or adher$ or non-adhere$ or co?operat$ or non-co?operat$ or conform$)).mp.<BR/>40 ((discontinu$ or abstention or abstain or stop$ or abandon$) adj3 (treatment$ or medication$ or medicine$ or therap$)).mp. <BR/>41 37 or 38 or 39 or 40 <BR/>42 (therap$ or medicine$ or medication$ or treatment$ or drug$ or drop$).mp. <BR/>43 29 and 36 and 41 and 42 </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2012-07-17 12:12:36 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2012-07-16 11:51:45 +0100" MODIFIED_BY="[Empty name]">PsycINFO and PsycEXTRA (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-17 12:12:36 +0100" MODIFIED_BY="[Empty name]">
<P>1 exp glaucoma/<BR/>2 glaucom$.tw.<BR/>3 ((intraocular or intra ocular) adj1 pressure$).tw.<BR/>4 ocular hypertensi$.tw.<BR/>5 (IOP or OHT).tw.<BR/>6 or/1-5<BR/>7 exp antihypertensive drugs/<BR/>8 antihypertensi$.tw.<BR/>9 (therap$ or treat$ or medicat$ or drug$ or drop$).tw.<BR/>10 or/7-9<BR/>11 exp compliance/<BR/>12 exp treatment compliance/<BR/>13 exp treatment dropouts/<BR/>14 exp treatment refusal/<BR/>15 exp health behavior/<BR/>16 exp health attitudes/<BR/>17 exp client attitudes/<BR/>18 exp Client Satisfaction/<BR/>19 (adhere$ or non adhere$ or complian$ or non complian$ or concordance or persistence or acceptance or coperat$ or co operat$ or conform$).tw.<BR/>20 ((discontinu$ or abstention or abstain$ or stop$ or abandon$) adj4 treat$).tw.<BR/>21 ((discontinu$ or abstention or abstain$ or stop$ or abandon$) adj4 medic$).tw.<BR/>22 ((discontinu$ or abstention or abstain$ or stop$ or abandon$) adj4 therap$).tw.<BR/>23 or/11-22<BR/>24 6 and 10 and 23<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2009-02-18 13:02:48 +0000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2009-02-18 12:38:03 +0000" MODIFIED_BY="[Empty name]">Web of Science search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-18 13:02:48 +0000" MODIFIED_BY="[Empty name]">
<P>Topic=(glaucoma* or ocular hypertension or IOP or OHT) AND Topic=(therap* or treat* or medic* or drug* or drop*) AND Topic=(adhere* or complian* or concordance)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2012-07-16 12:08:35 +0100" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2012-07-16 11:52:26 +0100" MODIFIED_BY="[Empty name]">ZETOC search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-16 12:08:35 +0100" MODIFIED_BY="[Empty name]">
<P> "glaucoma adherence"</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2012-07-16 12:14:26 +0100" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2012-07-16 11:53:18 +0100" MODIFIED_BY="[Empty name]">OpenGrey search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-16 12:14:26 +0100" MODIFIED_BY="[Empty name]">
<P>Glaucoma AND (Adherence OR Compliance OR Concordance)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-09" MODIFIED="2012-07-16 12:05:12 +0100" MODIFIED_BY="[Empty name]" NO="9">
<TITLE MODIFIED="2012-07-16 11:54:04 +0100" MODIFIED_BY="[Empty name]">metaRegister of Controlled Trials search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-16 12:05:12 +0100" MODIFIED_BY="[Empty name]">
<P>(Adherence OR Compliance OR Concordance) AND Glaucoma</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-10" MODIFIED="2012-07-16 12:05:35 +0100" MODIFIED_BY="[Empty name]" NO="10">
<TITLE MODIFIED="2012-07-16 11:54:59 +0100" MODIFIED_BY="[Empty name]">ClinicalTrials.gov search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-16 12:05:35 +0100" MODIFIED_BY="[Empty name]">
<P>(Adherence OR Compliance OR Concordance) AND Glaucoma</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-11" MODIFIED="2012-07-16 12:07:08 +0100" MODIFIED_BY="[Empty name]" NO="11">
<TITLE MODIFIED="2012-07-16 11:55:22 +0100" MODIFIED_BY="[Empty name]">ICTRP search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-16 12:07:08 +0100" MODIFIED_BY="[Empty name]">
<P>Glaucoma = Condition AND Adherence OR Compliance OR Concordance = Intervention<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-12" MODIFIED="2012-07-16 11:55:27 +0100" MODIFIED_BY="[Empty name]" NO="12">
<TITLE MODIFIED="2012-05-22 10:29:31 +0100" MODIFIED_BY="[Empty name]">Questions on patient knowledge</TITLE>
<APPENDIX_BODY MODIFIED="2012-05-22 11:49:38 +0100" MODIFIED_BY="[Empty name]">
<P>The following questions were used in <LINK REF="STD-Ring-2011" TYPE="STUDY">Ring 2011</LINK>. The participants were required to answer true/false. </P>
<OL>
<LI>Glaucoma is a disease that affects the eyes and no other parts of the body</LI>
<LI>Glaucoma is always painful</LI>
<LI>Raised eye pressure can cause glaucoma</LI>
<LI>Treatment for glaucoma is life long</LI>
<LI>The most common treatment for glaucoma is surgery</LI>
<LI>Eye drops have side effects that affect other parts of the body</LI>
<LI>Most people have symptoms that warn them that glaucoma is getting worse</LI>
<LI>Glaucoma affects the central part of your vision before the sides</LI>
<LI>Regular check-ups are not necessary</LI>
<LI>Lowering the eye pressure reduces the risk of sight loss in glaucoma</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2008-07-03 17:00:21 +0100" MODIFIED_BY="Trish Gray"/>
</COCHRANE_REVIEW>